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Abstract 
Despite the development of new biomarkers predicting prognosis in rheumatoid 
arthritis (RA) remains challenging and targeting of powerful biologics difficult. 
The presence of ectopic germinal centres (GC) within synovium has long been 
recognised (ectopic lymphoneogenesis [ELN]) and data have suggested that they 
manufacture antibody (Ab). High affinity class switched Ab production occurs 
through class switch recombination (CSR) and somatic hypermutation (SHM) both 
critically dependent on activation induced cytidine deaminase (AID). However, 
whether ectopic GCs express AID has not been known. Nonetheless data 
associating ELN with disease severity suggest a role for ELN in RA pathogenesis 
and as a potential biomarker. A classification system for RA synovium, based on 
the concept of ELN has been proposed as: (i) aggregate, (ii) aggregate GC+ and, 
(iii) an unorganised infiltrate. However whether these distinct pathotypes and/or 
degree of aggregation equate to disease severity is unclear. Thus my first aim was 
to develop and validate a pathological scoring system for rheumatoid synovium 
capable of quantifying the degree of ELN. My second aim was to investigate 
whether the presence and/or degree of ELN within the synovial membrane 
correlated with both clinical phenotype and predicted erosive damage. I 
demonstrate that the aggregational score developed is highly reliable and that ELN 
within synovial tissue associates with a higher level of synovial inflammation but 
is not predictive of damage. 
My third aim was to investigate whether GCs within RA synovium were 
functional. I provide evidence of functionality by demonstrating that ectopic GCs 
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invariably express AID, are surrounded by anti-CCP+ plasma cells, support 
ongoing CSR and the manufacture of anti-CCP Abs. 
My final aim was to characterise a cohort of synovial B cells consistently found 
surrounding ectopic GCs. I identify a novel B cell subset within RA synovium, 
interfollicular large B cells, (5)(5)(5) and demonstrate that interfollicular large B 
cells in lymph node express a somatically mutated IgH. 
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Chapter 1: Introduction 
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History 
Rheumatoid arthritis (RA) was first described by Landre-Beauvais in 1800 as 
"primary aesthenic gout", a disease made distinct from traditional gouty arthritis 
by a preponderance in women, a chronic course, systemic symptoms and a lack of 
uric acid crystals within joints(7; 8). The term RA was first coined by Garrod in his 
text published in 1859, but its classification as a disease distinct from osteoarthritis 
was not finalised until 1907. 
There is little evidence to suggest that RA existed much earlier than 1800 in 
Western Europe(9). However evidence of its existence in the USA 6500 years ago 
has been demonstrated(10) with skeletons dating back 6500 years displaying a 
symmetrical erosive polyarthritis. This appearance of RA in Western Europe 
coinciding with the discovery of the New World in the fifteenth century suggests 
disease transmission and thus an environmental aetiology to disease 
pathogenesis(8). 
Furthermore RA is the first autoimmune disease to be described, with the 
identification of rheumatoid factor (RF) in the serum of patients reported by 
Waaler in 1940(11). 
Definition and Classification 
RA is a chronic autoimmune inflammatory arthritis, characterised by the presence 
of inflamed synovium, loss of articular cartilage, associated bone erosion and in 
around 70% of patients the presence of autoantibodies in the serum. Arthritis is 
symmetrical, of a polyarticular form and deforming. Diagnosis is according to the 
1987 American College of Rheumatology (ACR) revised criteria (12)(Table 1) 
that are able to differentiate RA from other forms of inflammatory arthritis with a 
sensitivity of around 90%. However they are less useful in those patients in 
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remission(13; 14) and therefore are of less value in prevalence studies where 
diagnosis of inactive disease is required. As the emphasis on diagnosis has 
switched to the early diagnosis of disease, when many of these criteria may not be 
present, their usefulness in this cohort of patients is also limited, and so this has 
led to the development of new models for the diagnosis of early RA, using such 
criteria as anti-CCP positivity (15). 
Epidemiology 
RA is the commonest form of inflammatory arthritis affecting between 1-2% of 
the adult population worldwide. In the UK disease prevalence is 0.8%, a figure 
that has been consistently shown to be falling(16; 17) predominantly within the 
female population. The annual UK incidence of disease is around 14 per 100 000 
men and 36 per 100 000 women annually(18). It has a female to male ratio of 3: 1, 
a ratio that falls with increasing age(18). The peak age of onset is in the fifth to 
sixth decades(19). 
Several studies of prevalence and incidence of RA have been published in the last 
decades, suggesting considerable variation in disease occurrence between 
population groups. Such comparisons are limited somewhat by methodological 
differences adopted by investigators, these include diagnostic criteria, which 
changed in 1987 when the previously used 1958 criteria were reviewed, and so 
earlier studies may have included cases not corresponding to the current definition 
of RA. The use of the 1987 revised criteria however, has led to standardization and 
has revealed some characteristic trends seen in different ethnic populations that 
could be seen as independent from methodological issues. 
Geographical variation in disease prevalence has been marked with lower 
incidences in parts of China (0.2-0.3) than in Western Europe and the USA(20), 
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and lower prevalence rates in Southern than Northern European countries(21-23). 
Further, prevalence rates of up to 5.3-6% in Native Americans and Alaskans have 
been noted, perhaps explained by HLA associations. Interestingly, although RA is 
virtually undetectable in parts of Nigeria(24) and rural South Africa(25), 
prevalence rates rise to nearly 1% in black populations in urban areas further 
suggesting an environmental aetiology to disease pathogenesis. 
Clinical features 
RA presents as the gradual onset of joint stiffness, pain and swelling over the 
course of weeks or months, although less often can present more dramatically over 
24-48 hours, as an explosive onset. As RA is a systemic disease symptoms are not 
limited to joint involvement so in addition to fatigue, patients can present with a 
number of extra articular features (Table 2). 
RA has a variable clinical course, with differences in radiographic joint damage 
varying some 10-12 fold 10 years after diagnosis(26), this is of particular 
importance as radiographic damage increasingly explains functional disability as 
disease progresses(27). Further, RA patients experience increased mortality 
predominantly explained by an excess in cardiovascular disease(28). 
The chronic progressive nature of RA and associated morbidity and mortality 
result in a health economic burden in the UK alone of £1.2billion annually. 
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Table 1: 1987 revised American College of Rheumatology criteria for 
diagnosis of rheumatoid arthritis. 
1)*Moming stiffness in and around joints lasting for at least an hour before 
maximal improvement 
2) *soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician 
3)*swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or 
wrist joints; 
4) *symmetric swelling (arthritis) 
5) rheumatoid nodules 
6) the presence of rheumatoid factor; 
7) Radiographic erosions and/or periarticular osteopenia in hand and/or wrist 
joints. 
*Criteria I through 4 must have been present for at least 6 weeks. Rheumatoid 
arthritis is defined by the presence of 4 or more criteria. 
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Table 2: Extra articular manifestations of rheumatoid arthritis 
Organ Manifestation of involvement 
Skin V'asculitis, nodule, 
Cardiac Pericarditis, Myocardial fibrosis/granulomatous disease 
Pulmonary Interstitial pneumonitis, Rheumatoid Nodules, Serositis 
Neurological Mononeuritis multiplex, peripheral neuropathy 
Haematological Anaemia, Felty's syndrome 
Ophthalmological Scleritis, cipscleritis, keratoconjunctivitis sicca 
Exocrine Secondary Sjogren's syndrome 





The contribution of genes to the development of RA was initially proposed at the 
beginning of the 20`h century when the disease was noted to be prevalent in 
particular families. This observation led to further, more detailed studies later in 
the century which focused on the increased risk posed if a first degree relative was 
affected by RA. The conclusions were that the risk of developing RA was 
increased between 2 and 4 times if a first degree relative was affected. However 
more debate has surrounded the relative contribution of genetic factors to disease 
susceptibility rather than disease severity per se(29). 
The finding that concordance rates for RA are higher in monozygotic (12-15%) as 
opposed to dizygotic twins (3-4%) and higher in dizygotic twins than the general 
population provides further evidence suggesting a genetic component to 
disease(30; 3 1), but also supports the role of an environmental trigger. Extension of 
this work has shown that as much as 60% of a population's predisposition to RA 
can be accounted for by genetic factors(32). 
Human Leukocyte Antigen (HLA) associations 
The association between HLA genes and RA have been known for 30 years(33; 34) 
and around 30% of disease susceptibility can be accounted for by genes within this 
region(35), particularly the class II gene HLA-DRB 1 located on the short arm of 
chromosome 6(6p2l. 3)(32; 36). HLA-DRBI alleles associated with disease 
susceptibility across different ethnic groups encode a conserved sequence of 
amino acids in the third hypervariable region of the ß chain of the HLA-DR 
molecule and are collectively referred to as the shared epitope (SE) (35), and the 
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association commonly defined as the SE hypothesis(35). These residues are 
important as they occur within the antigen binding site of the MHC molecule and 
so can influence efficiency of antigen presentation to T cells. 
HLA DR4 subtypes, such as Dw10 and Dw13(37), have also been negatively 
associated with the development of RA, an association thought to be a result of 
either altered antigen binding site efficiency or by the induction of regulatory T 
cell pathways independent of peptide. 
In addition to disease susceptibility the SE also appears to influence disease 
severity with specific sequences associated with a poorer prognosis(38) and 
heterozygosity or homozygosity for certain alleles, for example DRB 1 
*0401/0404, carrying a risk for more severe disease(39). 
The SE hypothesis does not appear to be an essential aetiological factor however 
as it does not apply to all ethnic groups, with greater than 90% of Caucasian RA 
patients carrying HLA-DRB 1 alleles and less than 50% of black Americans (40). 
Recent data have demonstrated a gene-environment interaction with RA patients 
who both smoke and express the SE at much higher risk of sero positivity for RF 
and to a larger extent anti-CCP antibodies(4 1). 
Non HLA genetic associations 
Protein tyrosine phosphatase N22 (PTPN22) 
Of the non HLA genetic associations a polymorphism within the gene PTPN22 has 
been most reproducibly demonstrated over a number of studies for both RA and a 
range of other autoimmune conditions (42-46). PTPN22 encodes an intracellular 
protein lymphoid tyrosine phosphatase a negative regulator of T cell activation, the 
risk allele therefore permitting MHC II dependent T cell activation. The risk (T) 
allele has been associated in past studies with an odds ratio for RA of 
27 
approximately 1.8 (44), and the risk appears to be amplified in autoantibody- 
positive RA(47-50) and in patients homozygous for the variant T allele(48). In 
addition, a more recent report documents a multiplicative effect with smoking(5 1). 
Peptidyl deiminase type 4 (PADI4) 
The peptidyl deiminase type 4 gene encodes an enzyme involved in the post 
translational modification of proteins converting arginine to citrulline. An 
association with disease susceptibility was suggested by a study of Japanese RA 
patients(52). However, subsequent reports in Caucasian patients did not replicate 
the findings(53-55) but a more recent meta-analysis has suggested that this may 
reflect an association limited to patients of Asian, rather than European origin(56). 
The susceptibility haplotype is thought to stabilise PADI4 mRNA and therefore 
increase the cellular levels of PADI4 protein and citrullinated peptides. Despite 
this, no consistent association between PADI4 haplotypes and circulating anti- 
CCP antibodies has so far been demonstrated(52; 54; 57). 
Cytotoxic T lymphocyte associated antigen 4 (CTLA4) 
An association with RA and polymorphisms within the gene CTLA4 have been 
reported(49). In addition CTLA4 has been shown to be associated with a number 
of other autoimmune diseases such as type 1 diabetes, multiple sclerosis and 
autoimmune thyroid disease(58; 59). CTLA4 is a negative regulator of T cell 
activation that is rapidly up regulated following T cell activation. CTLA4 binds the 
molecules CD80 and CD86, both of which are expressed by antigen presenting 
cells and in the absence of CTLA4 bind to CD28 which functions to provide co- 
stimulatory signals to T cells and thus T cell activation (60). Polymorphisms for 
CTLA4 have been associated with an increased risk of RA in China and North 
America (49; 61) although not in other populations (62-64). This discrepancy may 
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be explained somewhat by different polymorphic variants associating with 
Asian(65) and North European populations(49). Interestingly, further stratification 
of patients has also revealed an increased risk for RA in certain populations only in 
association with anti-CCP(49) antibodies and specific HLA subgroups(66; 67). 
Macrophage inhibitory factor (MIF) 
MIF is a pro inflammatory cytokine expressed in a wide variety of cells including 
T and B cells and macrophages. Raised levels of MIF have been detected within 
both the serum and synovial fluid of RA patients and anti-MIF animals have 
demonstrated efficacy in delaying the onset of arthritis in animal models of 
disease(68). The first association of genetic polymorphisms within this gene with 
inflammatory disease was with juvenile inflammatory arthritis(69) and identical 
polymorphisms as well as additional variants have now been correlated with 
RA(70). However further studies have produced conflicting results with a large 
cohort study from Sweden and the USA which showed no association with RA 
(49), and differing reports of associations of specific polymorphisms of MIF with 
disease severity(70-72). 
Signal transducer and activator of transcription 4 (STAT4) 
A SNP haplotype in STAT4 has recently been associated with RA in a North 
American population(73; 74) with an odds ratio of RA associated with the risk 
allele of 1.32. This association has been further replicated in Swedish and Korean 
cohorts(74; 75). STAT4 encodes a protein expressed primarily by lymphoid and 
myeloid tissues(76). Although how the RA associated STAT4 haplotype affects 
STAT4 production is currently unknown, it is conceivable that as STAT4 plays a 
central role in the cellular responses to a number of cytokines including IL- 12 and 
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IL-23. This may result in a skewed Thl/Th2 response via IL-12 or influence via 
11-23 a pro inflammatory Th17 response(76). 
6g23 
The 6q23 locus has been identified in a number of genome wide studies from 
different populations as a risk factor for RA(77-79). The single nucleotide 
polymorphism (SNP) maps close to the TNF-a-induced protein 3 (TNFAIP3) 
(78; 79) and as its product is capable of down regulating inflammation mediated 
by TNF-a and by Toll-like receptors(80; 81) may well play a role in RA 
pathogenesis. 
TRAF 5-Cl 
This has also been identified in a genome wide study(82) and is a plausible 
candidate for RA pathogenesis as its product acts to negatively regulate T cell 
receptor and TNF receptor signalling(82). Further C5 as a critical component of 
the complement pathway is thought to play a role in mediating articular damage in 
RA. 
Programmed death receptor 1 (PDCD-1) 
PDCD-l was first isolated in 1992; it is a molecule whose expression is enhanced 
by apoptotic stimuli. PDCD-l is thought to prevent autoimmune diseases, 
including RA, by inhibiting activation of self reactive lymphocytes. 
Polymorphisms of the PDCD-1 gene have now been linked to a number of 
immune mediated diseases including RA(83-85), although the association does 




A search for an infectious trigger for RA has been ongoing for many years and a 
number of candidates have been proposed including mycoplasma (87-90), 
mycobacterium tuberculosis(91), Human retrovirus 5(92), alpha virus(93), 
Epstein-Barr virus (EBV) (94; 95), cytomegalovirus, rubella virus (96)and 
parvovirus B 19(97; 98). 
Parvovirus B19 has attracted much attention(99) not least as clinical infection is 
often accompanied by an arthritis that is initially clinically indistinguishable from 
RA, with a symmetrical inflammatory arthritis, sero positivity for RF and bony 
erosions. In addition, the detection of parvovirus B19 DNA in RA synovial tissue 
and fluid as well as data demonstrating an ability of B19 positive sera to transform 
normal synoviocytes into an invasive phenotype(100) have further supported its 
case as a putative trigger. More recent studies have not supported this role, 
however, with a prospective study of acute parvovirus B19 arthritis patients 
showing no development of chronic arthritis(101) and further data demonstrating 
detection of its DNA in the synovial tissue of healthy individuals(102). 
EBV has also been implicated in RA pathogenesis with the detection of high titre 
antibodies in the sera of RA patients(103). Interestingly the EBV glycoprotein 
gp l 10 shares amino acid homology with the protein encoded by the RA 
susceptibility associated HLA-DRB*0401 allele. This allele is thought to confer 
low T lymphocyte responses to gp110 and thus allow abnormally high EBV 
replication in specific RA patients(104). EBV DNA has further been detected in 
significantly higher amounts in the blood, synovial fluid and saliva of RA patients 
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than in healthy controls and patients with other inflammatory arthritidies and EBV 
encoded RNA detected in B lymphocytes from synovial tissue (reviewed in(95)). 
The remaining organisms have all been proposed as putative pathogens in RA but 
links are controversial. Indeed at present there appears to be no consistent evidence 
to suggest that a single infectious agent is responsible for RA pathogenesis, 
although many avenues of research are investigating such a possibility. 
Lifestyle factors 
Smoking 
Smoking has for some time been known to be the major epidemiological risk 
factor for the development of RA(105-107) and some evidence supports an 
association with disease severity(108; 109). The increased risk is seen particularly 
in RF positive and anti-CCP positive patients. Importantly in anti-CCP positive 
patients the combination of the presence of the SE and smoking increases the 
relative risk of developing the disease by 21 fold, if 2 copies of the gene are 
inherited, compared with non smokers without the risk gene (110). The 
explanation for the link between smoking and the presence of anti-CCP antibodies 
was proposed when an increased presence of citrulline modified proteins were 
noted in the lungs of smokers. This was particularly interesting as it was known 
that the citrullination of proteins appeared to confer affinity for binding of their 
peptides to the SE of the HLA-DR molecules(111). Thus it was proposed that long 
term smokers increased the conversion of arginine to citrulline in the lung by 
upregulation of enzymes such as peptidyl-arginine deiminase (PADI) in 
macrophages(112). In those individuals carrying the SE an immune response 
would be preferentially be established, considering the increased affinity of 
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binding of citrullinated peptides for the SE, and the adaptive immune system 
activated some years before the development of the disease. 
Obesity and diet 
Obesity has been found to be a risk factor for RA in female, but not male 
patients(113; 114). Diet has also been demonstrated to influence symptomatology 
where diets rich in omega- 3 fatty acids found in oily fish were associated with 
improved pain scores (115), decreased use of NSAIDs(116) and modest clinical 
improvements(117). These effects are thought to be mediated by direct 
competition of fatty acids with the pro inflammatory arachidonic acids. Conversely 
a diet rich in red meat has been linked to an increased risk of RA(118). Finally, an 
increased intake of vitamin D has been associated with a reduced risk of 
developing RA(l 19). 
Hormonal and reproductive factors 
The higher incidence of RA in women, particularly prior to the menopause, 
suggests a role for hormonal factors in disease pathogenesis, which is further 
supported by the observed improvement in RA concurrent with pregnancy. The 
exact mechanism for each of these effects is not clear. A widely held view 
however that male RA patients have lower levels of testosterone was not supported 
by a study showing that levels of androgen-anabolic hormones, such as 
testosterone, are not significantly altered in RA patients compared to 
controls(120). Data have also suggested a particular clinical phenotype for each 
sex, with male patients being associated with a more erosive accelerated disease 
course in one study(121), however this observation was not been supported by a 
later report (122). Exposure to exogenous hormones in the form of the oral 
contraceptive pill does appear to have a protective effect, an observation reported 
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by a number of groups(123; 124). However hormone replacement therapy does not 
appear to influence disease(125). The molecular mechanisms governing these 
effects are still to be elucidated. 
The beneficial effect of pregnancy on RA has been suggested to be a result of a 
number of factors, including HLA class II disparity between mother and 
foetus(126) and quantitative and qualitative changes in regulatory T cells during 
pregnancy and post partum (127). Pregnancy per se also appears to increase the 
risk of developing RA, an effect particularly noticeable during the immediate post 
partum period(128; 129) particularly in breast feeding mothers, thought to be due 
to a result of prolactin(130). 
Weather conditions 
Although long regarded as an old wives tale there has been some recent data to 
support an influence of prevailing atmospheric conditions on symptomatology, 
with 2 groups reporting an association of joint pain with cold weather(131; 132). 
Current prognostic markers in rheumatoid arthritis 
The overwhelming balance of expert opinion now favours the use of aggressive 
treatment in early RA(133; 134)in an attempt to induce remission before erosive 
damage becomes irreversible, as it is this progression of erosive damage that has 
been reported to explain the loss of function seen in patients over the course of the 
disease (135). Two recently reported studies(133; 134) have achieved rates of 
remission of around 50% using biological agents in early RA and confirmed the 
concept of an available window of opportunity early on in disease to induce 
remission, which in the absence of a cure is the best possible outcome. RA, 
however, has a very variable clinical course, and not all patients have a poor 
outcome, scores for joint damage varying 10-12 fold after 10 years of disease(136) 
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and importantly in 10% of patients severe joint damage with significant associated 
morbidity occurs within 2 years of diagnosis(137). Treatment ideally should be 
tailored on an individual patient basis, maximising treatment to those most likely 
to have the most severe course. Giving all patients with early RA maximal 
treatment would not only incur high costs but the substantial risks of side effects, 
which include an increased risk of infection(138), would be unacceptable. Further, 
current ACR classification criteria have been shown only to have diagnostic 
sensitivity and specificity in established RA and to miss a significant proportion of 
patients with early RA(139). Thus there has been a need to develop reliable 
prognostic markers capable of identifying those patients with early arthritis who 
are going to progress rapidly. 
A large amount of research has focused in recent years on an attempt to identify 
genetic prognostic markers. Among all the HLA-DRB 1 alleles examined HLA- 
DRB 1 *0401 and DRB 1 *0404 have been consistently associated with radiographic 
erosions and moreover, the effect appears to be dose dependent with patients with 
2 disease associated alleles having more erosions and more joint replacement 
surgery than those without(140; 141). Further, genes within the HLA region that 
have been associated with erosive progression are HLA-DMA*0103 in 
combination with HLA-DRB1*01(142). Further protective genes have also been 
identified, particularly polymorphisms of the HLA-DRB1 and uteroglobin genes, 
associated with a lower risk of erosions(143; 144). However, so far no genetic test 
is currently of use in clinical practice. 
Disease activity at onset has been shown to be predictive of poor prognosis, in 
particular high levels of ESR and CRP(145; 146). The health assessment 
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questionnaire also predicts outcome, although disability rather than erosive 
damage(147; 148). 
RF has for many years been considered as a useful prognostic factor and numerous 
studies have identified positivity along with high titres and IgA subclass as 
associated with a poorer outcome(145; 149-151). Anti-CCP antibodies have now 
been shown to have a superior specificity and similar sensitivity to RF in the 
diagnosis of RA, and moreover also predictive of erosive damage in early 
arthritis( 146; 152). 
Radiographic damage at baseline has been shown to be strongly predictive of 
further erosive damage by a number of studies(145; 146; 153), however its use as a 
prognostic tool is limited by a lack of erosions at disease onset in the majority of 
patients. Thus the use of both magnetic resonance imaging (MRI) and 
ultrasonography have been explored in an attempt to quantify erosive disease 
before it is identified on plain radiography. Both modalities have been shown to 
be sensitive to the early inflammatory and erosive changes seen in early 
inflammatory arthritis, but neither have been shown to be unequivocally predictive 
of or related to radiographic changes typical of RA, or to major clinical outcomes 
such as long-term functional abnormalities(reviewed in(154-156). Indeed a 
controlled study using MRI could only detect changes in MCP bone marrow 
oedema in patients with RA, in comparison to Sjogren's syndrome or systemic 
lupus erythematosus (SLE), and in particular erosive changes did not differ 
between patient groups (157). 
Finally the ratio of circulating osteoprotegerin (OPG) to receptor activator of 
nuclear xß- Ligand (RANK-L) has been demonstrated to inversely correlate with 
erosive damage in those patients with early RA(158). 
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A number of prognostic scores combining biological parameters such as ESR. 
CRP. RF, anti-CCP and HAQ scores to determine outcome have been developed. 
The most recent was a model proposed by Visser et al comprising 7 variables and 
allowing for discrimination between persistent and self limiting arthritis and 
erosive and non erosive arthritis(15). Unfortunately, until now this and other 
scores developed have not been validated on other cohorts of arthritis so do not 
currently form part of standard clinical practice. 
Immunopathology 
The core of RA pathogenesis is generally considered to be the result of a 
dysrcgulatcd immune system with multiple interactions between the innate and 
adaptive immune systems resulting in an inflammatory cascade. 
Innate Immunity 
The innate immune system provides a rapid first line defence mechanism against 
microbial pathogens. Elements of the innate immune system include anatomical 
barriers, secretory molecules and cellular components. Anatomical barriers 
include mucosal layers and epithelial cell shedding at surfaces continuously 
exposed to micro organisms such as is found in the skin, gut and lungs. In addition 
to these mechanical factors barriers also produce factors capable of inhibiting 
bacterial growth, such as lysozymcs and phospholipascs found in the salivary 
glands and fatty acids in sweat. Finally biological mechanisms such as "bacterial 
flora" exist on the skin and in the intestine that prevent the colonisation of the sites 
with pathogenic organisms. Cellular and secretory mechanisms of innate immunity 
arc activated following the recognition of pathogen-associated molecular patterns 
(PAMPS) expressed by the majority of micro organisms, by germ line encoded 
pattern recognition receptors (PRR). PRPs include lectins, mannosc-binding 
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receptors. dectin- l, DEC-205. pentraxins, NOD proteins and toll like receptors 
(TLRs) and are all expressed to a varying degree by cells of the innate immune 
system. The activation of PRR by PAMPs has a number of different outcomes 
dependent on the receptor and cell type that includes complement activation and 
opsonisation; phagocytosis and clearance of pathogens and cellular debris, 
antimicrobial peptide superoxide, nitric oxide, pro inflammatory cytokine and 
chcmokinc release and the upregulation of co stimulatory molecules. This 
production of proinflammatory cytokines and chcmokincs and the upregulation of 
co-stimulatory molecules in particular allows TLRs to provide a crucial link 
between the innate and adaptive immune systems. It has therefore been proposed 
that dysrcgulatcd TLR signalling may provide a pathway to autoimmunity(159). 
The role of TLRs in RA pathogenesis has thus received much interest and this 
concept is supported by the observation that TLR signalling appears to play an 
important role in animal models of arthritis such as streptococcal wall 
anhritis(160). A more recent and crucial advance has been the demonstration that 
chromatin activation of B cells via syncrgstic engagement of B cell receptors 
(BCR) and TLR9 can result in the production of autoantibodies(16l ). Furthermore 
both TLRs. in particular TLR2, TLR3 TLR4 and TR7(162-164)and receptor 
ligands. including heat shock proteins. hyaluronan and fibrinogen have been 
detected within the RA joint. Stimulation of these receptors on synovial fibroblasts 
has now been demonstrated to be associated with the production of a number of 
pm inflammatory cytokincs and mctalloproteinascs(165) (166; 167). This 
association provides a mechanism by which innate immunity can be actively 
involved in RA pathogenesis and indeed blockade of TLR signalling is being 
expkmd as a possible therapeutic option(168). 
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Adaptive immunity 
In contrast to the non specific innate immune response adaptive immunity is 
highly specific. It is mediated by both cellular and humoral immunity, a result of 
clonally expanded T and B cells and forms the basis for immunological memory. 
T cells 
aDT cells can be divided into two subgroups dependent on the expression of CD4 
and CD8, known respectively as T helper (Th) cells and cytotoxic T cells. CD4' T 
cells interact with MHC class 11 molecules bearing antigen expressed on antigen 
presenting cells such as dendritic cells or B cells. This interaction enables the Th 
cell to release cytokines, capable of a number of functions including providing 
stimulation to B and T cells to proliferate and attracting other immune cells such 
as macrophages. CDK' T cells in comparison act via MHC I directed antigen 
specific killing of target cells and via the production of cytokines, particularly 
IFN-y and TNFa. 
Classically naive Th cells have been thought capable of differentiating into 2 
possible lineages. Thl and Th2. Thl cells are known to secrete predominantly 
IFNy and lymphotoxin and arc responsible for clearing intracellular pathogens by 
activating macrophagcs(169). Similarly. Th2 cells secrete IL-4, IL-S, IL-13, IL-25 
and help in mediating immunity against cxtracellular pathogens with the 
production of IL-4 and IL-5 in particular resulting in the activation of cosinophils 
and mast cells(170). The cytokincs of a specific lineage have also been shown to 
both operate a positive feedback loop promoting further proliferation of that 
specific subtype whilst simultaneously inhibiting proliferation of the other subsets. 
Thus, while Thl cells induce pro-inflammatory responses such as delaycd-tYP" 
hypersensitivity. Th2 cells arc capable of mediating allergic reactions. 
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RA was long thought of as a Th 1 mediated disease until experiments 
demonstrating that the loss of IFNy did not prevent the onset of autoimmunity 
(171.172 )suggested that other pathways outside Th I may play a role in disease 
pathogenesis . It is now known that a third Th cell lineage exists, that of Th 17, 
promoted by TGFß. IL-6 and IL23(173-175). Importantly each of these separate 
Th lineages has inhibitory regulatory effects on the others. Th 17 cells have now 
shown to be a critical pathogenic component of a number of autoimmune diseases 
including RA, with demonstrated expression within the RA synovial membrane 
(I 76)and early studies on animal models of arthritis suggesting that IL-17 
inhibition maybe a viable therapeutic option(177). A further and interesting 
finding has been the reciprocal relationship of Th 17 cells with regulatory T cell 
production, mediated in part via an inhibitory effect of IL-6(178). 
B cells 
After birth B cells develop in the bone marrow and as soon as they have 
productively rearranged their immunoglobulin genes they then migrate to the 
periphery to mature within the spleen into long lived mature B cells (Figure 1). 
Transitional B cells 
Transitional B cells are functionally immature and can be characterisod by their 
short half lives, their propensity to dominate the early phases of B cell 
reconstitution and their capacity to undergo apoptosis rather than proliferation 
following OCR engagcment(179). They can be subdivided into three divisions 
(Figure 1). transitional (T) 1, T2 and the more recently recognised T3 subtype 
(110). TI cells are lgMhighCD23- . T2 cells are IgMhigh CD23+, and T3 cells 
IgMlow C'D23+(I Kp). Transitional B cells develop following migration from the 
bone marrow into either BI or B2 naive B cell subsets. B2 cells comprise follicular 
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and marginal zone B cells and arc thought to develop from T2 B cells. The origin 
of BIB cells is less clear, although as they are lacking in splenectomised animals 
and as the spleen is the site of maturation of T2 and T3 cells, they are thought 
likely to develop from T2 or T3 cells(181). T3 B cells, although once thought to be 
part of the linear development from immature to mature B cells, are now thought 
to represent primarily self-reactive ancrgic B cells(182) and thus play a role in the 
development of peripheral tolerance. 
Marginal Zone (MZ) B cells 
ML 13 cells arc known to be able to function in both T dependent and T 
independent immune responses. They have been demonstrated to be capable of 
antibody production following TLR stimulation via differentiation in to short lived 
plasma cells, following their migration out of the marginal zone to the red pulp 
zone of the splccn(183) and arc thus involved in the early non specific innate 
response. 
MZ B cells arc also able to deliver antigen to follicular B cells and thus stimulate a 
GC response. MZ B cells may also become involved in T dependent immune 
responses via their direct activation by T dependent antigens, and thus 
subsequently receive T cell hclp(184). Indeed the observation that MZ B cells 
express higher levels of MHC 11 molecules than follicular B cells makes them 
more efficient at presenting antigen to T cells(185). 
The We of T2 B cells to differentiate into either follicular or MZB cells has so far 
not been scttlcd, although 3 possibilities are debated. Firstly, the MZ or GC We 
may he determined by the quality of BCR-evoked signals and the subsequent 
expression of Notch protcins(186), alternatively MZ B cells have been suggested 
to have gone through a (K' response, as they lack expression of AID and have 
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mutated Ißt (187). Finally the expression of sphingospine-1 phosphate receptor I 
on the H cells may overcome the CXCL13 recruiting capacity to the GC(188). 
B1B cells 
B 113 cells have been primarily identified within mice, and as of yet no population 
has been clearly identified in humans. In mice both Bla and Bib subsets of Bi B 
cells are known to seed the peritoneal and pleural cavities. BIB cells arc known to 
be of importance in generating a 1gM response to T independent antigens and 
splcncctomiscd mice lacking B1aB cells have a low level of natural antibodies 
and do not responds to immunization with T independent polysaccharides(181). 
Although BIaB cells clearly contribute to innate-like immune responses, B- lbB 
cells arc thought capable of contributing to the adaptive immune 
rcsponsc( $89.190). It has been suggested that they may originate from a 
specialized B2 B cell in aT independent manner(190). 
Follicular 8 cells 
Once follicular B cells mature they attain the ability to recirculate in the spleen (or 
indeed in the bone marrow) and then migrate through the peripheral blood and 
lymph continuously to the B cell areas of lymph nodes, Peycr's patches and the 
spleen. It is within these B cell rich follicular niches that B cells can then present 
antigen to T cells and thus mediate T cell dependent immune responses to protein 
antigens. B cells arc additionally recognised to receive activation signals via TLR 
activation, but unlike MZ and B1 B cells require additional signals from BCR and 
CD40 to mature into antibody producing cclls(191). Activated follicular B cells 
can produce short lived plasmablasts that do not migrate and are part of the early T 
cell dependent immune response. This is in contrast to activated germinal centre B 
cells that can differentiate into plasmablasts that then migrate to the bone marrow 
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to become long lived plasma cells, sustained by the actions of APRIL and 
BAFF(192). 
A second niche for follicular B cells is within perisinusoidal niches in the bone 
marrow. These perisinusoidal B cells have been demonstrated to be able to 
respond to T independent antigens, via the production of IgM, but they cannot 
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Figure 1: Stages in B cell maturation 
B cell lymphopoiesis occurs exclusively in the bone marrow and immature cells 
transit to the spleen for final maturation. Follicular (mature), germinal centre, and 
plasma B cells compose the B-2 lineage. A second lineage found in the peritoneum 
is called B-1 (so far only identified in mice). The presence of this cell requires the 
spleen, which suggests possible derivation from the transitional or marginal zone 
B cell stage, or perhaps the splenic microenvironment is required for B-1 lineage 
maturation. Germinal centre formation leading to memory and plasma cells can 
occur in the spleen, lymph nodes, or mucosa associated lymphoid tissue (MALT). 
Plasma cells disperse and are found in the bone marrow, peripheral tissues, and 
spleen. Adapted from(194) 
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The germinal centre reaction 
The GC is a microenvironment that emerges in the follicular B cell zones of 
secondary lymphoid organs (Figure 1). The initial step is the presentation of 
antigen by DCs to naive antigen specific Th cells and is followed by clonal 
expansion of these antigen specific Th cells within the T cell zones. Clonally 
expanded Th cells then migrate to the T/B cell border to encounter antigen primed 
B cells. This movement of cells is governed by the tight expression of a number of 
key chemokines. CXCR5 expression on antigen activated Th cells induces 
migration to its cognate Ligand CXCL13, the CK critical for the organizing 
primary B cell follicles and FDC networks in the lymph nodes and spleen. In 
addition CCR7 is upregulated on activated DCs and naive T cells inducing 
migration to its ligands CCL19 and CCL21, expressed within T cell zones of 
secondary lymphoid organs. The interaction of antigen primed Th cells with B 
cells requires antigen primed B cells to have processed and presented antigen in 
the form of MHC II molecules, further co-stimulatory signals are provided by 
CD28/CTLA4Ig and CD80/86 interactions, as well as those between inducible co- 
stimulator (ICOS) and B7-h on resting B cells. This T/B cell interaction is 
followed by the clonal expansion of antigen specific B cells, either within the T 
cell area and resulting in the production of short lived plasma cells producing non 
class switched IgM or within primary follicles within the B cell zones. At about 
day 7-10 following initial antigen priming the resultant secondary follicle that has 
developed polarizes into a dark and a light zone, containing rapidly dividing and 
quiescent B cells. This is the GC reaction. Rapidly expanding cells are known as 
centroblasts and undergo diversification of their antigen receptor via SHM within 
the dark zone. This process results largely in death of the resulting centrocyte 
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within the light zone, as antigen binding is impaired, dying cells are then cleared 
via tingible body macrophages. Occasionally mutations are introduced that result 
in increased antigen binding of the receptor for antigen. In this event the 
centrocyte will receive survival signals 
and either remain within the GC and re enter the GC cycle, or exit as a long lived 
memory cell. Central to this process are FDCs, maturation of which require TNF 
and LT(3 as evidence suggests that FDCs provide proliferative signals to 
centroblasts(195). Complement receptors are known to trap antigen on FDCs that 
are then used to test centrocyte affinity for retained antigen. The GC reaction is 
known to persist for approximately 21 days following initiation. The main function 
is to produce memory B cells, which can be divided into long lived plasma cells, 
that reside mainly in the bone marrow and committed memory B cells that mainly 
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Figure 2: The germinal centre reaction 
This figure illustrates the cellular and molecular processes constituting a GC 
reaction. Antigen-specific B cells are recruited into the follicular regions within 
the B-cell zones of secondary lymphoid organs. Rapid clonal expansion results in 
the formation of the secondary follicle. Expanding centroblasts within the dark 
region are polarized from resting centrocytes within the light regions of the 
secondary follicle. Antigen-specific B cells diversify their BCR by somatic 
hypermutation and then `test' their variant BCR for antigen held as immune 
complexes on follicular dendritic cells (FDCs) within the light zone. Diminished 
binding for antigen leads to programmed cell death and rapid clearance of 
apoptotic B cells locally by tingle body macrophages (mc). Improved binding to 
antigen results in positive selection of the variant. There are two possible 
outcomes. The first is to return to the dark zone and resume the cycle of expansion, 
diversification, and selection. The second is to exit the GC cycle and thereby enter 
the memory B-cell compartment. 
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Interfollicular (IF) large B cells 
The pattern of somatic mutations within the V region genes of the IgH chain has 
been used to categorise B cells into either naive B cells (with unmutated V region 
genes) or GC/post GC B cells (with somatically mutated V region genes). A 
recent subpopulation of B cells, known as IF large B cells has been identified 
within lymph node and tonsils and found to carry somatically mutated V region 
genes(5). These IF large B cells have also been recognised to express AID and 
have thus been postulated to represent an extrafollicular GC independent pathway 
that could lead to the production of plasma cells(5). An alternative hypothesis, 
however, is that these cells represent post GC B cells, although an explanation for 
their continued expression of AID in this scenario is currently lacking, particularly 
as ongoing CSR at the interfollicular site occupied by these cells has been 
demonstrated(196). Indeed the molecular phenotype of these cells does not suggest 
that they represent errant GC B cells, as they lack expression of a number of 
classic GC B cell markers, such as Bc16 and p27(5)(Figure 3). In addition, the 
unusual phenotype of these large IF B cells suggests that these cells may play an 
antigen presenting role, in that often long dendritic like processes are noted to 
extend some distance from the nucleus(5), although they lack the classic co- 
stimulatory molecules such as CD80 and CD86 associated with DCs. Thus 
although IF large B cells appear to represent a unique B cell population their exact 
origin and function is currently unknown, and whether they are expressed within 
ectopic lymphoneogenesis is unknown. 
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Anatomical site Bone marrow Mantle zones Germinal centre Germinal centre Marginal T cell h Bone marrow 
(dark zone) (light zone) zone interfollricicular areas lymph node 
---- iý_ - ---- -- ---- 
medulla 
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Figure 3: Molecular characteristics of interfollicular large B cells and other B cells. 
Phenotype of individual cells depicted by diagrams above table (adapted from (5)) 
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Achieving antibody diversity 
The binding affinity of antibody to antigen is determined by the amino acid 
sequences within the variable region of antibody (Figure 4) and humans initially 
achieve antibody diversity within this region via random recombination of the 
variable (V), diversity (D) and joining (J) region genes, a process that occurs early 
in B cell development and under the control of recombination activation genes 
(RAG) (Figure 5). It results in the production of early B cells with randomly 
assorted VDJ segments of genome with further variability additionally being 
introduced by the generation of random linking N-sequences (via the action of 
terminal transferase). Thus early B cells are produced with the protein product of 
these genes displayed on the cell surface as its cell surface antigen receptor. 
When B cells subsequently come into contact with antigen two processes are 
initiated, that of SHM and CSR, both of which are critically dependent on the 
enzyme AID(197). The mechanism of action of AID has created some 
controversy, however it is now generally accepted to act directly on single 
stranded DNA deaminating cytidine to uracil(198). An alternative mode of action, 
as an RNA editing enzyme, was originally proposed and suggested that as AID 
bears remarkable similarity to other RNA editing members of the APOBEC family 











Figure 4: Basic structure of an antibody 
Antibodies exhibit a characteristic Y-shaped structure composed of two identical 
heavy (shown in blue right of image) and light chain (shown in red right of image) 
polypeptides. The variable domains (shown in red on left of image) of both the 
heavy and light chains form the target binding region of antibodies, whereas the 
constant regions of antibodies (shown in blue on left of image) determine the 
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Figure 5: VDJ rearrangement of the heavy chain immunoglobulin locus 
Recombination of the variable (V), diversity (D) and joining (J) region segments of 
the immunoglobulin gene occurs early in B cell development within the bone 
marrow. V region family members number 50, D region members 30 and J region 
members 6. The process is under the control of RAG enzymes. The first step is a 
recombination of randomly chosen D and J segments, followed by recombination 
of the DJ segment with a randomly chosen V segment. This results in a mature 
transcript which is transcribed along with the constant region. Further variation is 
introduced by the action of terminal deoxynucleotidyl transferase, an enzyme that 
anneals the recombining segments and does so by the introduction of up to 15 new 
nucleotides. The intervening DNA that is not used is cut out and discarded. 
54 
Somatic hypermutation (SHM) 
SHM is a process by which further variability is introduced into the VDJ region of 
the IgH chain locus via the introduction of point mutations. The action of AID to 
deaminate cytidine to uracil introduces mutations that are then processed following 
DNA replication as base excision repair or mismatch repair (Figure 6). SHM 
occurs within hotspots in the VDJ regions known as complementary determining 
regions (CDRs) (Figure 7), as the amino acids encoded by them have most contact 
with antigen and thus determine antigen binding affinity of antibody. Mutations 
occurring within the frame work regions determine folding of antibody and are 
thus selected against. SHM results in single base mutations in the vast majority of 
sequence changes with transition mutations exceeding transversions by up to 5: 1. 
SHM is traditionally considered to occur solely within the environment of the GC 
where B cells expressing antibody with high affinity for retained antigen receive 
survival signals and those with low affinity undergo apoptosis. Thus repeated 
cycles of GC selection result in the selection of high affinity antibody. B cells 
exiting the GC have been demonstrated to display antibody with antigen binding 
affinity increased some 100 fold (reviewed in (200)) and are subsequently 
recruited immediately to the immune cascade or alternatively to the immune 
memory. 
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Figure 6: Mechanism by which activation induced cytidine deaminase mediates 
somatic hypermutation 
Activation-induced cytidine deaminase (AID) deaminates cytidine residues in DNA, 
converting them into uridine. The U-G mismatch can then be processed either by 
base excision repair (BER) or mismatch repair (MMR). In somatic hypermutation, 
the mismatch can be replicated to produce a C-to-T mutation, nick processing by 
UNG can produce an abasic site, or a gap can be filled in by error prone 
polymerases. 
56 
IgH chain locus V DJ 
FR3 c ýluý FR2 Ilk') FR3 / IbIU IH 
Variable region Diversity Junctional 
region 
region ßi1. { IK); Ini 
Figure 7: The immunoglobulin heavy chain locus (IgH) 
The IgH encodes the heavy chain of antibody consisting of variable, diversity and 
junctional regions. Frame work (FR) and complementary determining regions 
(CDR) lie within each. The CDR3 region has most contact with antigen and thus 
confers the highest antigen-antibody binding affinity. Somatic hypermutation 
(SHM) preferentially occurs within CDR regions determining antigen binding, as 
oppose to FR regions that affect antibody folding and thus are selected against. A 
comparison of the CDR: FR mutation ratio allows determination of whether 
antigen driven SHM has taken place. 
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Class switch recombination (CSR) 
The effector functions of antibody are determined by the heavy chain constant 
region and during CSR the membrane expressed BCR is replaced with one of 
another isotype. CSR occurs via an intrachromosomal deletional recombination 
event, of specific constant regions of the immunoglobulin heavy chain region 
(Figure 8). It occurs between switch (S) regions located upstream of the constant 
region. S regions consist of tandem repeats of short G-rich sequences, differing for 
each immunoglobulin isotype. 
The first step in CSR is the production of germline (GL) transcripts specific for 
each S region. These GL transcripts are not actively transcribed but are thought to 
be necessary to direct AID to a specific S region and further to make the S region a 
suitable substrate for AID. CD40 ligation and/or TLR stimulation are required for 
the initiation of CSR with the specific isotype switch determined by local cytokine 
production by for by e. g. Th and DCs. AID then acts to introduce double stranded 
breaks within the S regions, resulting in subsequent looping out of intervening 
DNA and the product of a mature IgH locus. Repair occurs through a non 
homologous end joining repair system. A by product of this process is the looped 
out intervening DNA known as switch circles which contain a specific active I 
promoter, that directs the production of I-Cµ circle transcripts, that have been 
demonstrated to be a very specific and sensitive marker of ongoing CSR(201). 
Extrafollicular induction of AID 
Conventionally induction of AID expression and production of antigen specific 
antibody was thought to occur primarily within the microenvironment of the GC. 
Although IHC studies have recently led to the recognition that IF large B cells are 
capable of AID expression outside this environment. In addition recent data have 
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demonstrated that induction of AID expression can occur within B cells 
extrafollicularly within the gut and the spleen and that this expression is associated 
with CSR and low level SHM(202-204). 
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Figure 8: Mechanism of class switch recombination 
The mouse immunoglobulin heavy-chain locus is shown. Rectangles and ovals 
represent exons and switch (S) regions, respectively. V(D)J recombination 
occurs in the bone marrow, whereas somatic hypermutation and class-switch 
recombination occur in the peripheral lymphoid tissues. Class-switch 
recombination brings the downstream constant (C) region exon in the 
proximity of the V exon by deletion between Si'. and another S region upstream 
of the target C region. Deleted DNA is released as a circular DNA which is 
subsequently transcribed as a circle transcript. Reprinted by permission from 




In mammals there are 5 classes of antibody each with specific effector functions 
(Table 3). Antibodies have three main functions, firstly they are capable of 
activating effector cells, they do this via binding initially to the invading pathogen 
and causing linking of sequential antigens, a number of cells are then stimulated 
via recognition of the Fc (constant region of antibody). Effector cells that 
recognise Fc receptors include neutrophils, phagocytes and natural killer cells, all 
of which by varying mechanisms are capable of destroying the invading pathogen. 
In addition antibodies are capable of activating complement following binding to 
pathogens and thus via the activation of the classical complement system bacteria 
are killed via opsonisation (ingestion by phagocytes) and/or the formation of a 
membrane attack complex, that allows direct antibody mediated killing. 
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Table 3: Antibody classes 
Name No of function 
Subclasses 
IgA 2 Located in mucosal areas (e. g. intestine, respiratory 
tract) and in secretions (e. g. tears, milk). Prevents 
pathogenic colonisation. Secreted in a dimeric form 
IgD 1 The BCR on naive B cells yet to be exposed to antigen 
IgM 1 Expressed on the surface of B cells and in a secreted 
form. Acts as part of the early humoral immune 
response. Secreted in a pentameric form 
IgG 4 Provides the predominant antibody based defence 
against invading pathogens. It is also passed across the 
placenta, conferring passive immunity to the foetus. 
IgE 1 It binds to allergens and triggers the release of 
histamine from mast cells and basophils, and further 
provides protection from parasitic worms 
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Mechanisms of inflammation 
Cytokines 
The role of the cytokine cascade in RA pathogenesis has perhaps received the most 
intensive research interest of that of any other inflammatory disease(205). 
Cytokines are small (5 to 50kDa) non structural proteins or glycoproteins that 
serve as chemical messengers between cells. This messaging system is of critical 
importance to both the development and functioning of the innate and adaptive 
immune systems. 
Numerous proinflammatory cytokines have been demonstrated to be upregulated 
in both the sera and synovial fluid of patients with RA and the modulation of these 
systems has proven a powerful therapeutic tool. 
The TNF superfamily 
TNFa was identified in 1975(206). It is a soluble secreted 17KDa protein that 
exists as a trimer and binds to 2 different receptors TNFI and TNFII. Both 
receptors have intracellular regions and transducer signals for intracellular 
activation. Cleavage of the extracellular portion of the TNFa receptor results in the 
production of circulating soluble TNFa receptors, which are capable of 
sequestering TNFa and thus preventing binding to membrane bound receptors 
capable of cellular activation(207). 
Following its identification, its capacity to degrade cartilage (208) and bone 
(209)in vitro raised the notion of a potential role for it in RA pathogenesis. 
Subsequent work demonstrating that blockade of TNFa in synovial mononuclear 
cell cultures resulted in the down regulation of IL I (210)and GM-CSF(211), led to 
the proposal of a cytokine hierarchy controlling the inflammatory cascade. Further 
TNFa and its receptors were also shown to be expressed within synovial 
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tissue(212; 213). These findings along with data showing that TNF transgenic mice 
develop a spontaneous arthritis (214)and that CIA could be ameliorated with the 
administration of a murine specific monoclonal antibody against TNFa(215) 
provided the rationale behind the first trials of TNFa blockade in RA patients. 
A further member of the TNF superfamily, Lymphotoxin (LT) 0 has also been 
associated with RA pathogenesis. LTß is a cell associated molecule and is known 
to be crucial for both the induction and maintenance of GC in secondary lymphoid 
organs(216), and has been shown to be differentially expressed within RA 
synovium containing these structures(217). LTalß2 and Ligand for herpes virus 
entry mediator (LIGHT) are both ligands of the receptor for LTß and have been 
implicated in RA disease progression(218). Therefore the blockade of these two 
ligands with a LTOR fusion protein is being explored as a possible therapeutic 
option in RA, although initial reports are not promising (reviewed in(205)). 
Finally RANK-L a cytokine shown to be upregulated within the RA synovial 
membrane is known to be involved in RA pathogenesis. RANKL is expressed by 
fibroblast like synoviocytes and activated synovial T cells and has been shown to 
play a crucial role in osteoclast differentiation, maturation and activation and 
hence the associated bone damage characteristic of RA(reviewed in (219)). 
Expression of RANKL is itself regulated by TNFa as well as its naturally 
occurring inhibitor that of osteoprotegerin (OPG). The inhibition of RANKL is 
currently undergoing clinical trials in RA, with reports of efficacy in prevention of 
erosive damage(220). 
The BAFF/APRIL pathway 
The B cell activating Factor, BAFF (also known as TALL-l, BLyS, THANK and 
zTNF4) and a proliferation inducing Ligand, APRIL are both members of the TNF 
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superfamily(221; 222). BAFF is a type II transmembrane protein, but can also be 
secreted following proteolytic digestion as a soluble polymeric or homotrimeric 
form(223). APRIL however is cleaved in the golgi before release and only exists 
as a soluble secreted form(224). In addition a splice variant of BAFF, OBAFF has 
been detected, that is not released from the membrane and is capable of acting as a 
negative regulator of BAFF, by interacting with the full length protein to form 
multimers(225; 226). Finally APRIL is also capable of forming heterotrimers with 
BAFF (227)and a biologically active fusion protein with another member of the 
TNF superfamily, TWEAK (228). 
BAFF and APRIL are expressed by monocytes, macrophages, DCs, T cells and 
FDCs(194; 229-231). It has recently been demonstrated that non lymphoid cell 
lines are capable of expressing BAFF, and importantly for RA pathogenesis has 
included production by fibroblast like synoviocytes(232) and osteoclasts, the latter 
of which are also capable of expressing APRIL(233). The production of BAFF and 
APRIL by neutrophils, macrophages and DCs can be stimulated by a number of 
cytokines, in particular IFN7, IFNa, IL1O(229) and CD40 as well as 
lipopolysaccharides (LPS)(234) and peptidogylcans(235). 
Three receptors for BAFF have been identified, BAFF-R (BAFF-receptor also 
known as BR3), TACI (transmembrane activator and calcium modulator and 
cyclophilin ligand interactor) and BCMA (B cell maturation antigen) and all are 
expressed on B cells(194). BCMA is highly expressed on plasmablasts, plasma 
cells and tonsillar GC B cells(236; 237). BAFF-R is expressed by all peripheral B 
cells, although down regulated in GC B cells(236; 237). TACI and BAFF-R are 
additionally expressed on activated T cells and BAFF-R on regulatory T 
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cells(238). APRIL binds with high affinity to just BCMA and TACI (194; 239) 
and is also capable of binding to proteoglycans(238) (Figure 9). 
BAFF is known to be a crucial B cell maturation factor and this is illustrated by 
the lack of maturation of B cells beyond the immature Ti stage in mice deficient in 
BAFF(240-242) and further the overexpansion of the T2 and MZ B cell 
compartments in mice over expressing BAFF(243; 244). In contrast, the role of 
APRIL is less well defined as conflicting results have emerged from two studies 
using APRIL knock out mouse models, one demonstrating no overt phenotype 
(245)and the other impaired class switching function, larger GCs and increased 
numbers of effector T cells(246). 
From studies investigating the phenotype of both BAFF-R and BCMA deficient 
mice, it would appear that BAFF-R is the critical receptor mediating B cell 
survival as BAFF-R deficient mice appear similar to BAFF null mice(247) and 
BCMA deficient mice have only minor defects in the immune system(248). 
However the study of TACI deficient mice has demonstrated a negative role for 
this receptor in B cell activation, and as such survival mice have an over expanded 
B cell compartment(249-251). Such an inhibitory role may not be replicated in 
humans as mutations in TACI have been associated with immunodeficiency(252). 
Of crucial interest to RA pathogenesis is work surrounding the role of BAFF in 
regulating B cell tolerance. The elimination of autoreactive B cells from the B cell 
compartment before they become long lived plasma cells appears to be dependent 
on the inability of these cells to respond fully to BAFF as well as controlled levels 
of BAFF expression (253-255) and indeed mice over expressing BAFF produce 
autoantibodies as well as developing other autoimmune manifestations(256; 257). 
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Elevated levels of APRIL and BAFF and BAFF/APRIL heterotrimers have 
subsequently been found in the sera of RA patients and moreover levels of APRIL 
correlated with levels of anti-glucose 6 phosphate isomerase (G6PI) (258) and 
levels of BAFF with RF(259). Further unique polymorphisms within the BAFF 
gene that are capable of regulating BAFF expression have been associated with 
RA, providing further evidence supporting a role for BAFF dysregulation in RA 
pathogenesis (260). Inhibiting BAFF via the use of TACI-Ig has generated 
promising preliminary data in the CIA mouse model(261) and in humans, where 
treatment was associated with clinical response and falling levels of both RF and 
anti-CCP antibodies(262). In addition clinical trials of the anti-BAFF monoclonal 
antibody belimumab have shown positive results in the treatment of SLE(263) and 
reports of ongoing clinical trials in RA are currently awaited. However, there are a 
number of hypothetical reasons for using anti-BAFF agents as adjunctive to anti- 
CD20 directed B cell therapy. Firstly BAFF is expressed on a slightly different 
variety of cells than CD20, for example plasma cells. Secondly the peripheral B 
cell depletion following treatment with anti-CD20 agents is followed by increased 
levels of peripheral BAFF in the sera of patients(264), which has the potential to 
provide survival signals to emerging autoreactive B cells, resulting in a subsequent 
resurgence in autoimmunity. 
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Figure 9: Interaction and expression of ligands and receptors in the 
BAFF/APRIL system. 
A simplified version of the BAFF/APRIL pathway. Cell types that produce 
BAFF or APRIL are indicated in light blue boxes at the top of the figure with an 
arrow. In the bottom part of the figure receptors are represented left to right 
including heparin sulphate proteoglycans (HSPG). Below each receptor is a box 
that indicates cell types expressing these receptors. Interactions between ligands 
and receptors are shown by arrows (adapted from (2)) 
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The Interleukin (IL)-1 superfamily 
ILI is a 17 kDa protein that is produced by a number of cells including monocytes, 
macrophages, endothelial cells and T and B cells. Both ILla and ILIß are 
proinflammatory cytokines known to induce the production of TNFa by synovial 
mononuclear cells, prostanoids and metalloproteinases from synovial fibroblasts as 
well as the induction of catabolic chondrocytes pathways and osteoclast activation 
pathways leading to bone erosion (208; 265). IL1 binds to cell surface ILI 
receptors, (IL 1 R) type I and II, and only the type I IL 1R is capable of intracellular 
signalling(266). The type I receptor is found on a large range of cells(267), 
whereas the decoy type II receptor is found only on neutrophils, monocytes and B 
cells(268). An IL1R antagonist (ILIRa) is released by monocytes and 
macrophages and competes with IL I for binding to IL 1 R. IL la and IL 1ß along 
with IL 1 Ra have been found to be expressed by cells of the RA synovial 
membrane(269; 270) 
Animal studies have strongly implicated ILI pathways in the pathogenesis of 
arthritis, with data demonstrating that intra articular IL1 injection results in 
cartilage degradation in rabbits(271) and the amelioration of CIA with the 
administration of monoclonal antibodies against IL1 in mice(272). In addition 
mice deficient in ILRa develop a spontaneous arthritis(273), but the transfer of IL1 
blockade to RA patients, using a human ILRa has not met with such convincing 
results (274), although newer approaches e. g. monoclonal antibodies against IL I 
are currently undergoing clinical trials (reviewed in (205)). 
11,18, a further member of the IL1 superfamily has also been detected in RA 
synovium (275). Animal experiments have also implicated it in the pathogenesis of 
RA, with ameliorated CIA detected in IL18 deficient mice(276) as well as IL18 
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blockade reducing disease severity in CIA mice(277). Thus IL18 blockade is 
currently undergoing phase I clinical trials(278) 
An IL18 inducible protein, IL32, has also recently been suggested to play a role in 
RA. A splice variant IL32y has been demonstrated to be produced by synovial 
macrophages and promote PGE2 and cytokine synthesis in vitro(279). IL32 has 
further been demonstrated in the CIA model of arthritis to induce articular 
inflammation in a TNFa dependent manner(280) and in patients levels of IL32 in 
the sera to associate with ESR (279). 
Finally a newly identified family member, IL33(281), has been shown to be 
expressed within the RA synovial membrane, predominantly by synovial 
fibroblasts(282). It has been shown to be capable when administered of 
exacerbating CIA in mice and when deficient associating with reduced disease 
severity(282). 
IL6 
IL6 is an inflammatory cytokine produced by macrophages, monocytes, synovial 
fibroblasts and T cells. It has diverse biological functions including a role in B cell 
maturation to plasma cells, activation of cytotoxic T cells, the formation of 
osteoclasts, broad effects on haematopoiesis in the bone marrow and the 
proliferation of synovial fibroblasts (reviewed in (283)). It is primarily responsible 
for the acute phase response seen in RA and is implicated in the anaemia of 
chronic disease. Levels of IL6 in RA patients have also been shown to correlate in 
the sera with disease activity(284) and in the synovial fluid with radiological 
damage(285). The release of IL6 is induced by both TNFa and IL1. The receptor 
for IL6 is heterodimeric consisting of gp 130 and IL6R, and both receptors result in 
cellular activation and so targeting either has therapeutic potential(286). Following 
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work demonstrating a crucial role for IL6 in the pathogenesis of CIA (287) the 
targeting of IL6R in RA patients using a specific monoclonal antibody, 
tocilizumab, was commenced. This has now been approved by the European 
Medicines Agency in combination with methotrexate for use in RA, following 
convincing clinical trial data(288-290) (291). 
The IL12 superfamily 
IL12 is a heterodimeric cytokine consisting of a p40 and p35 subunit, it is released 
by antigen presenting cells, DCs and monocytes and macrophages. As IL12 is the 
main inducer of IFNy (292)and thus the production of a Thl mediated 
inflammatory response(293), a central role in RA pathogenesis was thought likely. 
This hypothesis was supported by animal experiments demonstrating an 
augmented CIA response when IL 12 was administered to mice(294) and 
attenuated disease when IL12 was blocked(295). In humans, data further supported 
a role for IL12 in disease pathogenesis with correlations reported between levels 
of IL12 in the sera of RA patients and clinical parameters(296; 297) however these 
results have created some debate in the literature(205). IL12 shares a component of 
its heterodimer, the p40 subunit, with a more recently recognised cytokine, 
IL23(298), and further both cytokines share a component of their heterodimeric 
receptor, IL12JRl(299). The observation that mice deficient in either IL12 and/or 
IL23 did not develop CIA, as opposed to mice lacking only IL12 developing 
severe disease, led to the hypothesis that the autoimmune actions of IL12 were in 
fact attributable to IL23(300). The primary function of IL23 has been 
demonstrated to induce proliferation of Th 17 cells, a proinflammatory T cell 
capable of the production of a number of inflammatory cytokines associated with 
the pathogenesis of RA(173; 301). 
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Lastly, IL27 has been recently identified as a cytokine of the IL12 superfamily, a 
heterodimeric cytokine with a subunit homologous to a subunit of IL12(302). 
Binding of IL27 to its receptor in mice results in the proliferation of naive T cells 
and promotes a Thl response, whilst suppressing the production of pro 
inflammatory Thl7 cells(303). A role in the pathogenesis of RA is supported by 
the suppression of CIA in prone mice by the administration of recombinant 
IL27(304), but this anti inflammatory effect maybe dependent on disease stage, as 
severity of experimental allergic encephalitis could be reduced by the 
administration of IL27 neutralizing antibodies, suggesting IL27 is capable of 
mediating both pro and anti inflammatory effects(205). 
IL17 
IL17 is the major cytokine produced by Th17 cells and has wide ranging 
proinflammatory effects. It induces HLA class I expression, the production of a 
number of proinflammatory cytokines and is osteoclastogenic (reviewed in (305)). 
A role for IL17 in animal models of arthritis has been suggested by a number of 
reports demonstrating that deficiencies in 11,17, either through neutralizing 
antibodies or genetic knock out result in ameliorated disease(306-308). IL17 has 
also been detected within the synovial membrane and synovial fluid of patients 
with RA(309) and strategies to block IL17 are currently underway in RA(205). 
4a-helix family 
This family of cytokines binds to receptors that contain yc and most attention 
within the area of RA pathogenesis has focused on IL 15, IL7 and IL21. IL 15 is an 
IL2 like cytokine that is produced by T cells, monocytes, fibroblasts and 
endothelial cells. It can stimulate the generation of cytotoxic T cells as well as 
activate a wide range of immune cells. It has been detected within the synovial 
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fluid and membrane of patients with RA and can induce the release of TNFa , 
IL17 and IFNy(310; 311). IL15 blockade has been shown to reduce the severity of 
CIA(312) and preliminary data from human trials of IL15 neutralization in RA 
patients have shown promising results(313). 
IL7 appears a likely candidate for involvement in RA pathogenesis as it is detected 
in the sera(314), synovial membrane(315) and synovial fluid(316) of RA patients. 
It is also known to play a number of immune mediated roles including the 
induction of a proinflammatory response in synovial cell cultures(315; 316) as well 
as playing a role in lymphoneogenesis(317), osteoclastogenesis (318)and 
modification of chrondrocyte function(319). In addition the persistence of IL7 
expression post anti-TNF treatment in some patients(315; 320), demonstrates a 
TNFa independent stimulatory pathway and suggests IL7 may well be an 
attractive option for therapeutic modulation. 
Finally IL21 has been detected in the synovial fluid and synovial membrane from 
the joints of patients with RA(315; 321; 322). Blockade of IL21 in in vitro cultures 
of synovial cells has been shown to result in the down regulation of TNFa, ILI and 
IL6(323). Further neutralization using an IL21 receptor fusion protein resulted in 
the amelioration of CIA in mice(324). It has additionally been shown to play a 
critical role in the differentiation of Th17 cells and thus these data together make 
IL21 an attractive pathogenic candidate for RA. 
Anti-inflammatory cytokines in RA 
Of note anti-inflammatory cytokines such as IL1O(176) and cytokine-inducible 
suppressor of cytokines (SOCS)-1 and 3 (325)are also detectable in the inflamed 
synovial compartment. It is thought that levels of these cytokines are sub optimal 
for biological effectiveness and that this resulting disequilibrium between 
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proinflammatory and anti-inflammatory cytokines leads to inflammation and 
subsequent joint damage. 
Chemokines (CKs) 
CKs are low molecular weight (8-14Kd) structurally related, secreted or 
membrane bound proteins, that function as cell attractants. More than 50 human 
CKs have so far been characterised, along with 18 receptors (326; 327). The binding 
of a CK on to its cognate receptor can induce a wide spectrum of effects, including 
the arrest and firm adhesion of blood-borne cells on endothelial surfaces and the 
transendothelial migration into tissues. CKs in particular allow leucocytes to 
circulate from the bloodstream to specific organs and move inside these tissues in 
a programmed fashion through spatial and temporal successions of CK 
gradients(328) but they can also participate in cell activation and are intimately 
involved in angiogenesis(329). CKs are produced in two main ways both 
constitutively and following up regulation in the context of inflammatory 
reactions. 
Secondary lymphoid organs are among the best anatomical sites where the 
constitutive expression and role of CKs have been studied. Under homeostatic 
conditions T and B lymphocytes circulate from the blood stream to secondary 
lymphoid organs, but only a selected few (mainly naive lymphocytes) are allowed 
to extravasate into the lymphoid tissues, via HEVs. This selectivity is due to the 
interaction between specific CK-Rs expressed by lymphoid homing cells and CKs 
constitutively expressed in secondary lymphoid organs for example the CK and 
CK-R pairings CCR7-CCL21 and CXCR5-CXCL13(330; 331). Lymphoid CKs 
have a central role in both the formation and maintenance of embryonic lymphoid 
structures(332) directing specific leukocyte populations to discrete compartments 
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and favouring interactions between distinct cell populations (e. g. DCs and T 
cells(333)). 
The main focus of interest in lymphoid CKs and RA arises from the relationship 
observed between chronic inflammation and ELN (217). Recent observations have 
demonstrated that the lymphoid neogenetic process is associated with the ectopic 
production of lymphoid-constitutive CKs, such as CXCL13 and CCL21, which are 
constitutively produced in the B and T cell rich areas of secondary lymphoid 
organs, respectively(334; 335). Importantly, lymphoid CKs have been shown to be 
powerful lymphoid tissue morphogenetic factors capable, when over expressed 
ectopically in the pancreas of transgenic mice, to act upstream in the process of 
lymphoid neogenesis(336). 
The expression of both CXCL13 and CCL21 have been shown to be critical to the 
process of ELN within the rheumatoid synovial membrane, with data 
demonstrating production in minor and unstructured aggregates (334) and further 
the demonstration by Weyand et al (217) that both these CKs (together with LTß) 
can predict the presence of different levels of organizational structures in patients 
with RA. 
Other CKs constitutively produced in secondary lymphoid tissues, such as CCL19 
and CXCL12, have been shown to be induced or up regulated in RA synovium. 
CCL19 involved together with CCL21, in the recruitment and localisation of 
CCR7+ lymphocytes and mature DCs within secondary lymphoid tissue T cell 
areas, has been found to be expressed at high levels by dendritic cells of RA 
patients with active disease. In addition CCL19 mRNA has been found to be 
expressed at increased levels in synovial tissue from RA patients than those with 
OA(337). 
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The participation of CXCL12 and its receptor (CXCR4) in the pathogenesis of RA 
has been previously suggested by several studies that have reported an up 
regulation of CXCL12 in RA synovium and a role for the ligand/receptor system 
in local leukocyte attraction(338) and further by in vivo data demonstrating that 
when CXCL12/SDF-1 is injected into human synovial tissue grafts implanted into 
SCID mice, U937 monocytoid cell recruitment from the bloodstream is 
promoted(339). Further CXCL12/SDF-1 is a TNFa independent CK(340) and its 
persistence in the synovia of patients treated with anti-TNFa suggests that it may 
be involved in alternative pathways mediating synovitis in RA(341). 
RA synovium has been shown to contain a complex mixture of other 
inflammatory-inducible CKs including CCL2(342), CCL3(343), 
CCL5(344), CXCL1O(345), CXCL9(346), CXCL6(347) and CXCL5(348) 
functioning in the recruitment of effector cell population such as neutrophils and 
activated T cells. 
In addition, CK and CK-Rs are also known to be involved in the migration of 
DCs, draining antigen from peripheral tissues, to secondary lymphoid organs 
where the priming and activation of naive lymphocytes takes place and similar 
mechanisms of up and down regulation of CKs and CKRs are thought to act in 
recruiting antigen presenting cells such as immature DCs from the blood stream to 
the inflamed joint and in the migration of primed mature DCs to the local lymph 
node. 
While, as mentioned above, CXCL12/SDF-1 appears to be produced 
independently from TNFa, the production of many inducible CKs is mostly 
regulated by inflammatory cytokines such as IL-1 and TNFa, known to play a 
critical role in synovial inflammation, via processes (amongst others) of 
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angiogenesis, integrin activation, chemotaxis and release of other mediators (e. g. 
MMPs). 
CXCL8/IL-8 is one of the best studied inflammatory CKs. It is produced by 
macrophages in the synovial compartment(349) and by fibroblasts following 
stimulation with IL-la, IL-1(3, TNFa or LPS (350). CXCL8/IL-8 has been shown 
to induce synovial inflammation in animal models (351)and to be up regulated in 
RA, specifically in affected joints(352), with its levels in the sera of RA patients 
correlating with disease activity(349). Furthermore, CXCL8/IL-8 is a potent 
mediator of angiogenesis and this function that has been demonstrated also in the 
RA joint(353). 
As mentioned, several other inflammatory CKs have been found to be up regulated 
in the serum, synovial tissue or synovial fluid of RA patients. However, given the 
nature of human studies most data elucidating the exact dynamics of inflammatory 
CK production and function has been established in animal models of arthritis. In 
rat adjuvant induced arthritis (AIA) higher levels of CCL3/MIP-la were shown 
early in the course of the disease and higher levels of CCL2/MCP-1 predominantly 
in the later stages(354) 
Other specific functions of CKs have been elucidated and they include the role of 
CXCL1/GROa in RA, which has recently been suggested as a potent stimulator 
for release of BAFF from neutrophils(355). Further, CXCL4/PF-4 is known to 
play a role in angiogenesis and has been suggested as a marker of RA associated 
vasculitis(356). 
Although there are many animal studies demonstrating the possibilities of 
manipulation of the CK system as therapy in RA, there has only been one 
published clinical trial investigating the effect of CCR2 inhibition on RA and this 
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demonstrated a lack of effect on clinical response or synovial biomarkers(357). 
This lack of response, as well as little further published data, is potentially due to 
several limitations including; the difficulty in using the prophylactic approach in 
arthritis prevention in humans; the fact that many CKs and receptors are species 
specific and the possibility that some ligands may act as agonists at one receptor 
and antagonists at another. 
The rheumatoid joint 
Histopathology of the synovial membrane 
The normal synovial membrane 
The normal synovial membrane covers the inner surface of joints and is a 
relatively acellular structure approximately 0.5-5mm thick. It consists of a loosely 
organised intimal lining layer 1-2 cells deep and a thicker sublining connective 
tissue layer. The lining layer is composed of 2 cellular subtypes: 1) Type A the 
macrophage-like synoviocyte and, 2) type B the fibroblast-like 
synoviocyte(358; 359). The sublining layer consists of a matrix of collagen, 
fibronectin, lamin and proteoglycan interspersed with macrophages, adiopocytes 
and type B fibroblasts(360). The synovium functions to produce synovial fluid 
through the production of hyaluronidan, lubricin and surface-active phospholipids, 
synthesised by both types of fibroblasts(361-363). Thus the synovial membrane 
and synovial fluid enables joint protection, lubrication and a facility by which 
nutrients can be transported to the joint cartilage and debris can be cleared(364). 
The synovial membrane in rheumatoid arthritis 
RA synovium, in comparison to that found in normal joints, has a transformed 
phenotype, with the ability to aggressively invade adjacent bone and cartilage. 
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Macroscopically the synovium appears thickened and hyperaemic with fronds of 
tissue within the joint. Microscopically the intimal lining layer is thickened to a 
depth of around 8 cells(365) and is associated with a cellular infiltrate of the 
sublining layer with pronounced angiogenesis. The predominant cellular infiltrate, 
accounting for up to 80% of cells of the sublining layer is type A fibroblasts which 
have been identified as infiltrating rather than proliferating cells originating from 
the bone marrow(366-368). This inflamed synovium is named pannus and at the 
interface with bone and cartilage multinucleated cells with an osteoclast phenotype 
appear and it is these that mediate the associated bone and cartilage destruction 
(Figure 10). Macrophages and synovial fibroblasts also release matrix 
metalloproteinases (MMPs), aggrecanases and serine proteases that digest collagen 
and proteoglycans degrading the extracellular matrix. This hyperplastic synovium 
is associated with an increased volume of synovial fluid with a hypercellular 
infiltrate consisting of largely polymorphonuclear cells, but also mononuclear 
cells, dendritic cells (DCs), T cells, B cells and natural killer cells as well as 
cellular and matrix debris(369-374). 
The marked angiogenesis seen within the sublining layer is known to be a 
prominent feature of early synovitis and thus permits the transfer of oxygen, 
nutrients and inflammatory cells to the synovium. The stimulus for angiogenesis is 
thought to be increased metabolic demand and hypoxia. A range of growth factors, 
cytokines and chemokines are known to influence angiogenesis within the 
synovial membrane and in particular vascular growth endothelial factor (VGEF) 
has been demonstrated to be expressed within both synovial tissue and fluid from 
RA patients. Further fibroblast 1 and 2 growth factors, platelet derived growth 
factor and hepatocyte growth factor have all been found to be expressed within 
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synovial tissue (reviewed in (375; 376)). The importance of angiogenesis in 
permitting synovial inflammation in RA has been further emphasised by the 
success of pro-angiogenic blockade in animal models of arthritis, for example with 
a soluble receptor for VEGF in the collagen induced arthritis (CIA) model(377). 
Finally the expression of angiogenic inhibitors in RA such as endostatin and 
thrombospondin 1 and 2 suggests that the hyperaemic synovium may well be a 
result of an imbalance between angiogenic promoters and inhibitors(378-380). 
The cellular infiltrate in RA is composed of mononuclear cells, including CD4+ 
and CD8+ T cells, plasma cells, B cells, NK cells, monocytes, mast cells and DCs. 
The cellular infiltrate is recruited via the expression of a number of adhesion 
molecules on endothelial cells, including E-selectin, ICAM-1 and VCAM-1(381). 
The organisation of lymphocytes into aggregates, a process termed ectopic 
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Figure 10: The synovial membrane in rheumatoid arthritis 
In the normal knee joint, the synovium consists of a synovial membrane (usually 
one or two cells thick) and underlying loose connective tissue. Synovial-lining 
cells are designated type A (macrophage-like synoviocytes) or type B (fibroblast- 
like synoviocytes). In early rheumatoid arthritis, the synovial membrane becomes 
thickened because of hyperplasia and hypertrophy of the synovial-lining cells. An 
extensive network of new blood vessels is formed in the synovium. T cells 
(predominantly CD4+) and B cells (some of which become plasma cells) infiltrate 
the synovial membrane. These cells are also found in the synovial fluid, along with 
large numbers of neutrophils. In the early stages of rheumatoid arthritis, the 
synovial membrane begins to invade the cartilage. In established rheumatoid 
arthritis, the synovial membrane becomes transformed into inflammatory tissue, 
the pannus. This tissue invades and destroys adjacent cartilage and bone. The 
pannus consists of both type A and type B synoviocytes and plasma cells. 
Reproduced with permission from (382) 
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Ectopic lymphoneogenesis (ELN) in rheumatoid arthritis 
In a number of autoimmune diseases, including Sjogren's syndrome, Hashimoto's 
thyroiditis and myasthenia gravis, as well as RA, the lymphocytic infiltrate of the 
target organ can become organised into GC-like structures(383). In RA the 
localization of T and B lymphocytes forming discrete perivascular clusters in the 
synovium is highly variable and can be the prominent picture in a subset of 
biopsies as well as in extrasynovial compartments such as the bone marrow 
(384; 385) and the lung (386). Histomorphometric analysis adopted by the group of 
Professor Pitzalis and others based on the aggregate radial cell count has led to the 
development of a grading system (G1,2, and 3) that has been used to investigate 
the relationship between microanatomical variables, cellular-molecular pathways 
involved in lymphoid organization and their link with clinical outcomes(334; 387- 
391). Using this system, recent studies in large cohorts of consecutive patients, 
analyzed at a single time point, have demonstrated a variable but consistent 
presence of synovial T-B lymphoid aggregates in approximately 30% (Grade 2-3, 
n= 103) (53) and 73% (Grade 2-3, n= 86) (387) of the specimens after 
arthroscopic biopsy in active knees, while they were detected in 44% (n = 64) of 
joint replacement samples in late stage arthritis(217). Although these data cannot 
be directly compared due to the different methods of analysis, previous studies 
performed in a single centre by the group of Bresnihan indicate the existence of a 
significant difference in the presence of lymphoid aggregates between bioptic 
specimens (36%, n= 29) and samples from joint replacement surgery (68%, n= 
22) (392). These latter results suggest that these parameters may be influenced by 
the disease stage or by sampling procedures. It should also be noted that the 
characteristics of the inflammatory infiltrate in the joint might be influenced by the 
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historical period of sample collection. As effective treatment can modify synovial 
histology, the recent introduction of tight control and more aggressive regimens in 
early disease stages should be considered as an additional variable. 
Whether this concept, proposed in a recent review article by Brennan and 
McInnes(205) can be applied to the prevalence of synovial lymphoid architecture 
in different cohorts remains to be proven. As the presence of lymphocyte clusters 
does not necessarily imply the organization of TLS, a critical issue is whether the 
process of lymphocyte aggregation in the synovium merely represents a 
disorganized accumulation of circulating cells or whether it can lead to a specific 
reprogramming phenomenon (lymphoid neogenesis) leading to the acquisition of 
structural and functional features constitutively involved in secondary lymphoid 
tissue immunological response (TLS organization). 
The recognition however, that lymphoid neogenesis takes place within a 
proportion of ectopic lymphoid clusters in human diseases(383) has led to the 
hypothesis that the process may be controlled by reactivation of pathways 
physiologically involved in secondary lymphoid organ embryonic development 
and adult homeostasis(393). Among the factors involved in these processes, a 
central role is played by the lymphoid chemokine CXCL13 and the CCR7 ligands 
CCL21 and CCL 19. These molecules, which are constitutively produced in the B- 
and T-cell rich areas of adult secondary lymphoid tissues, respectively, are 
induced prenatally in subsets of VCAM-1+ICAM-1+LTbR+ embryonic 
mesenchymal cells (defined `organizer cells') in the lymphoid anlagen and are 
essential for the local recruitment of CD3/CD4+IL-7R+RANK+ embryonic 
haemopoietic cells (defined `inducer cells'). Inducers cells, whose survival, 
differentiation, and expansion is supported by other signals, including IL-7R 
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ligands and RANK-L, provide the pivotal source of the TNF family member LTß 
which is in turn required for HEV differentiation, lymphoid chemokine expression 
amplification, and stromal architecture development (332) (Figure 11 A). 
Although the requirement of conventional `inducer-organizer cell' interactions in 
the mechanisms of adult ectopic lymphoid neogenesis is debated(394) , the 
possible activation of similar molecular pathways in RA has been proven by gene 
expression studies demonstrating that CXCL13, CCL19 and CCL21 can be 
aberrantly up regulated in the synovium, in association with increased expression 
levels of LTD, of genes related to the IL-7 signalling pathway, and that these 
systems are in turn linked with the presence of tertiary lymphoid structures (TLS) 
(217; 317). Functional evidence of the ectopic morphogenetic potential of 
CXCL13, CCL21, and CCL19 is provided by over expression experiments in 
normal mice demonstrating that these factors are sufficient to promote downstream 
organization of lymphoid tissue in the pancreas (336; 395) and thyroid (394). This 
process, whose developmental steps have been dissected in neo-forming clusters of 
progressively increasing size in CXCL13 transgenic animals(336), has been 
proven to be dependent on LTß delivered by incoming B lymphocytes and by the 
number of clusterising cells. In keeping with these findings, by examining through 
a grading system of lymphoid aggregate size, the inflammation-induced process in 
humans, the synovial environment has been demonstrated to be able to acquire 
specific lymphoid-like features, such as the formation of high endothelial venules 
(HEV), the enrichment of T and B cells in partially separated areas, the 
differentiation of follicular DC (FDC) networks and the local synthesis of 
homeostatic chemokines, and that these processes are linked with the formation of 
ectopic lymphoid tissue and with the local enrichment of B cells(334). As 
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lymphoid neogenesis is invariably activated in aggregate tissues and most of the 
synovial clusters lack complex lymphoid structural features (334), the same studies 
also demonstrated the relationship between chemokine expression and different 
degrees of lymphoid arrangement in situ. This work demonstrated that in an 
ectopic setting, CXCL13 and CCL21 can be synthesized both in the context of 
highly organized structures, with a trend to segregate with FDC, B and T cells, as 
well as in minor organizational stages, devoid of FDC networks and with 
intermixed lymphocyte distribution(334). Thus, under inflammatory conditions in 
humans, reprogramming of lymphoid molecular pathways can associate with 
reprogramming of cellular and structural features reminiscent of conventional 
lymphoid organs while lymphoid chemokine expression can be regulated 
independently from and possibly upstream of TLS organization, as has been 
shown during murine embryonic development and in experimental systems. 
Confirming the possibility that ectopic CXCL13 production can be independent of 
GC-localized FDC (considered the main source of this factor inside synovial 
lymphoid aggregates), it has been recognized that different subsets of 
haemopoietic cells such as monocyte-macrophages (396) and antigen-experienced 
CD4+ T lymphocytes(397) are capable of expressing CXCL13 in the joint, 
emphasising that both the innate and adaptive immune systems could play a 
critical role of in the organization of TLS. These data, together with the 
recognized absence of primary follicles in the synovial environment(217) (55,62), 
raises the possibility that the organizational process inside synovial aggregates, 
rather than being exclusively controlled by infiltration and aggregation-driven 
events, might be also dynamically influenced by the local immunological 
environment, as is the case with inducible lymphoid tissues(398) Figure 11 B). 
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Vascular remodelling in synovial lymphoid aggregates 
Beside their role in lymphoid tissue structural organization, lymphoid chemokines 
are also instrumental in regulating constitutive trafficking of naive and central 
memory T-B lymphocytes, a fundamental functional platform for homeostatic 
immune surveillance. Mechanistically, lymphocyte homing to LN is mainly 
sustained by the sequential binding of naive lymphocyte expressed L-selectin to 
peripheral node addressins (PNAd) on HEV, followed by firm adhesion and 
transmigration promoted by the activation of the lymphocyte chemokine receptor 
CCR7 by its locally expressed ligands CCL21 and CCL19. The same factors have 
been shown to be instrumental in the recruitment of CCR7+ mature DCs from 
afferent lymphatics, in their intra-tissue positioning in the T-cell-rich area, and in 
the establishment of the T-DC immunological synapse(399). Although this 
molecular apparatus is normally absent outside lymphoid tissues, several studies 
have demonstrated that both in RA and spondyloarthropathies, the inflamed 
synovial vasculature can undergo molecular remodelling with the acquisition of 
features typical of peripheral LN, such as high endothelial morphology and 
luminal expression of PNAd (334; 387; 400-402). These data have been confirmed 
by subsequent reports showing co-localization of synovial PNAd with the HEV- 
restricted sulfotransferase G1cNAc6ST-2 (also known as HEC-G1cNAc6ST, GST- 
3, LSST, or CHST4), an essential enzyme for the elaboration of L-selectin 
functional ligands as well as a critical epitope recognized by theMECA-79 
monoclonal antibody(403). 
To investigate further whether the molecular requirements for homeostatic 
lymphocyte trafficking can be re-programmed in the synovium, the characteristics 
of synovial ectopic HEV in relationship with chemokine expression have recently 
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been analyzed(50). These studies confirmed that a proportion of synovial HEV 
inside lymphoid aggregates can co-express PNAd in association with 
periendothelial synthesized CCL21, a distribution characteristic of human 
secondary lymphoid tissues (334; 396). Intraaggregate expression of CCL21, 
detected in about 40% of Grade 3 synovial clusters and in the majority of the 
samples with Grade 3 lymphoid aggregates, was mainly found to co-localize with 
smooth muscle actin (SMA)+ CD45) myofibroblast-like stromal cells(404), a 
phenotype that has been demonstrated in independent studies to identify the 
cellular source of CCL21 in human and murine LNs(404; 405). Collectively, these 
studies demonstrate the potential of the synovial stroma to re-program and acquire 
features of the vascular homing apparatus involved in lymphocyte homeostatic 
trafficking both at the morphological, cellular and molecular level, and that a 
vestige of the T-cell area of secondary lymphoid organs can form at ectopic sites. 
DC-T-cell immunological synapse 
Despite the above discussed similarities, synovial lymphoid aggregates can show 
appreciable differences from secondary lymphoid organs including the frequent 
absence of a complete T-B-cell segregation (often cells are interspersed) and a 
significantly lower number of SMA+ CCL21-expressing cells, with expression 
often limited to occasional cells within poorly demarcated T-cell-rich 
areas(334; 404; 406). Whether these qualitative and quantitative differences 
determine an altered functionality in terms of cellular recruitment and 
immunological activation is unclear. Previous studies from Miossec's group (407) 
demonstrate that despite the well-known enrichment of immature DCs (typically 
found in inflamed tissues) in the synovium compared to secondary lymphoid 
tissues, CCR7+DC-LAMP+ mature DCs are positioned specifically within 
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lymphoid aggregates co-localizing with intra-aggregate expressed CCR7 ligands. 
These data, confirmed in a further independent cohort (404), suggest that synovial 
lymphoid aggregates might actually acquire the potentiality to retain mature DCs 
through the establishment of chemokine gradients, creating a favourable 
environment for local antigen presentation. Additional evidence has been provided 
by Baeten et al. (408), who demonstrated that despite the increased alterations in T- 
cell receptor CDR3 length distribution associated with diffuse synovitis, the HLA 
DR4-complexed cartilage autoantigens gp-39 is presented in the synovium by 
subsets of DC co-localizing with ectopic lymphoid aggregates (409). Although 
direct proof that T-APC immunological synapses are established within the 
synovium and in synovial follicles is missing, recent transcriptional screenings of 
RA synovium demonstrated a relationship between the presence of TLS and gene 
signatures related to T-cell receptor signalling and co-stimulatory pathways 
involved in T-cell activation (317). Whether naive lymphocyte priming(402) can 
contribute to these molecular traits or whether the synovial environment represents 
a `privileged' niche for re-activation of antigen-experienced T cells (the main 
component of lymphoid aggregates)(410) and amplification of secondary 
responses, is unknown. 
Class-switch recombination and somatic mutation: role of activation-induced 
cytidine deaminase 
Physiologically, antigen-driven antibody responses take place within GCs of 
secondary lymphoid tissues where the processes of somatic hyper mutation (SHM) 
and class-switch recombination (CSR) of the Ig genes in GC-B cells occur which 
lead to affinity maturation and differentiation to memory B and plasma cells (81, 
82). It has now been clarified that both SHM and CSR are initiated by and 
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critically dependent on the expression of the enzyme AID (197). Although the 
exact mechanism of action of AID has not been fully elucidated, AID initiates 
SHM by introducing single point mutations in WRC (W = A/ T, R= A/ G) motifs 
hot spots within the Ig variable genes, which encode for the antigen-binding region 
of the antibody (199; 411). This process results in affinity maturation occurring 
through cycles of antigen-dependent selection within the GC. In addition, AID 
regulates CSR via its carboxyterminal region(412) by inducing double-strand 
breaks and recombination of Ig switch regions of DNA followed by excision of 
switch circles within the constant heavy-chain region. Ig class switching from IgM 
and IgD to IgG, IgE, or IgA profoundly influences antibody biological functions 
dramatically enhancing their effector capacity(413). In the mid-90s, several groups 
- by performing analysis of the V-gene repertoire from total RA synovial RNA 
extracts or from follicular structures microdissected from RA synovium - provided 
clear demonstration that a significant proportion of B lymphocytes accumulating 
within the synovial membrane of RA patients display an oligoclonal repertoire 
with highly mutated V regions, compatible with a local antigen-driven GC like 
reaction(414; 415). These data provided strong indirect evidence that RA synovium 
can support in situ diversification and expansion of B-cell clones. However, the 
definite proof that synovial lymphoid follicles can actively sustain the molecular 
machinery responsible for affinity maturation and class-switching has been lacking 
and has been challenged by recent analyses in whole tissue extracts reporting the 
lack of direct relationship between lymphoid aggregates, B-cell clonal expansion 
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Figure 11(A): Physiological lymphoid organogenesis. 
The initial step of lymphoid organ development involves the interaction of 
hematopoietic lymphoid tissue `inducer cells' with stromal `organizer cells'. 
Triggering of LTßR leads to the production of lymphoid chemokines CXCL13, 
CCL21, and CCL19. Chemokines induce accumulation of further hematopoietic 
cells that, upon interaction with stromal cells, determine the formation of a 
positive feedback loop via increased signalling through LT3R and up regulation of 
lymphoid chemokines. This phenomenon leads to the progressive formation and 
enlargement of lymphomononuclear cell clusters, with the differentiation of a 
mature stromal architecture and high endothelial venules (HEVs). Adapted from 
(332). 
(B): Development of tertiary lymphoid structures in RA synovium. 
Initial recruitment of lymphocytes in the sublining of the RA synovial membrane 
displays a disorganized accumulation of T (predominantly) and B cells around a 
central blood vessel (Gi / G2 aggregate, top left). The increasing size of the 
aggregate is accompanied by variable up regulation of key molecules regulating 
lymphoid organogenesis and homeostasis in physiological conditions, such as LTß 
and lymphoid chemokines CXCL13, CCL21, and CCL19. At this stage, CXCL13 
can be produced by a subset of antigen (Ag)-experienced T lymphocytes, by newly 
recruited monocyte-derived cells and differentiated stromal cells. Conversely, 
CCL21 is expressed by smooth muscle actin stromal cells surrounding new HEVs. 
Expression of lymphoid chemokines can lead to initial T/B cell 
compartmentalization, increased accumulation of LTß+ hematopoietic cells 
promoting further differentiation/ proliferation of stromal and vascular cells (G3 
aggregate, bottom left). Amplification of this process in the context of an Ag-rich 
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environment can lead (through T-cell dependent or T-cell independent 
mechanisms) to the formation of functional GC-like ectopic lymphoid structures 
characterized by differentiation of follicular dendritic cell (FDC) networks (CD2 1) 
and possibly activation induced-cytidine deaminase (AID) positive B cells, 
variably associated with other lymphoid structural features (CD3, T cells; CD20, B 
cells) (G3 aggregate, right). Microphotographs reproduced from(417). 
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Pathogenic relevance 
The production of autoantibodies by the synovial membrane has been 
demonstrated by a number of studies, in particular the observation that anti-CCP 
antibodies can be detected in the sera of SCID mice transplanted with RA 
synovium(418). Furthermore their detection within synovial fluid (419)and their 
demonstrated concentration at this site(420) suggests local autoantibody 
production. These data is further supported by clinical reports correlating 
lymphocytic aggregates within the synovial membrane with the presence of RF in 
the sera(421) and with the detection of ANAs in patients with JIA(422), suggesting 
a direct role for them in disease pathogenesis as the site of the production of 
autoantibodies. This is not the only work suggesting that ectopic GC maybe 
functional, an analysis of the IgH V gene repertoire of B cells microdissected from 
these structures demonstrated intraclonal diversity strongly suggesting an ongoing 
antigen driven B cell differentiation within these structures(423). However, all 
these observations have been questioned by two recent studies. The first(388) 
performed on synovial tissue obtained arthroscopically from 103 patients found 
not only a much lower incidence of ELN (8%) (as defined by the presence of 
FDCs) , 
but further no association between lymphocytic aggregates and the 
presence of autoantibodies (RF and anti-CCP) in the sera. The authors did observe 
higher levels of inflammatory markers and general synovial inflammation in 
patients with lymphocytic aggregates but did not observe increased severity of 
clinical symptoms and signs. The second study(416) investigated the association 
between ELN and the production of autoantibodies by correlating the presence of 
ELN within synovial tissue from 112 RA patients with the detection of 
autoantibodies (RF and anti-CCP) in both the sera and synovial fluid and 
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suggested that the lack of correlation seen did not support functionality of ELN. 
Interpretation of these result should consider that no conclusive data are available 
that determines whether ELN is stable throughout the disease process, and its 
heterogeneity both within and between joints. This is of crucial importance when 
studying small samples of material from one joint from a single time point and 
extrapolating this to explain pathogenic effects at different time points or 
distribution within the body. A point reinforced by data supporting functionality 
of lymphocytic aggregates by demonstrating their association with autoantibodies 
when examined locally within synovial tissue(424). 
The observation by Klimiuk et al (425) that pathological subtype of the synovial 
membrane correlated with clinical phenotype suggested a direct role for these 
structures in disease pathogenesis. This study demonstrated a significant 
association with the presence of lymphocytic aggregates and higher disease 
activity (measured by DAS, ESR, CRP and number of swollen joints) and erosive 
damage in comparison to patients with a diffuse infiltrate. This clinical association 
may not only be explained by the local production of autoantibodies but by the 
differential expression of a number of key cytokines within tissue containing 
ELN(421). 
Thus, whether the synovial membrane acts as a reservoir for long lived plasma 
cells or whether it is actively involved in the manufacture of autoantibodies and 
furthermore whether it is actively involved in mediating other pathways of RA 
pathogenesis is currently controversial(426). 
joint erosion 
The pannus mediated degradation of cartilage and bone is thought to be primarily 
driven by the release of proteolytic enzymes by macrophages and fibroblasts. 
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MMP-1 expression within synovial tissue, fluid and within sera has been 
correlated to the development of erosions in both early and established 
RA(427; 428). MMP3 has similarly been detected at elevated levels in the synovial 
fluid and sera of RA patients(429). 
Bone resorption and hence erosion is determined by osteoclast formation and 
activation. The formation of osteoclasts from monocyte/macrophage precursors is 
primarily driven by two factors macropage colony stimulating factor and receptor 
activator of nuclear xß Ligand (RANK-L), both of which are up regulated by IL-I 
and TNF-a(430; 43 1). Further, the relative levels of RANK-L along with its natural 
inhibitor osteoprotegerin (OPG) are known to determine osteoclast activity in RA, 
with increased ratios of RANK-L to OPG seen within the RA joint(432). 
This crucial role for RANK-L in RA pathogenesis has been harnessed for 
therapeutic intervention with the use of RANK-L inhibitors, which have shown 
demonstrated efficacy in preventing ongoing erosive damage(433). 
The synovial membrane as a prognostic marker in rheumatoid arthritis 
The use of the synovial membrane as a potential prognostic tool has received 
attention since its recognition as the primary site of inflammation in RA. Early 
work on the pathological appearance demonstrated some characteristic features 
such as the expansion of the synovial lining layer, palisading of the synovial 
cells(434), the presence of multinucleated giant cells (435), the tendency of the 
lymphocytic infiltrate to form follicular structures(335) and haemosiderosis(436), 
but none of these appearances were found to be specific for RA and hence could 
not be used as diagnostic criteria. The subsequent development of IHC, combined 
with specific recognition of novel markers by monoclonal antibodies, has allowed 
the demonstration of a diverse cellular infiltrate within the RA synovial 
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membrane, with qualitative differences in histological appearances and 
quantitative variations in cell types between sub-groups of RA patients, differing 
in both prognosis(437) and response to treatment(438-442). In addition, the 
microscopic changes of the synovial membrane have been demonstrated in 
clinically uninvolved joints(443) suggesting that the more accessible knee joint 
could be a valid source of tissue in most patients. Technically the advent of new 
methodologies for the acquisition of SM, such as ultrasound guided needle biopsy, 
provides means that allow for the feasible acquirement of synovial tissue in a 
broader range of clinical settings. Added to this progress has been the arrival of 
digital image analysis (DIA), which allows rapid semi automated processing of 
tissue and has revolutionised the examination of the synovial membrane. The 
validation of DIA has shown it to be not only equivalent to the gold standard of 
manual counting(444) but more sensitive to changes within the synovial 
membrane than semi-quantitative analysis(445). Put together these advances 
illustrate the realistic potential of the synovial membrane as a prognostic marker in 
RA. 
Current histopathological scoring systems 
Early work on arthroscopically obtained synovial membrane did not suggest a 
promising correlation between the histological appearance of the SM and clinical 
features of disease(446; 447), but subsequent studies on both arthroscopically and 
arthroplastically obtained synovial membrane have produced more positive results. 
An association between the presence of synovitis and degree of histological 
inflammation, as measured by 2 separate semi-quantitative inflammatory scores 
(the Rooney and the Tak score), was demonstrated in patients with early or 
established RA(447-449). The Rooney score(447; 448) which assesses 6 
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histological features of the SM (synoviocyte hyperplasia, fibrosis, proliferation of 
blood vessels, perivascular infiltrates of lymphocytes, focal aggregates of 
lymphocytes and diffuse infiltrates of lymphocytes), has also been assessed in a 
prospective study, involving 60 patients with established RA, but this failed to 
show its use as a prognostic marker as no correlation was seen with joint damage 
progression over a 2-year period (176; 447). A further semi-quantitative 
histological scoring system was initially developed by Koizumi et al. (447; 450) to 
allow reliable differentiation of RA and OA synovium, it examines 8 histological 
features of the synovial membrane. When this score was examined in a cross 
sectional study in end stage RA(447; 451)a significant correlation was found with 
the degree of erosive damage and levels of CRP, this study also found no 
significant correlation between the Rooney score and clinical features including 
erosive damage. The Koizumi score, to the best of our knowledge, has not been 
tested in a prospective study looking at erosive progression. In the quest for the 
identification of predictive biomarkers, macrophage numbers have received much 
attention, since an early study showed they correlated with the degree of pain (as a 
surrogate for arthritis activity) in the biopsied knee, in comparison to the number 
of CD4+ T cells(449) which did not. A further study, looking at T cell infiltration 
within the SM did show that an improvement in a composite clinical index of 
disease activity correlated with a decrease in T cell infiltration within the synovial 
membrane(447; 452). A small prospective study of 12 patients with RA 
demonstrated an association between the intensity of macrophage numbers at 
baseline with erosive damage (453) and this finding was replicated in a later larger 
study involving 26 patients followed for a mean of 5.8 years(437). The number of 
sub lining macrophages has also been correlated with the clinical course of RA and 
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response to treatment (454). In early arthritis matrix metalloproteinase-1 gene 
expression (MMP-1) correlated with the development of erosions in a study 
involving 20 patients, 12 of which had RA (427). In this study macrophage 
number again correlated with MMP-1 expression and erosive damage over 1 year. 
A second larger study, however, has not confirmed the usefulness of macrophage 
numbers in predicting outcome in early arthritis(455), suggesting numbers of 
granzyme B+ cytotoxic cells, T cells, and FLS as better correlates of erosive 
damage, the authors suggested patient selection and trial numbers as reasons for 
these conflicting results. 
Current therapies for rheumatoid arthritis 
In recent years the goal of treatment in RA has been to achieve disease remission, 
which is an achievable goal currently in around 20-40% of patients with early 
arthritis, but a more difficult aim in those with established disease. The most 
commonly used DMARDs are methotrexate, sulphasalasine and 
hydroxychloroquine and evidence now overwhelmingly supports the use of these 
drugs in combination in early RA to prevent the progressive erosive damage that 
equates with disability(456-459). Alternative DMARDs include leflunomide, a 
specific pyrimidine inhibitor developed for use in RA. In addition therapies such 
as gold, cyclosporine and azathioprine are being used with much less frequency, 
due to a comparative lack of efficacy and poor side effect profile. 
The advent of biologic therapies, however, has revolutionized the treatment of RA. 
Currently the most commonly used biologic therapies inhibit TNF: infliximab 
consists of a chimeric antibody to TNFa, adalumimab a humanised antibody to 
TNFa and etanercept consists of a TNF- receptor fusion protein that binds LT in 
addition to TNF. Data from a number of studies now support the use of anti-TNF 
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therapy in combination with methotrexate for maximal therapeutic efficacy and 
importantly the advent of anti-TNF therapy has demonstrated the realistic 
possibility of clinical remission (460-464). 
A more recently developed biologic therapy, abatacept, has a licence for use in 
RA. It inhibits T cell activation via the inhibition of the CD28-CD80/CD86 co- 
stimulatory pathway and consists of a recombinant fusion protein comprising 
CTLA4 linked to a modified Fc portion of human IgGi. Trials have demonstrated 
it to be efficacious in combination with methotrexate in patients known to have 
failed anti-TNF therapy, the ATTAIN study(465), as well as biologic naive 
patients and further to have superior efficacy when compared to infliximab, the 
ATTEST study(466). 
The use of B cell depletion therapy in RA is discussed on page 112 along with the 
more recent development of agents aimed to modulate B cell survival and 
activation. In addition there are a number of drugs either in development or newly 
licensed that aim to interrupt critical cytokine pathways involved in RA 
pathogenesis, and these are discussed within Cytokines (page 64). 
B cells in rheumatoid arthritis 
The presence of autoantibodies such as RF and anti-CCP in the sera of RA patients 
has long suggested a role for B cells in the pathogenesis of RA, and a central role 
in disease pathogenesis has now been confirmed by the demonstrated efficacy of 
the B cell depleting agent rituximab (467). It is now recognised that the role of B 
cells is not just limited to autoantibody production, but that they are efficient 
antigen presenting cells, mediators of T cell activation and producers of pro 
inflammatory cytokines. 
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Autoantibodies in rheumatoid arthritis 
Rheumatoid Factors (RFs) 
RF was first described in 1940 by Waaler (11) and as such RA was the first 
characterised autoimmune disease. RFs are antibodies directed against the Fc 
portion of IgG and are relatively sensitive markers of RA, but lack specificity 
being detected in up to 10% of healthy individuals as well as in other 
inflammatory diseases such as Sjogren's syndrome and SLE as well as in 
infections such as TB. RFs produced outside the context of RA however are 
generally of low affinity and lack the characteristic high ratio of replacement to 
silent mutations seen within CDRs of antibodies having undergone affinity 
maturation. It is thought that these RFs are produced primarily by CD5+ B cells. In 
comparison, work isolating RF producing B cells from rheumatoid synovium has 
demonstrated a high ration of replacement to silent mutations thus suggesting that 
these antibodies have undergone aT cell dependent affinity maturation 
process(468; 469). 
RF has been demonstrated to be capable of enhancing tissue destruction in RA, by 
the formation of immune complexes and subsequent complement fixation. 
Furthermore the ability of RF producing B cells to recognise, process and present 
antigen that would otherwise not be recognised by T cells theoretically could lead 
not only to the recognition of self as auto antigens but the perturbation of the 
inflammatory cascade by the development of the autoreactive B cell (Figure 12). 
Moreover, high titres of RF associate with a higher degree of erosive damage 
(150; 470)and thus there is a clinical indication that they may be directly involved 
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Figure 12: Self perpetuating B cells 
IgG rheumatoid factor (RF)-secreting B cells provide the simplest example of 
how autoreactive B cells might become 'self-perpetuating'. A B-cell receptor 
(BCR) specific for IgG (RF) can mediate the endocytosis of foreign antigens and 
acquire help from T cells specific for such antigens following antigen presentation. 
Soluble IgG RF can polymerize and acquire complement component 3d (C3d), 
which can amplify re-afferent (feedback) signals through BCR of RF specificity by 
co-ligation of complement receptor 2 (CR2). IgG-RF complexes are also pro- 
inflammatory. TCR, T-cell receptor. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Reviews Immunology ((471), copyright 2006) 
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Anti-citrullinated protein/peptide antibodies (ACPA) 
In 1964 Niehuis et al were the first to the report the detection of a new class of 
autoantibodies within the sera of RA patients, distinct from RF, in that they were 
able to bind to perinuclear granules in normal buccal mucosa(472). They named 
this antibody the perinuclear factor (APF). This was followed by a subsequent 
report in 1979 documenting the presence of autoantibodies reacting to the 
keratinized epithelial layer of rat oesophagus in the sera of RA patients, anti- 
keratin antibodies (AKA)(473). It was some 15 years later before it was 
recognized by 2 separate groups that both APF and AKA recognized the same 
epitope(474; 475), and further that the conversion of arginine to citrulline was 
required for such specificity(476; 477). This post translational modification is now 
known to be dependent on the enzyme peptidylarginine deiminase 
(PADI)(476; 477). More recently an additional antigen specific for RA has been 
identified, known as Sa antigen(478), and this has now been shown to be 
dependent on citrullination of the cytoskeleton protein vimentin(479). It is now 
known that citrullinated proteins can be found in a number of inflamed human 
tissues(480) as well as in joints of animal models of arthritis(481; 482), although 
neither of which in general lead to the production of specific antibodies . It 
therefore appears that the subsequent development of anti-citrullinated 
peptide/protein (ACPA) antibodies, rather than dysregulated citrullination, is 
highly specific for RA. 
Antibody reactivity has now been shown to be directed to a large number of other 
citrullinated proteins and peptides such as deiminated forms of a and ß 
fibrin(482; 483), citrullinated fibrinogen (484)and citrullinated peptides of 
collagens I and II(482; 485). 
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Initial assays for the detection of ACPA used linear stretches of citrullinated 
proteins, but these proved difficult to standardise and a cyclic citrullinated peptide 
(CCP) test was developed, known as the anti-CCP1 test(486). This was followed 
by a second generation assay, anti-CCP2, generated from a large library of 
citrullinated peptides/proteins, and known to have improved sensitivity (64-89%) 
and specificity (88-99%) compared to the first generation test(487). 
Anti-CCP antibodies have been detected in the sera up to 14 years prior to 
diagnosis of RA, raising the concept of an early break in central tolerance. They 
are a particularly useful tool in early arthritis to predict those patients, who though 
not yet fulfilling the current ACR diagnostic criteria, will go on to develop RA and 
in combination with RF have been shown capable of predicting RA with a 
sensitivity of between 30-39% and specificity of 98-100% . This is of crucial 
clinical relevance as it is now clear that there is an early window of opportunity to 
induce disease remission(133; 488) and thus the early identification of patients with 
poor prognostic features is of critical importance. 
Anti-CCP antibodies have further been demonstrated to be superior to RF in the 
identification of patients with greater disease activity, as measured by swollen 
joint counts, physicians global assessment of disease activity ESR and CRP 
(489)and to correlate with a higher erosive burden(152; 490). They have also been 
shown to fall in line with effective therapy(491). These data along with their pre 
clinical detection suggests a direct role for them in disease pathogenesis. Their 
link with the SE and smoking is discussed on page 26. 
Type II collagen (CII) 
CII was first proposed as a putative autoantigen more than 30 years ago, and its 
identification within articular cartilage as well as its ability to induce an erosive 
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arthritis in experimental animals provided further support for this hypothesis. 
Subsequently antibodies to both native and denatured collagen have been 
identified in the sera of 10- 30% of RA patients(492; 493), both in the synovial 
fluid and within synovial tissue(494). They also appear early in the course of the 
disease and have been suggested to be associated with a poor prognosis(495). Up 
to 37% of healthy individuals also have T cell responses to CII(496), and there 
have further been no consistent reports of associations with clinical markers. The 
use of oral collagen as a therapeutic tool to induce tolerance has also met with 
limited success(497). Thus the role of anti-CII responses in RA pathogenesis at 
present is unclear. 
Nuclear ribon ucleoprotein complex (anti-RA33/anti-hnRNPA2) 
RA33 is a component of the spliceosome and antibodies to this complex were first 
reported in 35% of RA patients nearly 20 years ago(498). They have subsequently 
been shown to be present in other autoimmune mediated diseases, such as SLE and 
mixed connective tissue disease(499). Anti-RA33 has also been identified in TNF- 
transgenic mice (500)and MRL/lpr(501) mice, both used as animal models of 
arthritis. Differences in antibodies detected in patients with RA/SLE in comparison 
to MCTD patients have been demonstrated to be a result of conformation 
differences in the antibody binding sites(502) which is interesting as their 
detection in SLE appears to correlate with an erosive phenotype(503). No 
predictive value for these antibodies with regard to disease severity or progression 
in RA has been demonstrated(504) despite their detection in the sera early in the 
course of the disease and thus their measurement is not part of routine clinical 
practice. 
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Antibodies to calpastatin 
Calpastatin is the endogenous inhibitor of calpains which are intracellular calcium- 
activated cysteine proteases. Calpains have been demonstrated to be over 
expressed in the synovial tissue of RA patients(505; 506) and capable of degrading 
components of articular cartilage(507). Antibodies have been described in the sera 
of patients with a number of systemic inflammatory diseases albeit at a 
significantly higher titre in RA patients(508; 509). It is possible that antibodies to 
calpastatin interfere with its ability to inhibit the action of calpains(5 10) and some 
in vitro work supports this hypothesis in that calpains are released from the 
calpain-calpastatin complexes in the presence of RA sera positive for anti- 
calpastatin antibodies(509). 
Heat shock proteins (HSP) including BiP 
HSP or stress proteins are intracellular molecules with a number of housekeeping 
and cytoprotective functions. These molecules are both constitutively expressed 
and capable of being induced by a number of triggers, including oxidative stress. 
They are also now known to be capable of both pro and anti-inflammatory 
modulation(511). Many groups have reported the detection of antibodies to HSPs 
in RA, although their detection does not appear to be disease specific(512). More 
recently the HSP BiP has been identified in both RA patients and experimental 
models of arthritis(513-515). BiP is a 78kDa glucose regulated endoplasmic 
reticulum chaperone that has been identified within the RA joint and in the sera of 
RA patients(516). Further BiP has demonstrated in vitro(517) and in vivo(518) 
immunomodulatory capacity and is therefore currently under investigation as a 
therapy for RA(519). 
108 
Anti glucose 6 phosphate isomerase (G6PI) antibodies 
The search for anti G6PI antibodies in RA patients was generated from their 
identification in the K/BxN mouse model of arthritis, which in many clinical and 
pathological respects mirrors RA(520). Of particular interest in this animal model 
was that the transfer of even small amounts of serum from K/BxN mice induced 
arthritis, even in non susceptible mice(521). G6PI is a ubiquitously expressed 
glycolytic enzyme and is not joint specific. Reports of detection in RA patients 
have been variable, with an initial report suggesting a sensitivity of around 64% 
and a high specificity(522). This was followed by work from a number of other 
groups that was unable to replicate the original data, explained by a contamination 
of the commercial G6PI preparation used in the initial study by other proteins 
which reacted with antibodies in RA sera(523-526). More recent work has 
suggested that anti-G6PI antibodies may be specific for RA patients with Felty's 
syndrome being identified in the serum of 12/13 patients tested(527). It remains to 
be determined whether such sero positivity reflects general dysregulation of 
autoimmunity in Felty's syndrome or whether anti G6PI antibodies are specific 
and indeed whether such results can be replicated in other patient cohorts. 
Autoantibodies as mediators of RA pathogenesis 
Several antibodies have been associated with RA in humans, including RF, G6PI 
and more recently ACPA. There is now evidence supporting a role for 
autoantibodies not just as markers of disease but as mediators of disease 
pathogenesis. Clinically both ACPA and RF are associated with a worse 
prognosis(470; 528-530) and both are present years before disease 
diagnosis(531; 532). In addition ACPA are highly specific for RA(529) and both 
PADI (533)and citrullinated proteins (534)have been identified within the synovial 
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membrane. Furthermore, animal models have demonstrated that autoantibodies are 
capable of both initiating (although not maintaining) disease(521; 535; 536). RF is 
thought to enhance tissue damage via formation of immune complexes, activation 
of complement and thus recruitment of inflammatory cells to the synovium. 
ACPA are also now thought to be directly pathogenic as work in the CIA mouse 
model has demonstrated their capacity to enhance collagen induced tissue 
destruction(48 1). In addition to the formation of immune complexes and activation 
of complement, antibodies are also capable of mediating tissue damage via Fcy 
receptor (FCyR) activation. This pathway has been demonstrated to be critical to 
disease development in the CIA model of arthritis as mice deficient in the 
inhibitory FcyRII exhibited more aggressive disease(537). A further effector 
function of autoantibodies appears to be the C5 component of the complement 
system. Data have demonstrated that both the CIA and KIBxN models of arthritis 
are dependent on the C5 for disease expression and further that administration of 
C5 antibodies in the K/BxN model ameliorates disease(538; 539). 
Autoantibody independent roles for B cells in RA pathogenesis 
B cells are one of a number of antigen presenting cells that are capable of 
processing antigen and presenting it to T cells via MHC class II molecules and 
are thought to be the predominant APC in later phases of the immune 
response(540). This ability to process and present antigen permits RF producing B 
cells to process antigen contained within the RF-Ag complex that would not 
otherwise be presented to T cells. In addition IgG RF has the unique ability to 
cross link and form immune complexes with C3d, and this cross linking has the 
potential to override negative signals from soluble self proteins. Thus, RF 
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producing autoreactive B cells have the potential to become self perpetuating (541) 
(Figure 12). 
Animal models have also provided evidence to support a role for autoantibody 
independent B cell activation in RA pathogenesis. Evidence in the proteoglycan 
induced model of arthritis has demonstrated a specific requirement for B cell 
induced T cell activation in disease induction, a role that could not be compensated 
for by other antigen presenting cells(542). Work in the Hu-RA SCID mouse model 
has also demonstrated a critical requirement for B cell induced T cell activation in 
the induction of ectopic lymphoid structures(543). 
Finally, recently reported data have demonstrated a role for TLRs in B cell 
activation, in particular TLR9. This pathway was shown to be activated by the 
simultaneous activation of TLR9 and BCR by chromatin containing immune 
complexes and resulted in the production of RF(161) thus demonstrating a critical 
link between the innate and adaptive immune systems in the development of RA. 
This work is supported by data on TLRs from animal models of arthritis, with 
TLR4 deficient mice exhibiting milder disease in the KBxN model of 
arthritis(544) and the induction of arthritis by intra articular injection of CpG DNA 
or double stranded RNA(545). 
A key development in B cell biology has also been the recognition that B cell 
deficient mice develop an exacerbated experimental encephalomyelitis, when 
compared to wild type animals, suggesting a protective role for B cells in 
autoimmune mediated disease(546). The protective subtype appears to be a result 
of IL10 producing B cells, named regulatory B cells, that have been shown capable 
of ameliorating CIA via adoptive transfer experiments (547). How regulatory B 
cells regulate the immune response is currently unknown, they may act either 
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through a restoration of Thl/Th2 balance, or a direct modulation of effector cells, 
such as macrophages or DCs. Finally, IL10 producing cells have also been 
suggested to function as secondary antigen presenting cells which could result in 
an abortive response and induction of anergic CD4+ T cells, or perhaps act via the 
recruitment and/or induction of differentiation of regulatory T cells (reviewed 
in(548)). 
Pharmacological modification of B cells in rheumatoid arthritis 
B cell depletion therapy 
The efficacy of the B cell depleting agent rituximab in RA was first reported by 
Edwards et al in 2001(549). The rationale behind its use was based on the concept 
that the removal of memory B cells may lead to a resetting of the immune system 
and hence induction of disease remission. Rituximab is a chimeric monoclonal 
antibody against the CD20 molecule that was first licensed for use for Hodgkin's 
lymphoma in 1997. CD20 is expressed on all stages of B cell development, except 
at the very early pre B cell stage and on terminally differentiated plasma cells 
(Figure 13) and is a particularly useful target as it is not shed or internalized on 
binding its antibody. Killing of B cells is thought to be mediated by 3 mechanisms, 
antibody dependent cytotoxicity, apoptosis and complement mediated lysis. 
Animal studies have shown that killing mechanisms differ in different 
microenvironments, and further that specific sites such as the splenic MZ and GC 
B cells within Peyer's patches are particularly resistant to killing(550). Although 
treatment with rituximab is invariably associated with near complete peripheral B 
cell depletion, animal studies have demonstrated that this is not the case for solid 
tissues such as lymph node(551). Further variable degrees of depletion have been 
shown within the synovial membrane in patients with RA in a number of studies 
112 
perhaps explaining the differing clinical responses observed(390; 552; 553). In 
addition recent data have challenged the concept that complete peripheral 
depletion is achieved in all patients, and has demonstrated - using highly sensitive 
FACS analysis - that detectable circulating B cells following initial rituximab 
infusion is followed by a poor clinical response (554). 
Other possible mechanisms for resistance following rituximab therapy in RA 
comprise drug pharmacokinetics, including penetration of structures such as lymph 
nodes and synovium, FC7R polymorphisms(555), local and systemic expression of 
B cell survival factors and resistance of specific B cell subsets (in particular 
marginal zone and follicular B cells)(550). 
Rituximab has been shown to be efficacious and safe when used in combination 
with methotrexate(467; 556; 557) and is currently licensed for use in clinical 
practice for patients who have failed one anti-TNF therapy. Rituximab is not 
administered continuously but rather given as 2 doses at an interval of 2 weeks, 
with repeat courses given at disease relapse. At present the current mean time to B 
cell repopulation is 6 months. Repeat treatment appears to be as efficacious as 
primary therapy, and safety data shows no excess morbidity with up to 4 treatment 
courses(558). 
In addition fully humanised antibodies to CD20 are currently in clinical 
development and include Ocrelizumab, a molecule with demonstrated efficacy in 
phase II clinical trials(559). 
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Figure 13: B cell development pathways. 
Stages of B-cell maturation are indicated by their anatomical site and the 
expression of cell-surface markers, including the target for rituximab, CD20. GC= 
germinal centre. Adapted from(471) 
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Other therapies targeting B cell survival or activation 
In addition to directly depleting CD20+ B cells a number of other biological 
therapies are currently either in clinical use or in development that target B cell 
survival or activation (14) and are summarised in Figure 14. 
Belimumab is a fully humanised monoclonal antibody specifically targeting BAFF 
and has been shown to have partial efficacy in treating RA which was associated 
with a fall in autoantibody levels(560). Belimumab is unlikely to be used as 
monotherapy due to its relatively poor ACR responses, but may have a role in 
combination with anti-CD20 agents. This is because treatment and subsequent B 
cell depletion with rituximab is followed by a rise in serum levels of BAFF(264), a 
mechanism by which autoreactive B cells may receive erroneous survival signals 
resulting in disease relapse. 
Atacicept is a fusion protein of TACI with the Fc portion of IgG, that acts to bind 
both BAFF and APRIL and again initial clinical trials have reported relatively 
modest response rates with only 32% ACR20, although with associated reductions 
in autoantibody levels(262). 
Abatacept is a fusion protein of CTLA4 and Ig Fc and has shown significant 
efficacy in RA (465). Abatacept selectively modulates the CD86 or CD80-28 co- 
stimulatory signal required for full T-cell activation. CD80 or CD86 on the antigen 
presenting cell binds to CD28 on the surface of the T cell which facilitates 
activation. CTLA4 is a naturally occurring inhibitor that is induced on the surface 
of the T cell, but has a higher affinity for CD80/86 than CD28, therefore abatacept 
modulates T cell activation by exploiting this pathway. In addition the expression 
of CD80/86 by activated B cells further modulates T dependent B cell 
activation(561), supported clinically by a reduction in production of 
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autoantibodies(465) in clinical trials of abatacept. It would appear also that 
memory B cell production is predominantly inhibited by CTLA4-Ig(561). 
Epratuzumab is an unconjugated humanised monoclonal antibody that recognizes 
a pan B cell marker (CD22) with a similar distribution to CD20, being found on all 
B cells past the pre-B cell stage to the pre plasma developmental stage. The 
function of this monoclonal antibody to CD22 is unlike that of CD20, in that it can 
deliver intracellular signals, either constitutively, or via interaction with its ligand 
which is an a2,6-sialic acid residue found in many glycoproteins, including IgM 
and other cell surface proteins. As CD22 is rapidly internalized by B cells, it is 
thought to be a relatively poor target for B cell killing, unlike CD20. The effect of 
CD22 signaling is generally, but not entirely negative or anti-stimulatory. It also 
modifies signaling through other cell surface molecules including the BCR, 
CD 19/21 and CD45. CD22 appears to have a direct link to the development of 
autoimmunity, which has been predominantly explored in SLE. CD22 knockout 
mice have a hyper responsiveness to BCR cross linking, and a reduced response to 
T independent antigens. There is also evidence linking CD22 polymorphisms in 
mice and humans to the development of SLE. Epratuzumab might therefore 
modify the action of B cells without killing them, explaining some of the clinical 
effects seen that are not accompanied by complete B cell depletion. It does not 
block interaction with its ligand, but in fact initiates signaling through the 
molecule. Therefore in early clinical trials of the drug in SLE, only partial 
depletion of B cells were seen and no effects on complement or autoantibody 
levels(562). Additionally early trials in Sjogren's syndrome have reported a 
clinical benefit, with 53% of patients achieving a clinical response(563), partial B 
cell depletion and no effect on serum Ig levels. So far no reports have been made 
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of the drug in RA, although a role in addition to rituximab has been postulated as 
this has shown some efficacy in treatment of lymphoma(564). 
Anti-CD40L blockade (IDEC-131- and BG9588), and hence blockade of an arm of 
the adaptive immune system, has been explored in SLE however trials have been 
halted due to a pro thrombotic effect of the drug. However positive effects were 
seen on levels of autoantibodies, including ds-DNA(565). A further drug that has 
been developed for use in SLE, raises an alternative approach attempting to 
selectively deplete pathogenic B cells. This drug (UP 394) attempts to cross link 
BCRs on DNA-specific B cells in SLE patients in such a way as to result in a 





Figure 14: Current and potential therapeutic targets modulating B cell responses 
in RA 
(1) B-lymphocyte depletion with rituximab anti-CD20, (2) epratuzumab anti-CD22, 
(3) LJP 394/abetimus; (4) blockade of T-cell co stimulation CTLA4-Ig (abatacept) 
(5) blockade of B-cell stimulation via CD40L with IDEC131 and BG9588, (6) 
belimumab an anti-BAFF monoclonal antibody (7) blockade of B cell survival and 
activation with TACI-Ig (atacicpet). Adapted from (4) 
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Preclinical animal models of Rheumatoid arthritis 
The crucial role of animal models in elucidating the current level of understanding 
of RA pathogenesis cannot be understated(567). Such models rely on the same 
inflammatory cascades identified within RA patients, but may utilise antigens such 
as collagen or peptidoglycans, as well as novel antigens such as xxx pristane 
(568; 569). Amongst their multitude of applications, animal models of arthritis 
have been key in the demonstrating the arthritogenicity of rheumatoid auto- 
antibodies via the transfer of disease via sera between animals(570) and further 
knockout/knockin mice for a wide variety of cytokines, chemokines, cellular 
receptors and signalling pathways remain important tools in the dissection of 
polyarticular joint disease. 
The induction of an auto-immune response to antigen is a common trigger in 
animal models of arthritis, however it should be noted that the type of immune 
response is important(571). The induction of inflammation into the joint need not 
necessarily lead to a sustainable destructive arthritis. Each type of inflammation 
occurs as a consequence of the activation of a different arm of the immune 
response, namely type of hypersensitivity as classified by Gel and Coombs. Each 
type may be induced in mice using a combination of three basic ingredients: 
Animal strain; Antigen; and adjuvant. Adjuvants are agents added to antigens that 
enhance the translocation of antigen to the lymph node, enhance retention at the 
site of injection to prolong delivery of the antigen, induce local reactions involving 
mast cells and Th cells to enhance chemokine synthesis, induce local cytokine 
synthesis and systemic cytokines to increase the circulating population of immune 
cells, and stimulate the innate response through accessory cell pattern recognition 
receptors (Toll receptors). The latter serves to direct the immune response towards 
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Thl cell mediated immunity and IgG synthesis, diverting it from Thl IgE 
dominated allergic responses. 
There is a sensitisation step to an antigen, during which antigen presenting cells 
process the antigen and present it (or them) to T cells to produce cell mediated 
immunity. T cells also co-operate with B-cells to produce an IgG humoral 
response. The fixation of complement by these antibodies, and their binding to Fc 
receptors (FcyR) that can regulate neutrophil as well as macrophage function can 
be a key event in disease initiation and joint inflammation occurs thereafter. Since 
individual animals may succumb to disease at different times, the initiation of the 
disease may be synchronised by a boost injection comprising either the antigen in 
adjuvant, or a toll receptor agonist such as lipopolysaccharide (LPS). 
Sampling of tissues for gene or cytokine analysis is one the prime advantages for 
the use of animal models. In models of arthritis, sampling serum, synovial tissues, 
spleens, lymph nodes, synovial washouts or even whole joints provides very useful 
pathobiological information. 
A number of animal models are described below, but the list is by no means 
exhaustive. Importantly, for the purposes of this thesis, the SCID-Hu RA mouse 
model is described in detail. 
Rat Adjuvant Arthritis 
Adjuvant arthritis takes its name from the agent that induces it, Freund's complete 
adjuvant (FCA). This is 85% mineral oil (Bayol F) and 15% emulsifier (Arlacel- 
A), complete with finely ground heat-killed mycobacterial fragments. This is 
commonly Mycobacterium tuberculosis (Mtb. ) strain H37ra, or Mycobacterium 
butyricum (Mbt. ). This is administered at the base of the tail. Tracking of the 
mineral oil and mycobacterial particles shows that they distribute quickly 
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throughout the body, and accumulate in lymph tissues. A powerful systemic 
invasive inflammatory periarthritis is induced that involves not only the joints, but 
the formation of granulomas within meninges, skin, bone marrow and eyes, as well 
as in the connective tissue. The animals lose body mass and the predominant 
feature is a profound and crippling inflammation of the hind paws. The joints of 
the ankle and paws become seriously eroded, but the knees are less involved. The 
disease is accompanied by splenomegaly, increased gut permeability and liver 
involvement(572). 
Adjuvant arthritis is an auto-immune disease, since it can be passed to non-arthritic 
irradiated recipients through T cell transfer from diseased animals(573; 574), these 
T-cells express CD4 and the a, ß-TCR(575). Susceptibility is conferred by genes 
within the MHC class II region(576). It is not transferred by serum, but serum 
from adjuvant arthritis rats can induce a flare in rats with cyclophosphamide 
attenuated disease, whilst serum from the cyclophosphamide animals does 
not(577). The MHC phenotype is weaker than that for the rat collagen arthritis, but 
exerts a strong influence on the severity of disease(578; 579). Thus non-MHC 
phenotypes have a significant contribution to play. The MHC gene is Aial found 
on chromosome 20. Non-MHC quantitative trait loci include Aia2 and Aia3 on 
chromosome 4(579). Conserved synteny among rats, mice and humans, suggests 
that Aial, Aia2 and Aia3 contain candidate genes for several autoimmune diseases 
including diabetes (Aia3 : IDDM9), SLE, inflammatory bowel disease, 
asthma/atopy, multiple sclerosis, and RA (Aia3 : RA2)(579). 
Histologically, the predominant cell is the neutrophil, the synovial lining is 
destroyed. At initiation, fibrin is deposited along the bone shafts followed by fibrin 
deposition in the joints. The striking feature is a strong periosteal inflammation 
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comprising monocytic cells that progresses to invade the joints. Bone erosion is 
both osteoclastic and due to the inflammatory tissue(572). Osteoblastic production 
of new perisoteal bone can be seen with osteoclastic erosion of old bone. Articular 
cartilage remains relatively untouched, though dead cartilage can be seen as 
associated with neutrophils or macrophages. Bone is ultimately eroded away from 
under the cartilage leaving it supported by fibrocartilage. At late stages fibrosis 
occurs with ankylosis. Lymphocyte aggregates and plasma cell infiltrates are not 
seen. Whilst a polyarthritis, there is special focus on destruction of the ankle 
joint(572). 
Numerous candidates for the endogenous antigen involved in adjuvant arthritis 
have been proposed(580; 581). Muramyl dipeptide induces adjuvant disease similar 
to adjuvant arthritis (582; 583) and heat shock protein-65 (HSP-65) is also 
considered to be a major endogenous antigen(580; 584). Susceptible rats do not 
appear to be fully tolerant to rat HSP65, and HSP65 pre-treatment induces disease 
tolerance(585-587). 
Rat Collagen Arthritis. 
This model, discovered accidentally by Trentham and colleagues (588) during 
attempts to generate anti-type II collagen (CII), was the first collagen derived 
arthritis which was followed by the mouse version some years later. Whilst 
similar to adjuvant arthritis described above, it is milder and often preferred for 
this reason(588). The arthritis is induced by the sensitisation of susceptible rat 
strains to native heterologous collagen emulsified in a mineral oil, namely 
Freund's incomplete adjuvant (FIA)(589). The inoculum can be injected i. d. in 
several places on the lower back, or at the base of the tail. Old protocols utilised 
sensitisation in the footpad, but this is now discontinued on concerns for animal 
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husbandry. Some protocols utilise a boost, but arthritis is elicited between 11 to 14 
days reaching a maximum at around 20 days. A boost at 20 days can be given to 
establish a long term erosive disease(590-592). 
Like adjuvant arthritis, it appears that fibrin deposition and a periostitis occurs 
prior to inflammation within the joint space. Fibrin is deposited over the fat pad, 
soft tissues and cartilage, followed by synovial hyperplasia, and infiltration by 
neutrophils and monocytes. The periostitis and intense mononuclear accumulation 
is associated with areas of ligament attachment, which then moves into the 
synovial space leading to invasion of the joint space, with an influx of CD90+ 
CD4+ Ly2- (CD8-) Ia (MHC class II) expressing T -cells, with little evidence of 
suppressor T cells, and subsequent destruction of cartilage and bone(588). The 
pattern of erosions differs to adjuvant arthritis, being less severe, but involving 
both the ankle and midfoot(588). 
A hallmark of the CIA rat model of arthritis is the dominant B cell component of 
the immune response, which is specific for triple helical epitopes(591; 593). The B 
cells generated are autoreactive and produce arthritogenic 
autoantibodies(594; 595). There is also evidence for a critical role for T cells in 
disease pathogenesis, however(596; 597) the relative importance of T and B cells 
during the effector phase of the disease is at present unclear(572). 
An interesting observation in rat CIA is the presence of citrullinated proteins in the 
synovium, along with the enzyme responsible for citrullination, peptidyl arginine 
deiminase-4. This study further demonstrated the capacity of citrullination to break 
B cell tolerance to the endogenous antigen, rat serum albumin and correlated the 
levels of both PAD4 and citrullinated proteins with severity of inflammation(598). 
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Mouse Collagen induced Arthritis. 
Mouse CIA was developed from the original rat model of CIA, due to the use of 
this species in gene technology(599). As in the rat, a polyarthritic response is seen, 
but different sources and batches of collagen coupled with different strains of 
mice, results in different patterns of disease. It is initiated in susceptible strains, 
namely the DBAI/J and NFR/N mice (haplotype H-2q) and the C57. B1ORIII (H- 
2r), with better responses seen in males. Heterologous collagen is used, usually 
either bovine or chick type -II collagen to initiate disease. In addition, as in the rat, 
the type and form of the collagen is important. Cl does not induce the arthritis and 
neither does denatured CII(588; 599). Contrary to the situation in rat CIA, in which 
either incomplete or complete Freund's adjuvant can be used to trigger 
disease(589), in mice disease induction usually requires the presence of heat killed 
mycobacterium tuberculosis(599). 3-4 weeks following disease initiation with CII 
and CFA a severe polyarthritis enthuses with a subsequent remission of the disease 
after 2-3 weeks. In addition the use of autologous, rather than heterologous CII 
results in a disease characterised by a more chronic nature(592; 600). The 
generation of mouse CIA is known to require both T and B cells, with the adoptive 
transfer of T helper cells alone unable to reliably confer disease(601; 602) and 
overwhelming evidence indicating a critical role for anti-CII antibodies in disease 
initiation(603-606). 
Murine CIA, comparable to human RA, appears predominantly a Th 1 driven 
disease. Evidence for this concept comes from studies demonstrating that 
manipulation of the Th1/2 balance, via the administration of IL4 or IL10 (607-609) 
or the blockade of IFN-y(610; 611) which results in a therapeutic effect. 
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A common feature of RA is the presence of RF and anti-citrullinated peptide 
antibodies (ACPAs). CIA mice do not express rheumatoid factor. However CIA 
DBA/1 mice have been demonstrated to generate antibodies to citrullinated 
epitopes and furthermore this model has demonstrated the capacity of ACPA to 
enhance disease(481). Citrullination of CII has been shown to enhance its 
antigenicity and interestingly transgenic mice with the human HLADRB 1 shared 
epitope, have an exaggerated CD4 T-cell response when exposed to peptides that 
are citrullinated at the shared epitope specific recognition sites(111). Mouse CIA 
may be unique amongst the mouse models in exhibiting ACPAs. 
Passive collagen antibody induced arthritis 
Passive transfer of collagen arthritis (termed collagen antibody induced arthritis 
[CAIA]) can be performed with anti-type II collagen monoclonal antibodies, a 
mixture of which includes the complement binding IgG2a(606; 612). 
Commercially available kits recommend the use of DBA mice along with LPS for 
enhanced expression of disease. CAIA can be induced in T and B cell deficient 
mice, though the effect is less severe(612). The administration of CTLA4-Ig, 
capable of interrupting T-cell APC interactions, does attenuate CAIA if 
administered in the chronic phase of disease(613). Thus there is evidence that 
auto-antibodies in turn induce a secondary T cell reaction that further exacerbates 
the disease. Neutrophils are also important mediators of disease pathogenesis as 
their depletion reduces the severity(612) and a massive neutrophilic infiltration of 
synovium is found within joints of diseased animals(612). IgG FcyR engagement 
is also very important. Knockout mice for the FcyR chain are resistant to disease. 
FcyRIII knockout mice have reduced severity(614), whilst absence of the 
inhibitory form, FcyRIIb, exacerbates CAIA disease(615). Complement is also a 
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factor, C3 depletion with cobra venom factor reduces the response(616), as does 
C5 knockout(617). 
K/BxN Arthritis 
The group of Mathis and Benoist fortuitously discovered that T-cell receptor 
transgenic mice - recognizing an epitope of bovine RNase (KRN) - crossed with 
non-obese diabetic (NOD) mice, generated offspring (K/BxN mice) that develop a 
spontaneous arthritis resembling human rheumatoid arthritis(520). The most recent 
of the major arthritis models discovered that the knowledge from previous models 
described above, and the application of transgenic, biologic and analytical 
technologies has meant that much has been learned within a short space of time. 
The onset of arthritis is observed at 3-4 weeks of age presenting clinically as a 
chronic, progressive, polyarthritic disease with a distal to proximal gradient of 
severity(520). The transgenic TCR recognizes glucose-6-phosphate isomerase 
(GPI) as the antigen presented by NOD antigen presenting cells in the context of 
MHC class II molecule I-Ag7. It was this finding in the K/BxN model that led to 
several studies investigating the role of GPI antibodies in humans, although the 
data generated from these studies currently remains somewhat 
controversial(524; 527). This molecule is also recognised by antibodies generated 
in the murine CIA. It was this ubiquitously expressed glycolytic enzyme that is 
identified to be the crucial driver for T-lymphocyte initiation and B-lymphocyte 
production of arthritogenic immunoglobulins that leads to disease in the offspring. 
Early T-lymphocyte requirement is determined by the fact that administration of 
anti-CD4 neutralising antibodies prevent disease but only if given at least 5 days 
before the disease onset(618). Furthermore, KRNxNOD mice lacking B- 
lymphocytes do not develop arthritis, confirming the necessity of this cell type for 
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initiation of disease(619). The effector phase of the disease has been demonstrated 
to be initiated by the binding of immunoglobulins to joint surfaces(620). 
Antigen -induced arthritis. 
Originally described in the rabbit using bovine serum albumin, this model is now 
used in the rat and more commonly in the mouse. Animals develop an 
inflammatory arthritis when primed with an antigen (e. g. methylated BSA in 
complete Freund's adjuvant [mBSA]) and thereafter face re challenge with 
intrarticular injection of the same antigen(62 1; 622). 
The induction of arthritis is T cell dependent, B cell activation is not considered to 
be involved in the generation of the hypersensitivity response of this model. CD4+ 
cell depletion inhibits both the acute reaction, and severity of the chronic 
disease(623). Antigen induced arthritis is transferred into SCID mice by CD4+ 
cells and not CD8+ cells(624). 
RA is characterised by phases of disease flare. This can be mimicked in the 
antigen induced arthritis. During the chronic phase, if mBSA is injected 
intravenously, an exudative flare reaction in the affected joint is induced, that is 
abrogated by T cell depletion, and not complement depletion, confirming the T 
cell dependence of the immune compartment (as opposed to erosive compartment) 
of the disease(625). In addition, re-challenge into the knee around one month after 
primary challenge elicits the formation of lymphoid aggregates similar to those 
found in RA(626). Many of these possess discrete T and B cell zones and further 
CXCR5-/- mice possess reduced erosive disease(626). 
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K/BxN serum transfer model 
A major problem with the transgenic model has been the limited availability of the 
mice. However, what has been most useful is that serum from KRNxNOD 
offspring can transfer disease to a wide panel of inbred-strains and gene-disrupted 
mice with the same onset of arthritic features being observed in almost 100% of 
mice, in a fashion similar to that seen with the transfer of arthritis by anti-CII 
antibodies. Whilst a single i. p. injection of antibodies confers a transient arthritis 
related to the level of residual circulating antibodies, multiple administrations 
confer an erosive arthritis similar to that seen in the KRNxNOD mice. The 
antibodies appear to be of the IgG 1 (Th2) subclass, with indications that they are 
closely related and thus derived from a narrow range of B-cells(627; 628). Like the 
passive CII model, except for the fact that CIA antibodies are of the Th1 IgG2a 
and IgG2b class, mixtures of antibodies derived from serum are required though an 
arthritis-inducing monoclonal anti-body has been developed(627). 
The SCID-human RA mouse model (SCID-HuRA) 
SCID (severe combined immune deficiency) mice are homozygous for the 
spontaneous mutation Prkdcs`; a and are characterized by an absence of functional 
T cells and B cells, lymphopenia, hypogammaglobulinemia and a normal 
hematopoietic microenvironment. They were first discovered in 1983 and found to 
carry a DNA repair defect and a defect in the rearrangement of genes that code for 
antigen-specific receptors on lymphocytes. Most homozygotes have no detectable 
IgM, IgGI, IgG2a, IgG2b, IgG3, or IgA. Thymus, lymph nodes, and splenic 
follicles are virtually devoid of lymphocytes. These characteristics make SCID 
mice ideal for transplantation of human tissue that can then be biologically 
manipulated in an environment devoid of immunological interference from the 
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host. Their discovery was followed by a number of experiments in which tissues 
such as human haematopoietic stem cells(629) and human thymus(630) were 
successfully transplanted into SCID mice without subsequent rejection. 
The first full report to describe the use of the SCID-HuRA was made in 1993(631) 
and was of particular importance to research as although a number of animal 
models of arthritis had been developed none was capable of recapitulating the 
conditions found within the synovium of RA patients. This report demonstrated 
that when both normal and inflamed RA synovial tissue was transplanted under the 
renal capsule of C. B 17 SCID, mice tissues were noted to survive and maintain 
phenotypic and histological characteristics of pre transplanted tissue albeit with a 
reduction in T cell numbers. Further reports demonstrated that engraftment of 
human RA synovium into the knee joint of SCID mice was able to elicit an 
arthritis(632) and also that synovium transplanted at this site has the capacity to 
destroy cartilage(633). 
The use of the SCID mouse was limited however by the presence of natural killer 
cells, macrophages and granulocytes, none of which are affected by the SCID 
mutation and which led to low levels of engraftment, amongst other problems. 
However, the beige mutation (Lyst bg) in mice is associated with neutropenia, 
lack of NK cytotoxic activity and lack of functional macrophages(634) and so 
SCID and beige mice were subsequently backcrossed and a SCID/beige on a C. 
17B background was developed. 
Thus the immune deficient status of SCID mice can be taken advantage of to 
transplant pieces of human rheumatoid synovium and investigate their function in 
vivo without the accompanying problems associated with ex vivo organ culture, 
such as artificial growth medium and tissue necrosis through poor oxygen 
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perfusion and nutrient diffusion(635; 636). After transplantation, the human 
synovial vasculature anastamoses with the mouse via a fibrous capsule and the 
tissue becomes perfused with the host blood(637). The grafts remain stable for 
over a month and often longer before starting to slowly lose their architecture. 
Some grafts appear to recruit murine monocytes or T-cells over time to a minor 
degree, whilst others do not. Immuno-fluorescence assays of human cell markers 
in the main do not detect human cells in host mouse lymphoid organs after 
transplant. Some report that grafts become depleted of T-lymphocytes(637-640) 
which could indicate turnover of T cells in the diseased tissue, and others that CD3 
cells remain after engraftment(641). At 4 weeks cells still express Ki-67 or 
PCNA, markers of cell division, and the grafts continue to release human 
immunoglobulins and IL6 for example(641), all of which can be detected in the 
circulating blood. PCNA is associated with the proliferating avß3 angiogenic 
blood vessels, and proliferating fibroblasts. CD68 macrophages start with a 
concentration at the synovial lining layer, which becomes less demarcated and 
distribution more diffuse. CD3 cells can congregate around blood vessels. 
Fibroblasts become denser with time, and the tissue become more densely packed 
and organised unlike the looser less organised tissue at implantation. Engrafted 
pannus at four weeks contains cells expressing a variety of markers such as those 
indicating helper cells (CD4), fewer T-suppressor cells (CD8 subsets), and B-cells 
(CD20). B-cell aggregates are maintained throughout, although become less 
organised(641). Cytokines are synthesised, IL-6, TNFa for example, though IL-6 
synthesis can wane unless stimulated by a further stimulus or recruitment of T- 
cells(637; 638). Enzymes indicating the graft's potential to degrade bone and 
cartilage, such as tartrate-resistant acid phosphatise positive cells (osteoclasts) and 
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matrix metalloproteinases (MMPs) including MMP 1,3 and 9, are found to be 
expressed within grafts(642). 
Once the vascular anastamoses are established (3 weeks) human lymphocytes can 
be injected i. v. and their accumulation within the graft assessed; either through 
labelling with a tracer (e. g. technetium, indium) or via histology using human 
specific cell markers. Isolated blood lymphocytes, monocytes or T-cells can be 
studied and U937 cells, a human myeloid precursor cell line, can also be used. 
Care should be taken if specific RA tissue homing is being investigated since it 
can be shown that human cells can traffic to other inflammatory tissues as well, 
showing certain systems are a general feature of the tissue inflammatory state. To 
control for cell trafficking under non-inflamed conditions, human skin can be 
transplanted as a control in the same mice. 
Adhesion molecule expression changes over time. VCAM-l and E-Selectin 
expression decreases with time, whilst ICAM-1 is maintained. The injection of 
TNFa (1000U) into the graft significantly up regulates ICAM-1, and this is 
accompanied by an anti-ICAM-1 inhibitable enhancement of human mononuclear 
cell recruitment into the grafts after i. v. infusion(637). The anti-inflammatory 
cytokine IL-10 reduces ICAM-1 expression and its partner IL-4 a mild increase in 
ICAM-1. IL-10 and IL-4 reduce human peripheral blood mononuclear cell 
recruitment by the grafts(643). These are important observations, establishing the 
importance of ICAM-1 in the recruitment of mononuclear cells into human RA 
synovium. 
The SCID-HuRA mouse model allows a number of important research 
applications in RA (Table 4) including the ex vivo testing of biological 
agents(644), the development of synovial specific compounds(645), as well as an 
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increased understanding of the pathogenic role of specific cytokine and chemokine 
pathways in RA synovium(339; 637). Recently, the presence of human 
autoantibodies has also been detected in the sera of HuRA-SCID mice(418), 
raising the possibility that these antibodies are manufactured directly within the 
synovium. As has been previously discussed and is of particular interest, the 
synovium has long been recognised to contain sites of ectopic lymphoneogenesis. 
Whether these sites are truly functional and involved in the production of 
pathogenic antibodies has caused ongoing debate in the literature(416; 426). 
When using this system to assess the efficacy of human specific biologics, one end 
point can be tissue size - anti-human IL-6 receptor antibodies reduce graft size by 
half, whilst auranofin (an oral disease modifying anti-rheumatic drug) treatment 
does not(642). Anti-IL-6 reduces inflammatory cell involvement, and the grafts 
are replaced by fibrous and adipose tissue. MMP 1 and MMP9 expression is 
markedly reduced(642). This would indicate that the erosive potential of the 
tissues would be reduced. The erosiveness of the RA synovium can be assessed 
either through the determination of metalloproteinase expression, or implantation 
in juxtaposition with cartilage(640; 646). Synoviocytes can be seen to adhere and 
erode into the matrices. In the case of human cartilage co-implants, tissue can be 
seen to burrow into the matrix creating furrows and tunnels. The implants can be 
graded according to their erosive capacity, and will depend on the donor tissues. 
Normal donor tissue is not erosive. The cell types associated with this erosion 
appears to be fibroblastic (type B synoviocytes), and some macrophages (type A) 
with little contribution by lymphocytes. 
Selective depletion and reconstitution experiments have also provided very useful 
information. The depletion of T-cells with anti-CD2 for example results in not 
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only an almost total suppression of TNFa, IL-lß, IFNy, and IL-15 mRNA 
expression, but also the expression of MMPs. In addition to this, CD68 stained 
cells also disappear. The administration of autologous CD4 T cells restores TNFa 
synthesis, stimulates IFNy synthesis and maintains CD68 cells. IFNy will replace 
the role of CD4 T-cells in anti-CD2 treated mice(647). Non-cytotoxic CD8 
suppressor T-cells cells (lacking CD40L, the cytotoxic molecules perforin and 
Granzyme-A) derived from autologous RA synovium have the opposite effect. 
These cells are seen as closely associated with lymphoid aggregates and their 
selective depletion results in disaggregation of the germinal centres, an inability to 
retain dendritic cells and reduced IgG synthesis by the grafts. The depletion of B- 
cells from synovial tissues containing B-cell germinal centres, results in 
dissociation of the aggregates, loss of CD4 T -cells, and reduced inflammatory 
cells, IFNy and IL-1B(543). Micro-dissection of follicle derived CD4 cells 
followed by expansion and injection stimulates graft IFNy, TNFa and IL-10 
synthesis(543). 
The active angiogenesis within the grafts enables research into this area. The grafts 
express vascular endothelial growth factor (VEGF) and angiopoitein-1, both potent 
angiogenic factors. The administration of anti angiogenic factors such as 
endostatin and TNP-470 (aka AGM-1470) reduce blood vessel density and the 
retention of inflammatory cell infiltrates. Cell apoptosis is also induced within the 
grafts(648; 649). 
Prospective mining of novel targets in the synovial structures is also enabled 
through this model. This is exemplified by the screening of bacteriophage for 
adhesion to synovial structures in vivo in the transplanted mice(645). This 
approach has resulted in the identification of novel and selective molecular 
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structures within RA synovium that can be selectively ligated by novel peptides 
and have the potential for drug targeting. Genetic manipulation of cells derived 
from RA synovium can be investigated, one such example are RA synovial 
fibroblasts, whereby manipulation of MMP, cytokine, cell signalling pathway, 
expression has been manipulated to provide detailed knowledge of the function of 
these cells in cartilage erosion in vivo (reviewed in (650)). 
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Table 4: The use of the SCID-human RA mouse model (SCID-HuRA) 
Mechanisms in the maintenance of the rheumatoid structure 
Synthesis of human RF and ACPA antibodies. 
Human lymphocyte migration into the graft: adhesion molecules, chemokines 
Human lymphocyte subsets, cloned, or transgenic cell function 
Erosive capacity and mechanisms 
Human cytokine and chemokine synthesis and actions 
Human rheumatoid gene expression 
Human rheumatoid gene expression under resting and investigational conditions 
Assessment of human species specific biologics 
Determination of the translational utility of experimental therapeutics in a human 
in vivo system 
Comparisons between OA, RA, and other human inflammatory conditions 
Drug delivery to human RA synovium 
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Summary and hypotheses 
RA is the commonest inflammatory arthritis with associated major health 
economic implications. At present - despite the revolution that has followed the 
introduction of biological agents -a number of challenges still face clinicians 
treating the disease. Importantly, at present it is difficult to predict those patients 
early on within a defined window of opportunity who have the worst prognosis 
and will progress to suffering the greatest erosive burden and associated morbidity. 
Thus refined prognostic markers are required and evidence suggests that these 
biomarkers may lie within the synovial membrane, the primary site of 
inflammation in RA. In particular the presence of ELN within the synovial 
membrane has been suggested to be associated with clinical phenotypes, but its 
predictive power in a prospective study has not been explored. In addition a robust 
quantitative means to assess the degree of organisation (and hence ectopic 
lymphoneogenesis) within the synovial membrane has not been reported. 
The prognostic role of synovial ELN is tightly linked to a suggested role for these 
structures in RA pathogenesis and this concept has generated much debate in the 
literature. Crucial questions to address are whether ectopic GCs are merely the by- 
product of inflammation, whether they are capable of functionality and in 
particular are they involved in the local production of autoantibodies? 
Thus the central hypothesis of this thesis is that ELN within the synovial 
membrane: 
1. Identifies specific RA clinical phenotypes 
2. Is functional and involved in RA pathogenesis via the local production of 
autoantibodies 
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Specific aims and objectives 
The specific aims and objectives of this thesis were therefore to: 
1. a) Develop and validate a pathological scoring system capable of quantifying 
the degree of aggregation within the synovial membrane, b) Determine 
whether the degree of aggregation associates with certain key pathological and 
molecular markers within the synovial membrane, c) Determine whether the 
degree of cellular organization within the RA synovial membrane associates 
with specific clinical phenotypes and, d) Determine whether in established 
disease the degree of aggregation within the synovial membrane predicts joint 
damage progression. 
2. Determine whether ectopic lymphoid structures in RA synovium are 
functional by determining whether they: a) Express AID, the enzyme required 
for SHM and CSR of Ig genes; b) Support ongoing CSR and the production of 
high-affinity ACPA; and c) Remain functional and promote B cell survival, 
proliferation, and autoantibody production in a RA/SCID chimera model 
devoid of any new immune cell influx into the synovium and where the 
ongoing immunological activity of secondary lymphoid organs is excluded. 
3. To elucidate further the functionality of ectopic GCs by determining, a) 
Whether a population of large CD20+, IgD- B cells surrounding ectopic GCs 
represent the novel population of large interfollicular B cells, recently 
described surrounding GCs in secondary lymphoid organs and b) Whether 
extrafollicular AID expression within IF large B cells within lymph nodes and 
within the RA synovial membrane is associated with a somatically mutated 
IgH. 
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Chapter 2: Materials and Methods 
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General Protocols 
The general protocol sections reported in this chapter (Immunohistochemistry, 
Quantitative Taqman real-time PCR and Western Blot) describe procedures that 
have been specifically optimised for work presented in this thesis and are included 
in the standard operating protocol of the lab. Relevant modifications of these 
protocols and additional protocols specific for each chapter are reported within the 
dedicated materials and methods sections of each chapter. 
Immunohistochemistry 
All materials were purchased from Dako (Glostrup, Denmark), Sigma Aldrich 
(Poole, UK) and VWR (Poole, UK) unless otherwise stated. 
Sample fixation and embedding 
Fixation is required to stabilize cells and tissues, therefore making the Ag 
insoluble (and thus detectable) and protecting the tissue from processing and 
osmotic damage caused by solutions used during the staining procedures. 
All paraffin samples were fixed with 4% formalin or paraformaldehyde (aldehyde- 
based fixatives) for 24-48 hours prior to embedding. 
Frozen samples were fixed prior to staining with cold acetone (-20°C for 10 
minutes), paraformaldehyde (4°C for 10 minutes) or 100% ethanol (room 
temperature) (Appendix I). 
Acetone, ethanol and aldehyde based fixatives were both used in this study. 
Acetone and ethanol fix the tissue by coagulating proteins and inducing 
denaturation. Conversely, paraformaldehyde and formalin induce the formation of 
cross links between proteins, making them insoluble. 
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Paraffin embedding 
The process of formalin fixation followed by paraffin embedding allows tissue to 
be fixed and stored with good preservation of both tissue architecture and cell 
morphology for prolonged periods of time. 
Following dissection, fresh tissue was immediately fixed in 4% paraformaldehyde 
(Appendix I) for 24 hours at room temperature. The tissue was then placed into 
embedding cassettes and processed as follows: 
1) 70% Ethanol, two changes, 1 hour each 
2) 80% Ethanol, two changes, 1 hour each 
3) 95% Ethanol, two changes, 1 hour each 
4) 100% Ethanol, three changes, 1 hour each 
5) Xylene, three changes, 1 hour each 
6) Paraffin wax (56-58 C), two changes, 1 'h hours each 
Finally, the tissue sample was embedded into paraffin blocks and place on a cold 
plate until completely cooled and set (approximately 20 mins). 
Paraffin embedded samples were stored in boxes at room temperature until use. 
Frozen sample embedding 
Fresh tissue was dissected and a drop of O. C. T. (optimal cutting temperature) was 
placed on the top of a small piece of labelled cork. More O. C. T. was placed on the 
sample to cover the tissue completely. A small plastic beaker filled with 
isopentane (2-methyl butane) was placed in liquid nitrogen to bring the isopentane 
to its freezing point (-160°C). The cork with the embedded sample was then placed 
in the ice-cold isopentane and left in the solution until completely frozen (O. C. T. 
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turned white). The sample was then wrapped in aluminium foil, placed in a falcon 
tube and stored immediately at -80°C freezer until use. 
Sample cutting 
Paraffin embedded samples 
Human tissue samples were placed in boxes filled with ice to cool down for 1 hour 
prior to cutting. Sequential sections were cut at a thickness of 3µm on a Leica 
microtome (Knowlhill, UK). The sections were then floated on a warm water bath 
(45°C), before being picked up onto Superfrost Plus slides (sequentially numbered) 
and excess water allowed to drain from the slides before being placed on a 70°C 
hot plate for 1 hour. The slides were then removed from the hot plate and stored in 
cardboard boxes at room temperature until use. 
Frozen samples 
5µm sequentially cut sections were obtained by cutting the specimens in a cryostat 
(Leika) and mounting the tissue onto glass slides (SuperFrost Plus). Slides were 
left overnight at room temperature to dry. Subsequently each slide was 
individually wrapped in aluminium foil, labelled and placed in boxes stored at - 
80°C until future use. Prior to use for immunohistochemical experiments each slide 
was defrosted for 10 mins at room temperature before being unwrapped and fixed. 
Deparaffinisation and rehydration of paraffin embedded tissues 
The use of paraffin embedded samples allows the identification of the Ag of 
interest within the context of a preserved histological structure. However, a 
rehydration process is necessary in order to permeabilise the tissue before staining. 
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Before each immunohistochemical experiment (including Haematoxylin and Eosin 
staining), paraffin embedded tissues were mounted onto slides and treated 
according to the following protocol. 
Slides were placed in a slide holder (glass or metal) and incubated in xylene (2 to 3 
changes, 5 minutes each), followed by passages in 100% absolute ethanol (2 
changes, 5 minutes each), 70% ethanol (2 changes, 5 minutes each) and 50% 
ethanol (2 changes, 5 minutes each). Slides were then immersed in distilled water 
for 5 minutes and placed in jar containing Tris buffer saline (TBS) (Appendix I) 
until use. 
Note: frozen tissue mounted onto slides does not need to be rehydrated before use. 
Haematoxylin and Eosin (H&E) staining 
In order to accurately visualize the microscopic structure of the specific tissue 
under study, H&E staining was performed on all tissue samples. 
H&E staining, by the use of two diverse dyes, permits the visualization and 
differentiation of the cellular nuclei and cytoplasm under light microscopy. 
Haematoxylin stains the chromatin within the nucleus with a deep purplish-blue 
colour, while Eosin stains the cytoplasmic material, connective tissue and collagen 
with a pink colour. 
Frozen or paraffin sections (following rehydration) were placed in jars containing 
filtered Mayer's Haematoxylin for 5 minutes. Slides were then rinsed in tap water 
and placed in 1% Acid Alcohol (Appendix 1) for a few seconds. The acid alcohol 
passage removes the excess of Haematoxylin from the cytoplasm thus allowing 
Haematoxylin to stain only within the nuclei. The slides were then washed again in 
tap water and placed in Eosin for 5 minutes. Finally the slides were washed in tap 
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water, dehydrated and mounted in an organic solvent soluble mounting medium 
(DePeX). 
Toludine Blue staining 
Toludine blue is a basic dye that stains nuclear material blue and sulphated 
polysaccharides purple, it facilitates sharp structural detail. 
Following rehydration, paraffin sections were placed in jars containing Toludine 
blue solution for 2 mins, rinsed in tap water, dehydrated and mounted in an 
organic solvent mounting medium (DePeX). 
Ag retrieval 
The use of formalin (aldehyde-based fixative) during the fixation process of 
paraffin embedded tissue causes the formation of methylene bridges (inter- and 
intra-molecular bridges), which cross link proteins in the embedded samples. 
Formalin-fixed tissue sections therefore require treatment with an Ag retrieval step 
prior to immunohistochemical staining in order to open free sites for the 
antigen/antibody binding. 
Two methods of Ag retrieval are used within subsequent experiments described 
within this thesis: 1. proteolytic-induced antigen retrieval, and 2. heat induced 
antigen retrieval. In some staining experiments requiring the identification of two 
Ags, double retrieval was performed with both Ag retrieval methods. 
1. Proteolytic induced Ag Retrieval 
The protein cross-links formed during the fixation of formalin-fixed paraffin 
embedded samples can be partially broken by the use of proteolytic enzymes 
(Trypsin, Proteinase K, Pepsin). During the procedure some of the Ags (and 
indeed overall tissue morphology) may be altered or destroyed by the use of 
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enzymes and in particular, false binding sites may be created due to excessive 
tissue digestion. It is important therefore to accurately time (to seconds) the 
incubation of the tissue with the enzyme. 
The enzyme used for Ag retrieval of specimens within this thesis was proteinase 
K. Prior to use, proteinase K was warmed up to 37°C for 15 min (in order to 
achieve the optimal enzymatic activity) and placed on the tissue sections on the 
slides for 5 minutes. After incubation, slides were carefully rinsed in TBS and then 
immersed in fresh TBS until staining. 
Heat induced Ag Retrieval 
Heat induced Ag retrieval uses solutions of variable pH (pH 6 or pH 9) to remove 
the weaker binding formed during fixation (Schiff bases). Heat mediated antigen 
retrieval techniques can involve the use of microwave oven irradiation, pressure 
cooker heating, autoclave heating, water bath heating, steamer heating, or 
incubator. 
For immunohistochemical experiments within this thesis I used a water bath to 
heat Dako Target retrieving Solution in plastic jars to a temperature of 96°C, 
requiring a water bath temperature of between 95-99°C. Following 
deparaffinisation and rehydration steps, slides were immersed in preheated target 
retrieval solution and placed in the water bath and incubated for 30-50 minutes 
(depending on the Ag). After incubation, slides were kept in the jars and target 
retrieval solution but removed from the water bath and allowed to cool down for at 
least 20 minutes at room temperature. Importantly the target retrieval solution 
turned opaque on heating and was allowed to return to its original clear colour 
during cooling. After retrieval slides were rinsed in TBS and left in TBS until use. 
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Immunohistochemical detection of human Ags 
Immunohistochemistry allows the localization of a specific Ag/s within tissue 
sections. This system is based on the recognition of a specific Ag/s by a 
conjugated (direct method) or un-conjugated (indirect method) primary antibody 
(first layer). 
The first layer is followed by one or more incubations with a secondary antibody 
linked to enzymes (commonly horseradish peroxidase HRP or alkaline 
phosphatase AP) or a biotinylated antibody followed by enzyme-linked Avidin 
complexes. The use of a substrate solution and a chromogen, while reacting with 
the used enzyme, allows the precipitation of the colour (colorimetric methods) on 
the site of antibody-antigen binding. 
Colorimetric methods: horseradish peroxidise and alkaline phosphatase 
The two more diffuse colorimetric methods used in immunohistochemistry are 
based on the activity of two enzymes, horseradish peroxidase (HRP) and alkaline 
phosphatase (AP). HRP reacts with chromogen substrates (3,3'-diaminobenzidine 
or DAB and 3-Amino 9-ethylcarbazole or AEC). Immunohistohemical 
experiments described within this thesis use DAB that develops as a brown 
product, insoluble in alcohol and other organic solvents. Since endogenous 
peroxidase activity is present in many tissues (including lymph node and tonsil) 
and can be non-specifically detected with the DAB substrate, pre-treatment of the 
tissue section with hydrogen peroxide or blocking solution was performed prior to 
incubation of primary antibody in order to avoid non specific staining. The 
synovial membrane however lacks endogenous peroxidase activity and thus a 
blocking step was not required on synovial tissue sections. 
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AP catalyzes the hydrolysis of phosphate-containing products in the basic pH 
range. Its enzymatic activity is visualized by using a pink or blue chromogen in an 
alkaline buffer. The chromogen can be either soluble in organic solvent or 
permanent. Endogenous alkaline phosphatase is diffusely expressed in human 
tissue, therefore the inhibition of the endogenous enzyme is mandatory in order to 
avoid unspecific staining in the section. 
Within experiments described in this thesis the chromogen was Vector Red 
(Vector Lab) and was used according to the manufacturer's instruction (Appendix 
I). In addition, Levamisole was added to the substrate solution in order to inhibit 
endogenous activity within tissue sections of alkaline-phosphatase (Appendix I). 
Staining procedures: The Avidin-Biotin Complex (ABC) Method 
The Avidin-Biotin Complex (ABC) method is based on the strong affinity that 
Biotin (a small molecular weight vitamin) displays for Avidin (a large 
glycoprotein of 68 Kd). Avidin presents four binding sites for biotin providing the 
backbone for a macromolecular amplification complex. Avidin can be labelled 
with various enzymes (horseradish peroxidase or alkaline-phosphatase) and 
fluorochromes, allowing diverse methods of detection to be used. In this study I 
used the DAKO Avidin-Biotin Complex (ABC) (Appendix 1) linked to horseradish 
peroxidase or alkaline phosphatase. The method requires three layers: the first 
layer is unlabeled primary antibody, the second layer is the biotinylated secondary 
antibody and the third layer is the enzyme HRP or AP-Avidin conjugate. The used 
enzyme is then visualized by the use of the appropriate chromogen and substrate. 
The experiments described within this thesis use HRP and AP conjugated Avidin- 
Biotin kits from Dako. 
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In order to avoid non-specific binding to endogenous biotin (present in diverse 
tissues) pre-treatment with unconjugated avidin saturated with biotin was 
performed on each slides stained with the ABC system. Tissue sections underwent 
blocking of endogenous biotin activity using the Dako Biotin Blocking System. 
Tissue sections were primarily incubated for 10 minutes with preprepared avidin 
solution. The slides were then rinsed in TBS (x two 5 mins) and then incubated for 
a further 10 minutes with preprepared biotin solution. This was followed by a 
thorough washing of the tissue sections with TBS. 
Staining procedures: Dako EnVision System Polymeric Method 
This system, in comparison to the ABC method described above has higher 
sensitivity while reducing the number of the staining layers and thus the overall 
experimental time. The secondary antibody (anti-mouse or rabbit) is directly 
linked to a dextran polymer binding a large number of HRP or AP molecules. 
Therefore, after the first layer of unconjugated primary antibody, the EnVision 
secondary is applied to the tissue sections and after washing and application of the 
substrate chromogen, the colour is developed. The EnVision double staining 
system allows the simultaneous detection of more than one Ag in the same tissue 
section by using mouse or rabbit primary antibodies. 
An indirect immunohistochemical staining method on paraffin embedded 
samples was mainly used within experiments described within this thesis. 
Following tissue fixation and antigen retrieval, a wax circle was drawn around 
tissue sections using a DAKO Pen in order to inhibit the dispersion of solutions 
applied to the section and thus subsequent tissue desiccation. 
All the incubation steps were performed in humid chambers at room temperature. 
All the washes were performed in TBS (1 %). All primary antibodies were 
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unlabelled, diluted in the antibody diluent and incubated for 1 hour unless 
otherwise stated. Appropriate biotinylated secondary antibodies were used. Single 
staining was performed either by indirect AP-avidin-biotin complex or by indirect 
HRP avidin-biotin complex. 
Envision AP or HRP labelled polymers were used as secondary reagents for all 
mouse and rabbit primary antibodies. Double staining was performed using the 
Envision double staining or combining a single staining with avidin-biotin 
complex with an Envision single staining. 
Colour development for both AP and HRP was performed under direct light 
microscopy and enzymatic reaction blocked as appropriate by immersion in 
distilled water. 
Following immunohistochemical staining of tissue sections using the appropriate 
substrate for colour development (organic solvent soluble or permanent) the slides 
were immersed in haematoxylin to define nuclei (10 seconds) and then rinsed in 
tap water and either mounted with aqueous mounting medium or dehydrated 
through passages of alcohol and xylene and mounted in a xylene soluble mounting 
medium (DEPEX). 
Antibodies and titration experiments 
For primary and secondary antibodies, pilot titration experiments were run to 
determine the optimal working dilutions on positive controls (human lymphoid 
tissue). The optimal working dilutions were then used in subsequent experiments. 
A complete list of primary antibodies, isotype matched controls and secondary 
antibodies for detection of human targets used in this study is reported within 
Table 5. 
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Table 5: Primary and secondary Antibodies used for IHC 
Clone Primary Abs Specificity Host Source 
L-26 Human CD20 Mouse DAKO 
A2452 Human CD3 Rabbit DAKO 
1F8 Human CD21 Mouse DAKO 
124 Human Bcl-2 Mouse DAKO 
IgD Human IgD Rabbit DAKO 
PG-B6p Human Bcl-6 Mouse DAKO 
EK2-5G9 Human AID Rat (196) 
M7187 Human Ki67 Mouse DAKO 
M115 Human CD138 Mouse DAKO 
Secondary Abs 
Rabbit anti-rat biotin Rat Ig Rabbit (biotinylated) DAKO 
Goat anti-mouse Mouse Ig Goat (biotinylated) DAKO 
Rabbit anti-mouse biotinylated Mouse Ig Rabbit (biotinylated) DAKO 
Goat anti-mouse ALEXA 488 Mouse IgG1 Goat Invitrogen 
Goat anti-mouse ALEXA-594 Mouse IgG2ai Goat Invitrogen 
Goat anti-rabbit Goat DAKO 
ABC-HRP/AP DAKO 
Streptavidin Alexa 555 Biotin Invitrogen 
Envision AP/HRP DAKO 
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Image capture of tissue sections 
Images for IHC were captured using a Nikon digital camera linked to a motorized 
light microscope (BX60) from Olympus (London, UK). PhotoShop software was 
used to save and reduce the size of the images. 
Quantitative Taqman real-time PCR 
Extraction of total RNA from human tissues 
RNA was extracted using the Qiagen RNeasy mini kit according to the 
manufacturer's instructions. Tissues stored at -80°C in RNA Later were defrosted 
on ice, weighed and then cut in order to obtain approximately 20mg (30mg of 
tissue is the maximum amount suggested in the protocol to avoid reduction in 
RNA yield and purity). RNA was also extracted from human lymph node as a 
positive control. 
Tissues were placed in a sterile, RNase free tube and 600µl of RLT buffer 
(containing denaturing guanidine thiocyanate with the addition of lOgl of fresh ß- 
Mercaptoethanol/ml of RLT buffer) were added. Tissues were homogenised using 
a rotor-stator homogenizer until the sample was uniformly homogeneous (usually 
20-40 sec). Tissue lysates were centrifuged for 3 minutes at maximum speed 
(13000rpm) in a micro centrifuge and the supernatant transferred to a new RNase 
free micro centrifuge tube. An equal volume of 70% ethanol was added to the 
lysate and immediately mixed by pipetting in order to precipitate RNA, which 
remains in the aqueous phase. An aliquot (700p1) of the sample was added to the 
RNeasy mini column, placed in a2 ml collection tube and centrifuged for 15 s at 
2! 8000 xg (>_10,000 rpm) to allow the RNA to bind to the silica column. The flow- 
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through was discarded and the remaining sample (approximately 500µ1) added to 
the RNeasy mini column and centrifuged as above. 
To avoid any possible DNA contamination, a DNase step was included according 
to the manufacturer's instructions. 350µl of Buffer RW 1 was added to the column, 
centrifuged for 15 s at ? _8000 xg(? _10,000 rpm) and 
the flow-through discarded. 
lOµ1 of DNase I stock solution (previously prepared by dissolving solid DNase I 
(1500 Kunitz units) in 550 µl of RNase-free water) was added to 70µl of Buffer 
RDD, gently mixed and added to the RNeasy mini column silica-gel membrane. 
Following a 15 minute incubation at room temperature (RT), 35Oµ1 of Buffer RW 1 
was added to the column, centrifuged for 15 s at 2_8000 xg (>10,000 rpm) and the 
flow-through discarded. 
The RNeasy column was transferred into a new 2 ml RNase free collection tube. In 
order to wash away contaminants (residual DNA and protein) in the organic phase, 
500 µl of Buffer RPE was pipetted onto the RNeasy column and centrifuged for 15 
s at 28000 xg (>_ 10,000 rpm) to wash the column. The flow-through was then 
discarded and another 500 µl Buffer RPE added to the RNeasy column. The tube 
was centrifuged for 2 min at 28000 xg (2_10,000 rpm) to dry the RNeasy silica-gel 
membrane and the flow-through discarded. To eliminate any chance of possible 
Buffer RPE carryover the tube was centrifuged again for 1 min at full speed 
(13,000 rpm). 
For elution, the RNeasy column was transferred to a new RNase free 1.5 ml 
collection tube, and 30 µl of RNase-free water was pipetted directly onto the 
RNeasy silica-gel membrane and the tube centrifuged for 1 min at 28000 xg 
(210,000 rpm). The elution was immediately frozen at -80°C until required. 
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Quantification of total RNA 
Total RNA isolated within each sample was determined using the NanoDrop® 
ND-1000 UV-Vis Spectrophotometer. This instrument allows for the accurate 
quantification of RNA held within 1 µd of solution and eliminates the need to waste 
large volumes of precious RNA in traditional cuvettes used in standard 
spectrophotometers. The principle behind RNA quantification using NanoDrop 
technology is based on quantification of UV absorbance by nucleic acids, namely 
the Beer-Lambert law. This law predicts a linear change in absorbance with 
concentration of nucleic acids. Absorbance is measured at both 260 and 280 nm. 
An absorbance at 260nm of 1 is equivalent to approximately 40µg/ml of RNA and 
as such this reading is used to determine RNA concentration in solution. As RNA 
has its maximum absorption at 260nm, a further reading at 280nm is used to assess 
purity of RNA in solution. This is determined by the knowledge that pure RNA 
has an A260/A280 of 2.1, thus a value between 1.8-2.0 indicates a relatively pure 
RNA sample although this result is dependent somewhat on the possible 
contaminants. 
1-2µl of sample is pipetted directly onto the measurement pedestal and surface 
tension holds the sample in place whilst measurement is made, which takes less 
than 10 seconds. The spectrum and its analysis is then displayed on the screen of 
the attached personal computer. The Nanodrop provides a scan of the absorbance 
of sample from about 200nm up to 350nm, the relevant range for determining 
RNA concentration and purity. 
Determination of RNA quality and integrity 
RNA integrity was assessed by resolving total RNA on a 0.8% agarose gel. 
Agarose powder, in 1x Tris Acetic Acid EDTA (TAE) buffer (see Appendix II) 
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was boiled in a microwave for 2 minutes, then ethidium bromide (a fluorescent 
dye that binds to nucleic acids) was added and the solution poured into a minigel 
tray where a well-comb was inserted. After polymerization, the comb was 
removed and the gel was placed in a minitank and covered with Ix TAE running 
buffer (Appendix II). 
Samples were mixed with blue loading dye (1: 6) to monitor migration, loaded into 
the gel wells and run at 80V (voltage) for 30 minutes. RNAs were visualized by 
fluorescence of the incorporated ethidium bromide using a UV light 
transilluminator and examined for RNA degradation and DNA contamination. 
RNA should demonstrate two bands on electrophoresis (corresponding to the 28S 
and 18S of eukaryotic ribosomal RNA), with the intensity of the 28S band being 
approximately double that of the 18S band. If the 18S band appears more intense 
than 28S band, or a smear is present, RNA degradation is likely. Extra bands at 
high molecular weight normally indicate genomic DNA carry-over. 
Reverse Transcription PCR 
In Reverse-Transcription PCR (RT-PCR), mRNA is converted to complementary 
DNA (cDNA) using a reverse transcriptase step before being amplified. RNA was 
reverse transcribed to cDNA using the Thermoscript RT-PCR System for First- 
Strand cDNA Synthesis (Invitrogen, cat#11146-016). Briefly, 1µg of extracted 
total RNA from each sample was mixed with 1 µl of Oligo(dT)20 Primers (50 
µM) and 2 µl of 10 mM dNTP mix and brought to a 12 pI volume reaction with 
DEPC-treated water in a 0.5m1 PCR tube. After briefly spinning down in a 
microcentrifuge, samples were incubated for 5 min at 65°C to denature RNA 
tertiary structure and samples were immediately cooled on ice to allow RNA and 
oligos to anneal. For the final reaction, 8 µl of a master mix containing 1 µl of 
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ThermoScriptTM RT (15 U/µl), 1 . tl of 0.1 M DTT, 1 gl of RNaseOUTTM 
Ribonuclease Inhibitor (40 units/µl), 1 gl of DEPC-treated water and 4 gl of 5X 
cDNA synthesis buffer were added. After mixing and a brief spin down of the 
tubes, the reverse transcription to cDNA was run in a PCR machine (Applied 
Biosystems 9700) for Ih at 50°C and the reverse transcriptase was inactivated at 
85°C for 5 min. In order to remove the original RNA that could interfere with the 
quantitative real-time PCR analysis, RNA digestion was performed using 1 gl of E. 
coli RNase H (2 units/µl) at 37°C for 20 min. Finally, the completed cDNA strand 
was diluted to a final concentration of 1 Ong/µl with DEPC-treated water and stored 
until used. 
Quantitative Taqman real-time PCR 
PCR involves amplification of a specific DNA sequence, which spans between 
two sequences of primers. Real-time PCR monitors the fluorescence emitted 
during the reaction as an indicator of amplicon production during each cycle (in 
real time) as opposed to the endpoint detection by conventional quantitative PCR 
methods; it is based on the detection and quantification of a fluorescent reporter 
whose signal increases in direct proportion to the amount of PCR product in the 
reaction. 
For quantitative Taqman real-time evaluation of mRNA expression levels of 
human genes, sequence-specific primers and probes from Applied Biosystems 
were used. Each gene expression assay contains, together with the forward and 
reverse primers, a Taqman MGB probe with a FAM reporter dye at the 5' end. 
Within the probe, the dye is linked to a non-fluorescent quencher; during the 
polymerase reaction, the probe is detached from the cDNA and the quencher is 
released allowing fluorescence emission from the reporter dye. 
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The real-time PCRs were run in triplicate on 384-well PCR plates (Applied 
Biosystems) with an equal loading of lOng of cDNA/well and detected using the 
ABI PRISM 7900HT Instrument. The thermal cycling conditions used, comprised 
a2 min UNG activation step at 50 °C, a 95 °C Taq polymerase enzyme activation 
step for 10 min, and cycles of 95 °C denaturation for 15 sec and 60 °C 
anneal/extension for 60 sec. Results were then analyzed after 40 cycles of 
amplification using the ABI PRISM 7900HT Sequence Detection System Version 
2.1 (SDS 2.1). In addition cDNA from normal human lymph nodes was used as a 
calibrator. Relative quantification was measured using the Comparative Ct 
(Threshold Cycle) Method. Two different endogenous controls (human beta-actin 
and mammalian 18S) were used to normalize for the cDNA of each sample. The 
OCt for each of the triplicate (Ct of the target gene minus Ct of the endogenous 
control) and then the average iCt of the triplicates were calculated. When a single 
value within each triplicate differed substantially from the other two values the 
skewed value was excluded from the analysis. To calculate the QQ Ct, the Q Ct of 
each sample was subtracted to the chosen reference sample (usually a RA 
synovium from a normal individual). The relative quantity was then calculated 
following the equation RQ= 2-'--: - c '' where 2 represents doubling of the amount of 
the product of amplification after each PCR cycle. 
Western blotting 
Western blotting was used to determine effective citrullination and the specificity 
of citrullinated fibrinogen for ACPA. Sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (SDS-PAGE) involves the separation of a 
mixture of proteins, the blotting of these separated proteins onto a nitrocellulose 
membrane and their detection using specific antibodies. The polyacrylamide gels 
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are run in the presence of the anionic detergent SDS that denatures and binds to 
proteins in a constant-weight ratio leading to identical charge densities for the 
denatured proteins. Thus, the SDS-protein complexes migrate in the 
polyacrylamide gel according to size and not charge. 
SM-Polyacrylamide Gel Electrophoresis (SDS-PA GE) 
Proteins can be separated based on their molecular weights. They migrate in 
response to an electrical field through the pores of a SDS polyacrylamide gel 
matrix toward the anode, under denaturing conditions. A discontinuous buffer 
system was used, with buffers of different pH and composition to generate a 
discontinuous pH and voltage gradient in the gel. 
Polyacrylamide gels form after polymerization of monomeric acrylamide into 
polymeric polyacrylamide chains and cross-linking of the chains by N, N'- 
methylenebisacrilamide. The discontinuous polyacrylamide gel consisted of an 
upper 4% stacking gel with large pore size where proteins were concentrated and a 
10% lower separating gel with smaller pore size where they were separated. 
A separating gel mix was carried out using a mini Protean II system (Bio-Rad): in 
a beaker, 10% acrylamide/bisacrylamide separating gel monomer solution 
containing 1.5M Tris-HC1 and 10% SDS was de-gassed under vacuum for 20 
minutes in order to avoid the inhibition of acrylamide polymerisation by oxygen; 
the polymerisation initiator and enhancer, 10% APS and 0.1% TEMED 
respectively, were then added and the solution poured between two glass plates 
separated by 1.5mm spacers. A thin layer of water was placed on top of the 
solution to exclude oxygen during polymerisation. 
After Ihr the layer of water was poured off, a well-forming comb was inserted 
carefully and a 4% acrylamide/bisacrylamide stacking gel monomer solution 
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containing 0.5M Tris-HCI, 10% SDS, 10% APS and 0.1% TEMED, was poured 
on top of the separating gel. The stacking gel was left to polymerise for Ihr, after 
which the comb was removed and the wells washed twice with electrophoresis 
running buffer (containing 0.2M Tris base, 1.5M glycine and 10% SDS). The gel 
was assembled in the electrophoresis tank according to the manufacturer's 
instructions (Bio-Rad) and electrophoresis running buffer poured into both the 
inner and outer chambers. 
The results of the DC colorimetric protein assay were used to calculate the 
volumes of samples required to ensure the loading of an equal amount of protein. 
Equal amounts of protein samples (usually -40µg) were denatured by five minutes 
boiling in 6x loading buffer, containing 0.5M Tris-HC1(pH 7.4), 30% glycerol and 
1% bromophenol blue colorant, in the presence of 10% SDS and the reducing 
agent ß-mercaptoethanol. 
The protein samples were loaded into the gel lanes and then separated by 
electrophoresis at 140V for the first 10 minutes and 100V for the subsequent 60 
minutes. 
A pre-stained molecular weight marker containing labeled proteins of specific 
molecular weights was run in parallel and used to visualize protein migration and 
calculate protein molecular weight. 
Blotting onto nitrocellulose membrane 
Following electrophoresis, proteins were transferred from the polyacrylamide gel 
to a nitrocellulose membrane, with 0.45µm pore size, using a mini transblot 
apparatus (Bio-Rad). Membrane, gel, two pieces of filter paper and two fibre pads 
per gel were soaked in the blotting buffer (containing 1M Tris base, 1M glycine, 
10% SDS and 20% methanol) to equilibrate for 10 minutes. 
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A transfer cassette was assembled consisting of a sandwich containing the 
following layers; fibre pad, filter paper, gel, membrane, filter paper and fibre pad. 
The cassette was then placed in the blotting tank according to the manufacturer's 
instructions, all fully covered with blotting buffer. 
Electrophoretic transfer of negatively charged proteins from the gel to the 
membrane was achieved by the application of a 100V current for lhr. 
Equal protein loading and transfer efficiency to the membrane was verified using 
the protein dye Ponceau S. The membrane was rocked gently with 0.1 % Ponceau S 
staining solution for 10 minutes and then destained with water until pink protein 
bands appeared on the membrane. 
Enhanced Chemiluminescent (ECL) detection 
Immunocomplexed bands were detected by enhanced chemiluminescence 
according to the manufacturer's protocol (Amersham Life Science). 
The method is based on the detection of the emitted light resulting from the 
dissipation of energy from a substance (in this case, luminol) in an excited state. 
Briefly, the HRP enzyme catalyses the oxidation reaction of luminol in the 
presence of enhancers (phenol). Following oxidation, luminol is in an excited state 
of energy. During its decay to ground state it emits light, at a maximum 
wavelength of 428nm, which can be captured on autoradiography film. The 
intensity of light emitted is proportional to the amount of HRP enzyme and, 
consequently, to antigen present. 
The membrane was incubated with an ECL reagent mix (0.125m1/cm2 of 
membrane) containing luminol and enhancers for 1 minute at room temperature. 
The membrane was then wrapped in Saran Wrap and exposed, under red light, to 
light-sensitive autoradiography film (Hyperfilm ECL) for various time periods. 
158 
Table 6: Genes, specific primers and probes used for QT-PCR 
Gene RefSeq Gene Expression Assay ID 
AID NM 020661 Hs00221068 m1 
CD21L NM_ 001006658 Hs01079084_ gl 
BAFF NM_ 006573 Hs00198106 ml 
APRIL NM_ 003808 Hs00182565 ml 
Uß NM_ 002341 Hs 00242737 ml 
CXCL13 NM_ 006419 Hs00757930_ ml 
TNFa NM_ 00594.2 Hs00174128_ ml 
Human ß actin NM_ 001101 Hs99999903_ ml 
Source of all primers and probes: Applied Biosystems. 
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Single cell laser capture micro dissection (LCM) and amplification of IgH 
The technique of LCM allows for the selective adherence of visually targeted cells 
to a thermoplastic membrane. The equipment for LCM comprises an inverted 
microscope under the control of a personal computer an infrared laser and control 
unit, a microscope stage controlled by a joystick and a colour monitor (Figure 15). 
A cap with the adherent thermoplastic membrane is held by a robotic arm over the 
tissue section which is mounted onto a membrane covered slide. A laser beam is 
used to melt the membrane under the tissue section and once adherence of the 
tissue to the activated membrane within the cap overcomes adherence of the tissue 
to the slide, selective removal of desired cells is achieved (Figure 15). The cap 
then fits onto a standard microcentrifuge tube suitable for use in subsequent PCR 
reactions. 
Statistical analysis and Ethics 
Statistical methods and ethics approval are discussed within the materials and 
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Figure 15: Schematic representation of laser capture 
microdissection 
(A) Activation of the laser leads to focal inciting of the 
polymer membrane. (B) Lifting of the cap selectively 
detaches the cells adherent to the activated membrane. 
Reproduced from (3) with permission from the BMJ 




Chapter 3: the Generation and Validation of a Novel 




Rheumatoid arthritis (RA) is one of the most important chronic inflammatory 
disorders in the UK. It affects 1% of adults and causes considerable morbidity, 
substantially reduces quality of life and has a significant mortality(651) (652; 653). 
It results in large direct medical costs (in the UK, this amounts for more than £600 
million (654), with comparable figures reported in the USA(655)) as well as 
extensive indirect societal costs for the individual and their family and carers. 
Treatment of RA remains unsatisfactory despite major advances over the last two 
decades. Conventional disease modifying anti-rheumatic drugs (DMARDs) such 
as methotrexate improve symptoms, and reduce disease progression (rather 
than)but do not prevent the development of erosions(656) (657-659). The 
concurrent use of combinations of two or more DMARDs results in a greater 
improvement but still rarely does more than slow the rate of erosive damage(660) 
(661). Importantly over time it is this erosive damage that accounts for the 
disability that is seen in RA (662). Recent data have shown for the first time that 
we are now able to prevent the onset of erosion by use of biological agents such as 
anti TNF(663) (133; 134) early on in disease. Hence expert opinion now favours 
the use of aggressive treatment (664) during an apparent "window of opportunity" 
as if this is missed erosive damage is inevitable. Use of these agents is, however, 
limited by their high costs (approximately £10k/patient/annum) (665). In addition, 
even in combination with methotrexate 30-40% of patients do not respond to 
treatment (666). The reasons for this are not currently known, but it is clear that 
RA as currently classified, encompasses a heterogeneous group of conditions with 
genetic, biological and clinical variability. This heterogeneity is expressed as a 
very variable clinical course, with not all patients having a poor outcome and 
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scores for joint damage varying 10-12 fold after 10 years of disease (26). Recently 
published data have shown that the heterogeneity seen in radiographic scores 
appears to be divided into 6 main patterns, with some 20% following a more 
benign course(667). For these reasons treatment ideally should be tailored on an 
individual patient basis, maximising treatment to those most likely to have the 
most severe course, as giving all patients with early RA maximal treatment would 
not only incur high costs but the substantial risks of side effects would be 
unacceptable (665; 668). There are some well-known markers of poor outcomes, 
particularly the presence of high levels of auto antibodies including rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies (669). However 
these markers are insufficiently sensitive (670) (671) to reliably identify patients 
within this window of opportunity who go on to have the worst outcomes. 
A potential source of prognostic biomarkers is the synovial membrane. Weyand 
and colleagues(217) have characterised the inflammatory infiltrate into three 
mutually exclusive patterns: diffuse infiltrate (50%), aggregate with a variable 
degree of TB cell segregation (25%) and follicular structures (ectopic lymphoid 
neogenesis [ELN]) with the formation of germinal centres (GC) (25%). 
Importantly Weyand has reported that: follicular synovitis is associated with a 
more severe disease both clinically and radiologically and that each pattern of 
synovitis is associated with a particular cytokine profile (which may explain the 
associated degree of erosive damage seen)(421; 425). This classification, however, 
relies on research from a single group and is predominantly inferred from 
synovium obtained from a small patient cohort during arthroplastic surgery in 
severely destroyed joints, the histological appearance of which may be different to 
that in established and early RA(672). Recent reports have also shown that the 
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synovial membrane has a more continuous spectrum of inflammatory infiltrate 
without the originally proposed mutually exclusive distinction between 
grades(334; 388), making the application of the Weyand histological subtypes 
unfeasible. This is emphasised by the variation in diffuse infiltrate seen between 
synovial tissues with some lacking any infiltrate whilst others having a densely 
infiltrated, albeit unorganised synovium, both of which would be termed diffuse 
under the Weyand system, although they may reflect distinct clinical phenotypes. 
Indeed, a sized based classification system for lymphoid aggregates has been 
proposed with a division into three grades according to radial cell count, grade 1 
(2-5 cells), grade 2 (5-10 cells) and grade 3 (>10 cells) (391). Ectopic GC like 
structures have been shown to be exclusive to grade 3 aggregates (334) and 
importantly to be capable of functioning as sites of antigen driven B cell 
proliferation (415; 673). This suggested functionality is further supported by their 
association with the presence of RF in the serum, suggesting a role for them as 
ectopic sites of autoantibody manufacture (673). 
Thus in order to compare reliably synovial biopsies for both degree of organisation 
and diffuse infiltrate, both sequentially and between patients, a quantitative 
pathological scoring system is required. A number of reports have already 
attempted to link synovial histological scoring systems with clinical phenotype 
including the semi quantitative Rooney(448) and Koizumi scores (450)and the 
quantification of sublining macrophage number. The Rooney score does not 
associate with joint damage progression in established disease(176). The Koizumi 
score only associates with erosive damage in a cross sectional cohort (451) and 
reports of macrophage number as a potential biomarker produced conflicting 
results(454; 455). 
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Further the advent of digital image analysis (DIA), which allows rapid semi 
automated processing of tissue, has revolutionised the examination of the synovial 
membrane. Indeed validation of DIA has shown it to be not only equivalent to the 
gold standard of manual counting (MC) (444) but to minimize bias, to be valid for 
the widest range of pathological markers and to be more sensitive to changes 
within the synovial membrane than semi-quantitative analysis (445)and has 
therefore been suggested to be the optimum tool for pathobiological assessment of 
the synovial membrane in randomised control trials(674). 
Thus there is a pressing need for novel biomarkers in RA and lymphocytic 
organisation appears to hold potential. It was on this basis that I aimed to develop 
and validate a quantitative scoring system for rheumatoid synovial tissue, using 
DIA to accurately quantify both the degree of aggregation and diffuse infiltrate 
within each tissue sample. 
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Aims and objectives 
The aims of this study were to: 
i. Validate the use of DIA within our laboratory as a means to quantify 
mononuclear cell number within synovial tissue 
ii. Develop a quantitative aggregational score (QAS) using DIA to determine 
sensitively and reliably the degree of lymphocytic aggregation and diffuse 
infiltration within RA synovial tissue. 
iii. Validate the QAS by a comparison with a previously reported system of 
histological classification (334) 
iv. Validate the QAS by determining intra and interobserver reliability 
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Materials and methods 
Patients and samples 
Paraffin embedded synovial tissue was collected from 24 RA patients following 
arthroplastic joint surgery and was used for the generation and validation of the 
quantitative scoring system. All patients fulfilled the 1987 revised American 
College Rheumatology (ACR) guidelines for RA. All procedures were performed 
following written informed consent approved by the hospital's ethics committee 
(REC 05/Q0702/ 1). 
In addition paraffin embedded synovial tissue was available from 60 patients from 
the DAMAGE study cohort, described in detail in (176) and, this tissue was used 
to determine reliability of the histological scoring system developed. All patients 
fulfilled the 1987 ACR criteria for RA(12). All patients gave their informed 
consent for biopsy and the study received approval from the Ethics of Human 
Research Committee of St George Hospital, Sydney, Australia. 
Validating Digital Image Analysis to quantify synovial cellular number 
within our laboratory 
Although the validation of DIA has shown it to be equivalent to the gold standard 
of MC in determining cellular number within synovial tissue(444), it was 
important to validate the technique within our laboratory. Thus in order to 
determine whether the application of DIA within our laboratory could reliably 
determine number of nuclei within a defined area of synovial tissue, 12 RA 
patients were identified from the synovial biopsy bank and 5µm thick paraffin 
embedded sections cut from each block and stained with standard H&E. Sections 
were then digitised to create a stitched together image of the whole section of 
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tissue using an Olympus microscope fully slaved to an Image analysis programme. 
5 random areas within each tissue were then defined using a digitising tablet 
coupled to the image analysis software and the number of nuclei within each area 
(region of interest [ROI]) determined using MC. A second independent observer, 
blinded to initial results, then used the colour threshold technique to discriminate 
haematoxylin stained nuclei (and hence cellular number) within each defined area. 
Numbers of nuclei within the defined area were then determined using the image 
analysis software programme and correlated with numbers of nuclei determined by 
MC. In addition as nuclei within lymphocytic aggregates were noted to be at a 
higher density than in intervening tissue areas and thus potentially more difficult to 
discriminate, aggregates within all tissue sections were defined (Figure 16) and 
nuclear number (and nuclear area using DIA) within aggregates determined using 
both MC and DIA. 
Determining the effect of different histological staining techniques on 
the reliability of DIA to determine nuclear number 
As DIA uses colour threshold analysis to discriminate nuclei within synovial tissue 
sections I hypothesised that different tissue staining techniques may have an effect 
on the accuracy of DIA to determine nuclear number within tissue sections. Three 
RA patients were identified from the synovial tissue biopsy bank with varying 
degrees of synovial inflammation and from each patient three sequential 5µm 
sections of paraffin embedded synovial tissue were stained each with standard 
H&E, toludine Blue and the B cell marker CD20 as previously described(675) and 
then developed with alkaline phosphatase and vector red (Vector Red Labs). 
Three aggregates within each section were then identified and nuclei counted 
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manually and then quantified using DIA by a second blinded observer. Results 
from DIA were then correlated with number of nuclei as determined by MC. 
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a. 
Figure 16: Segmentation of haematoxylin stained nuclei 
Using colour threshold analysis haematoxylin stained structures were 
discriminated within synovial tissue within areas defined by a digitising tablet 
(outlined in red) coupled to the Image analysis software. Size based filters particles 
were used to eliminate any small nonnuclear structures. Scale bars represent 
200gm. 
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Development of a quantitative aggregational score for RA synovium 
As published data describing methods of histological scoring of rheumatoid 
synovium had used a system of random sampling of tissue to allow the rapid 
assessment of large quantities of tissue (676) I initially applied this methodology 
to develop a scoring system termed the "montage method". In addition a novel 
approach to assessing synovial tissue, "the overview method" was also developed. 
In both methods sections were digitized using an image analysis package slaved to 
a fully motorized Olympus microscope (Figure 17a) and an aggregate was defined 
as "a clearly demarcated region of high mononuclear cell density, distinct from the 
surrounding tissue, organized concentrically, perivascularly and greater than 5 
cells in diameter". 
Quantification of aggregational tendency of synovial tissue using "the montage 
method" 
H&E stained 5µm thick sections of paraffin embedded RA synovial tissue were 
examined at low power (x4 magnification) and a complete image of each section 
constructed by automated image capture if identifiable lining layer was present 
(Figure 18). The complete image of each synovial section was then used to 
automatically generate a series of systematic uniform random samples of high 
power fields (hpfs) (x20 magnification) overlying the section representing 
approximately 20% of the total section area (Figure 18). Any hpfs containing areas 
of synovium without at least one border of lining layer were excluded from further 
analysis. A digitizing tablet coupled to the image analysis software was used to 
outline the area occupied by synovium and mononuclear cell aggregates on each of 
the selected hpfs. Next, the haematoxylin stained nuclei per field were segmented 
(separated from other synovial structures) using colour threshold analysis (Figure 
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16). The area fraction (A/a) of total synovial tissue analysed occupied by 
mononuclear cells in aggregate form was determined by integrating the regions of 
interest previously delineated with the nuclear density data provided by threshold 









Figure 17: The overview method 
ý.  
1. Sections for both the montage and overview methods were digitised using an 
image analysis package slaved to a fully motorized Olympus microscope 
2. A digitised section of RA synovium. Total area of section (A) is outlined in blue. 
Aggregate areas (AG) within the section are outlined in red 
3. Nuclei within an aggregate area are discriminated using colour thresholding via 
a histogram 
4. The original digitised section can be viewed at higher resolution without loss of 
quality (c) 




Figure 18: A complete image of each section of synovial tissue constructed by 
automated image capture "the montage method" 
A complete image of each synovial section was generated. Individual squares 
within the overlying grid represent each individual high power field (hpf). The 
image analysis software was used to automatically generate a series of systematic 
uniform random samples of hpfs that were then used for analysis of lymphocytic 
organisation. 
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Quantification of aggregational tendency of synovial tissue using the 
"overview method 
5µm thick paraffin embedded haematoxylin stained sections of RA synovial tissue 
were first examined and those without an identifiable lining layer were omitted 
from the analysis. Sections were then digitized to obtain a stitched together 
overview image of each synovial section (Figure 17b). Using a digitizing tablet the 
boundary of the section was outlined (A), the section was then examined at higher 
magnification (Figure 17 d and e) and areas within the tissue occupied by 
mononuclear cell in aggregate form (AG) defined. Any aggregate with a radial cell 
number greater than 5 (grade 2 aggregate (334)) was included in the analysis. A 
histogram was then used to discriminate nuclei within the outlined areas (A and 
AG) (Figure 17b) and to calculate the area occupied by nuclei. This could then be 
used to calculate the following: 
1. The Aggregate Score (AS) = area fraction of whole tissue occupied by 
mononuclear cells in aggregate form 
2. The Diffuse score (DS) = area fraction occupied by mononuclear cells in the 
remaining tissue. 
The overview method is summarised in Figure 20. 
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Tissue preparation 
1. Stain sections with H&F. 
z. Iay& not present 
Acquire digital images of sections (see Figure) 
using 20x objective and a computerized image analysis package (analysis GmBH) slaved to a fully motorized 
microscope (Olympus BX61 with motorized x, y and z axes) section is digitised to create a photomontage of the 
entire section area 
Discard empty hpfs and generate random starter number between 1 and 5 
Assign regions of interest (ROIs) within each haf 
Total area (A) of synovhxn within each hp! (n.... ) determined 
Mononuclear cells In aggregate form(>Scells diameter) digitisedwithin each hpf (AG) 
Area occupied by haematoxylin stained nuclei within ROI determined 
Results 
Total area occupied by each aggregate (AG), Section area (A) Nuclear area (NA) 
Total Aggregate area (AGA =F AG,... AGN) 
Aggregate nuclear area (AGNA = nuclear area bounded by AG) 
Aggregate nuclear area fraction (AGNAF = AGNA/AGA)) 
Aggregate score = AGNAIA"100 
Figure 19: Flow chart illustrative of the montage method for quantifying degree of 
mononuclear cell aggregation within synovial tissue 
177 
Pilot study to determine feasibility and validity of two methodologies 
1. The montage method: As the montage method randomly samples hpfs 
within each synovial section a feasibility study was conducted to determine 
the optimum sampling intensity (via assessment of inter and intra sample 
variability) necessary to accurately characterise the inflammatory infiltrate. 
Thus in order to determine the minimum number of hpfs required to obtain 
an accurate mean of area fraction occupied by mononuclear cells in 
aggregate form within a tissue, two patients were identified one with a 
highly inflamed synovium and one with a less inflamed synovium. For 
each patient a section from each available site was digitised and all hpfs 
within each section sampled exhaustively. 
2. The overview method: the same two patient samples identified above were 
also analysed with the overview method by a second observer blinded to 
initial results. 
Results obtained from each methodology generated from the pilot study were then 
compared in order to determine consistency in methodology. 
178 
Tissue Dreoaration 
1. Stain sections with H&E. 
2. Sections examined and discarded if lining layer not present 
using 20x objective and a computerized image analysis package (analysis GmBH) slaved to a 
fully motorized microscope (Olympus BX61 with motorized x, y and z axes) section is digitised 
to create a photomontage of the entire section area 
The perimeter of the section is digitized to produce a ROI of the sectional area (A)'. only sublining lying 
beneath an intact lining layer used for analysis 
Each perivascular mononuclear cell aggregate >5 cells in diameter' within the section perimeter is 
manually digitized to give aggregate areas (AG, -.. 
AG, ) 
Colour thresholds are selected to discriminate haematoxylin stained nuclei. 
Automatically segment nuclear profiles using the above thresholds. 
Results 
Total area occupied by each aggregate (AG), Section area (A) Nuclear area (NA) 
Total Aggregate area (AGA =F AG,... AG. ) 
Aggregate nuclear area (AGNA = nuclear area bounded by AG) 
Aggregate nuclear area fraction (AGNAF = AGNA/AGA) 
Diffusely inflamed area (DIA=A-AGA) 
Diffusely inflamed nuclear area (DINA = NA-AGNA) 
Aggregate score = AGNA/A'100 
Diffusescore= DINA/DIA '100 
Figure 20: Flow chart illustrative of the overview method for quantifying 
degree of mononuclear cell aggregation and diffuse cellular infiltration within 
synovial tissue 
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Comparison of the overview method with a semi-quantitative 
inflammatory score 
Following the pilot study the overview method was selected for further 
application. In order to further validate the QAS 25 sections of paraffin embedded 
synovial tissue from 7 different patients were assessed using the QAS. A second 
independent observer blinded to the QAS result then graded tissues using a semi- 
quantitative aggregational score modified from a previously reported method(334). 
Tissues were graded as either aggregate or diffuse and then as either aggregate 1,2 
or 3 according to the presence of grade 1,2 or 3 aggregates within the tissue 
section, or diffuse. Results of the QAS were then compared to the results of the 
semi-quantitative score. 
Determining inter and intra observer reliability for the QAS 
In order to determine both inter observer and intra observer reliability 150 5µm 
sections from 60 RA patients (available from a historical cohort "the DAMAGE 
study")(176) were digitised and underwent QAS analysis by an observer blinded to 
study data. Measurements were then repeated by the same observer following a2 
week interval. 10 random sections were then analysed by a second independent 
observer. Intra-class correlations (ICCs) for each were determined. 
Statistical analysis 
Linear regression analysis was performed to determine the relationship between 
MC and DIA in determining nuclear number. Spearman's correlation coefficients 
were used to investigate the correlation between nuclear area/number (DIA) and 
nuclear number (MC). ICCs were used to analyse reproducibility of the QAS. 
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All results were analysed using GraphPad Prism version 3.03 for Windows, 




Digital image analysis reliably determines number of nuclei within 
synovial tissue sections 
In order to determine whether DIA was as reliable technique as MC (the gold 
standard) in determining nuclei number 5 random areas within digitised sections of 
12 synovial tissue samples were outlined as ROI with a digitising tablet (Figure 
18). The number of haematoxylin stained nuclei within each ROI was counted 
manually and a second independent observer then used DIA to determine the 
number of nuclei within the same ROI. A close correlation between MC and DIA 
for determining nuclear number was observed (r2 0.98, linear regression) validating 
the technique of DIA for determining nuclear number within our laboratory 
(Figure 21). A similar analysis was subsequently performed on the same tissues 
correlating number of nuclei within aggregate areas of tissue as determined by MC 
and DIA and the tight correlation between MC and DIA was not preserved 
(r20.51). This poorer correlation reflected the tightly packed nuclei without distinct 
borders within a number of densely packed aggregates, in which the Image 
analysis programme was unable to distinguish individual nuclei. Thus area 
occupied by nuclei within each aggregate was correlated with number of nuclei as 
determined by MC, and as a tighter correlation was seen (r2 0.85). Therefore area 







Variance in number of nuclei determined with MC 
Figure 21: Linear regression analysis comparing variance in number of nuclei 
determined by DIA and number of nuclei determined by MC. 
12 sections of synovial tissue were digitised and the number of nuclei within 
specific delineated regions of interest within the tissue determined firstly by 
manual counting (MC) and then using digital image analysis (DIA). A tight 
correlation was seen between MC and DIA demonstrating reliability for the 
technique. r2 value shown. Lines represent 95 and 99% confidence intervals- 
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The highest correlation between manual counting and digital image 
analysis is seen when synovial sections are stained with toludine blue 
In order to quantify the effect of staining technique on reliability of measurement, 
number of nuclei as determined by MC was compared to area fraction of nuclei 
determined by DIA within aggregate areas within sections stained with H&E, 
Toludine Blue and the B cell marker CD20 (developed with vector red). Three 
aggregates within each section were outlined as regions of interest within each of 3 
sequentially cut 5µm synovial sections from 3 different patients and nuclei 
quantified for each different staining method. The highest correlation between MC 
and DIA was seen when sections were stained with toludine blue (r 0.99). A 
relatively poor correlation was seen when sections stained with CD20 were 
examined (r 0.80) and a good correlation when H&E stained sections were 
examined (r 0.98) (Table 7). 
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Table 7: Spearman's correlation coefficients (and p values) for correlations of 
Digital Image analysis vs manual counting using different histological stains. 
In order to determine whether different staining techniques affected reliability of 
DIA to quantify nuclei, three sequentially cut sections of paraffin embedded 
synovial tissue from three different patients were stained with haematoxylin and 
eosin (H&E), toludine blue and the B cell marker CD20. Manual counting (MC) 
was then used to determine number of nuclei and digital image analysis (DIA) to 
determine area occupied by nuclei within each of three aggregates defined within 
each tissue section. Results show correlation between number of nuclei counted 
using MC and nuclear area defined by DIA. Results were analysed using 
Spearman's rank, p values <0.05 were taken as significant. 
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The overview and montage methods demonstrate internal consistency 
in determining area fraction of tissue occupied by mononuclear cells in 
aggregate form but the montage method is highly time intensive 
The montage method:. In order to determine the minimum number of randomly 
chosen hpfs required to represent accurately the overall aggregational tendency of 
the tissue 13 synovial samples were analysed exhaustively (Table 8) and the 
results expressed as a plot of the progressive sample mean area fraction vs. number 
of hpfs examined (Figure 22). The number of hpfs at which the sample mean lies 
consistently within the 95% confidence interval for the sample population was 
determined and used as the basis for the number of fields required for examination 
in subsequent studies. Increasing the sample number further would produce no 
significant improvements in the accuracy of the mean and would increase the costs 
of analysis disproportionately. 
For tissue (a) the optimum number of hpfs examined was 35 and the area fraction 
of tissue occupied by mononuclear cell aggregates is 0.03 (Figure 22a). For tissue 
(b) the optimum number of hpfs was 46 and the area fraction of lymphocytic 
aggregates 1.79 (Figure 22b). Thus a minimum of 46 hpfs are required for accurate 
determination of lymphocytic aggregation within each sample. 
Overview method: the same patient samples (Table 8) used for the montage 
method were also analysed with the overview method (Table 9) by a second 
observer blinded to initial results. 
The pilot study demonstrated that use of the montage method would be unfeasible 
for practical application to clinical studies, as the analysis of 46 hpfs would be 
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highly time intensive. When results for mean area fractions of mononuclear cells 
in aggregate form obtained by each method were compared however no significant 
difference was seen between the methodologies thus demonstrating internal 
consistency. On this basis the overview method was chosen for all subsequent 
analyses and is referred to from herein as the quantitative aggregational score 
(QAS). 
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Table 8: Number and sites of synovial samples analysed for pilot study 
2 patients were identified for inclusion in the pilot study to compare use of the 
overview and montage methods for quantifying cellular organisation within 
synovial tissue. 
Biopsy site No of biopsies 
per site 
Patient I (inflamed tissue) SPP 2 
C' P. ) 2 
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Figure 22: Progressive mean plot of area fraction of mononuclear cell 
aggregates within a sample of RA synovium versus number of high power 
fields examined. 
The progressive mean is an empirical tool used to illustrate intra-sample 
variability. As the number of hpfs (x-axis) increase the rate of change of the mean 
reduces to a point where further sampling provides no further increase in the 
accuracy of the parameter estimate (in example a. the optimum sampling intensity 
lies in the region of 35 fields (vertical drop line, in example b the same is true at 
46 fields). (Blue horizontal lines show mean +/- 95% confidence for the 
population mean) Mean for tissue a is 0.03 (expressed as area fraction) and 1.65 
for tissue b (expressed as % of total area). 
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Patient Mean area fractions (+/- SD) of synovial tissue 
identification occupied by mononuclear cells in aggregate form 
no. 
1 (n=6) 
2 (n=7) 1.65 (0.7) 1.79 (0.8) >0.5 
Table 9: Results from the pilot study demonstrate internal consistency in both 
the overview and montage methods of analysis 
Mean area fractions (+/- SD) of synovial tissue occupied by mononuclear cells in 
aggregate form were determined for 2 different patients. There is no significant 
difference between mean scores as determined by either the montage or overview 
method. N=number of samples examined per patient 
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2.88(l) 3 (1.3) >0.5 
A higher quantitative aggregational score correlates with a higher semi- 
quantitative aggregational score 
In order to determine whether the QAS as determined by the overview method 
could reliably distinguish aggregate from diffuse tissues, and whether tissues with 
more organised aggregates generated higher aggregate scores, results from the 
aggregate score component of the QAS were compared to a previously published 
semi quantitative aggregational score(334). 25 sections from 7 patients were 
analysed in total and the results demonstrated that tissues classified as aggregate 
achieved a much higher grade in the QAS (Table 10), with the highest aggregates 
scores in tissues containing predominantly grade 3 aggregates, whilst tissues 
graded as diffuse had much lower aggregate scores. 
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Table 10: A higher quantitative aggregational score correlates with a higher 
semi-quantitative aggregational score 
7 different patients were identified with widely varying inflammatory infiltrates. 
Synovial tissue from a number of sections from each patient were graded as either 
diffuse, aggregate 1,2 or 3 according to a previously published semi-quantitative 
aggregational score (334). A second observer blinded to these results then assessed 
the tissues using the quantitative aggregational score (QAS) described within this 
chapter. Patients graded as aggregate had consistently higher aggregate score (AS) 
component of the QAS than those graded as diffuse. 
Tissue (no sections 
Mean AS per tissue Grade of tissue 
sampled) 
(+/- SD) 
19816 (5) 2.88 (1.41) 
11958(3) 1.64 (1.51) 
12449 (3) 0.08 (0.01) 
2450(2) 0 







The QAS is a highly reproducible pathological scoring system 
In order to determine whether both components of the QAS, the aggregate (AS) 
and diffuse scores (DS), were reproducible, intraclass correlation coefficients 
(ICC) were determined for both intraobserver (n=152) and interobserver variability 
(n=10). Excellent reliability in measurement was demonstrated with ICCs >0.9 for 
both scores and both measurements (Table 11), suggesting that the QAS would be 
a sensitive measure of variability within the synovial membrane. 
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Table 11: Intraclass correlation coefficients (ICC) for inter and intra observer 
variability for aggregational score and diffuse score 
In order to determine interobserver variability 150 sections of synovial tissue 
underwent scoring using the QAS, generating both aggregate (AS) and diffuse 
scores (DS). Scoring was repeated by the same observer following a two week 
interval. In addition in order to determine intra observer variability a second 
independent observer analysed 10 randomly chosen sections. 
Intra observer variability (n=10) 0.92 0.90 
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Discussion 
Predicting the prognosis of individual RA patients is at present difficult and new 
prognostic markers are urgently needed in order to tailor the most intensive 
expensive treatments to those most in need. The synovial membrane, as the 
primary site of inflammation in RA, shows potential as a biomarker and as such a 
number of synovial histological scoring systems have been developed although 
none currently has been shown to predict reliably prognosis(455). A number of 
factors, including the use of less sensitive semi quantitative scoring methods may 
have affected these results, as well as the inclusion of a number of non 
inflammatory measures within the scores. Aggregate structures within the synovial 
membrane have been associated with a poorer prognosis in cross sectional studies 
and as such their identification is a putative biomarker(42 1), with an emphasis on 
quantification as larger aggregates have been associated with functionality(334). 
DIA is the preferred means of analysis of synovial tissue for clinical trials, as it is 
an efficient method of analysing large quantities of tissue and further has been 
demonstrated to be sensitive to pathological change within the synovial membrane 
(444; 445; 674; 677). Thus the aim of this study was to develop and validate a 
quantitative aggregational scoring system using DIA capable of accurately and 
sensitively determining organisational tendency of the inflammatory cells infiltrate 
within rheumatoid synovial tissue for use in clinical studies. 
I first validated the use of DIA to determine number of nuclei within our 
laboratory, and as has been shown by other groups(444), demonstrate that DIA 
approaches the reliability of the gold standard MC in determining nuclear number 
on H&E stained tissue. It is important to note that if densely infiltrated aggregates 
were analysed where nuclear borders overlapped, it became difficult for the image 
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analysis programme to distinguish separate nuclei. A more representative measure 
of cellular infiltration was area fraction of tissue occupied by mononuclear cells 
and this was subsequently used. As nuclei are discriminated using a colour 
threshold technique I also investigated the effect of different staining techniques 
on DIA reliability in detecting nuclear number. I found that staining synovium 
with toludine blue produced equivalent results to those obtained with H&E, but a 
poorer correlation was noted when counting numbers of CD20+ B cells identified 
with IHC and developed with vector red. This variation is likely the result of a less 
distinct histogram produced when discriminating nuclei within tissue following 
IHC staining, a result of a wider red spectrum. Thus my approach to developing a 
scoring system used H&E stained tissues, a preferable stain to toludine blue as the 
implementation of the scoring system would include historical cohorts of patient 
tissues already stained with H&E. 
Two scoring systems were developed, the montage and the overview method. The 
initial step for both methods was the generation of a digitised image of a tissue 
section. The montage method randomly sampled a number of hpfs within the 
tissue and determined the area fraction of mononuclear cells within each hpf in 
aggregate form. As only a fraction of the total area of section was sampled it was 
thought that this would produce a highly efficient means of sampling large 
volumes of tissue, in fact the converse was true and as data produced from a pilot 
study demonstrated a minimum requirement of 46 hpfs to be examined in order to 
determine a mean for the whole tissue, this technique was determined unfeasible 
for future practical application. The overview method, paradoxically, although 
analysing the whole tissue section was significantly less time consuming. The 
pilot study also demonstrated internal consistency between both methodologies, 
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i. e. the same result was produced if the tissue was analysed by either method. Thus 
the overview method was adopted as my method of choice. Analysis of synovial 
tissue with the overview method resulted in two scores, the aggregate score (AS) 
and the diffuse score (DS), the AS reflecting the area fraction of whole tissue 
occupied by mononuclear cells in aggregate form and the DS reflecting the area 
fraction of tissue occupied by mononuclear cells in the remaining tissue. 
The overview method, subsequently referred to as the quantitative aggregational 
score (QAS) was subsequently validated against a number of measures. By 
comparing the QAS with a semi-quantitative inflammatory score, I demonstrated 
that tissues with a high degree of inflammatory cell organisation (as determined by 
the semi quantitative score) had a higher AS. In addition I also noted that one 
patient received a classification of diffuse using the semi-quantitative 
aggregational score and conversely received a positive AS. This was a result of a 
much more thorough analysis of synovial tissue using the QAS and so the likely 
identification of more aggregates and further tissue being graded as aggregate in 
the semi-quantitative methodology only if aggregates were the predominant 
infiltrate, rather than an occasional grade 2 aggregate leading to a positive AS 
when using the QAS. It remains to be seen whether either the semi-quantitative 
histological score or the QAS holds potential as a prognostic marker, or indeed 
whether the QAS is a superior histological score, although a study investigating 
this is currently underway in early arthritis within our group. I also investigated 
inter and intra observer variability and demonstrated that the QAS had excellent 
reliability in measurement for both the DS and AS, suggesting that the QAS would 
be highly sensitive to change within the synovial membrane. 
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In summary I have developed a novel QAS for rheumatoid synovium that 
determines both the degree of aggregational tendency of infiltrating mononuclear 
cells within synovial tissue and the degree of diffuse cellular infiltration and have 
demonstrated this score to be highly reliable, suggesting that it would be highly 
sensitive to change within the synovial membrane and thus of practical application 
in clinical trials. 
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Chapter 4: A Novel Quantitative Histomorphometric Score for 
Rheumatoid Synovium: Clinical, Biochemical, Synovial and 
Imaging Correlates from the Damage Study Cohort 
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Introduction 
The rheumatoid synovial membrane is now acknowledged to be critical in driving 
rheumatoid arthritis (RA) pathogenesis. This concept is further strengthened by the 
demonstration that synovial biomarkers do not alter in the absence of effective 
therapy, unlike clinical assessment using disease activity scores (DAS) which have 
been shown to fluctuate with placebo therapy(678). Further the development of 
minimally invasive synovial biopsy techniques(679) has made the acquisition of 
tissue, including sequential biopsies, for both clinical studies and randomized 
control trials (RCTs) feasible and highly desirable. 
Until recently data correlating ectopic lymphoneogenesis (ELN) with clinical 
phenotype was limited to small patient cohorts with samples from arthroplastic 
joints and thus end stage disease, with no data available from early and established 
disease. Furthermore no reports have investigated the role of ELN as a prognostic 
marker for joint damage progression. In addition although the pathogenic potential 
of ELN is currently causing much debate in the literature (426) a crucial question 
in addressing pathogenicity remains unanswered i. e. whether the distribution of 
ELN varies significantly throughout the joint. 
Critically, the debate surrounding the role of ELN in RA has taken on increased 
importance as a pivotal role for B cells in the pathogenesis of RA, including in the 
synovial compartment, has been highlighted by the efficacy of B cell depleting 
agents(467). Moreover recent evidence suggests that the presence of ELN defines 
patients resistant to anti-TNF therapy(387), and that B cell infiltrates within the 
synovial membrane may play an important role in determining response to B cell 
depletion therapy(424; 552; 680). 
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In order to reliably compare synovial biopsies, both sequentially and between 
patients, I developed and validated a pathological scoring system, the quantitative 
aggregational score (QAS), capable of quantifying both the degree of aggregation 
(aggregate score [AS]) and diffuse infiltrate (diffuse score [DS]) within synovial 
tissue (Chapter 3). As a number of crucial questions remain regarding both the role 
of ELN in defining clinical phenotype and prognosis I aimed to use both clinical 
data and synovial tissue from a historical cohort of patients (the DAMAGE study 
cohort (176)) to test the hypothesis; whether in established RA, the level of 
synovial lymphoid organization predicts clinical phenotype, synovial cellular and 
cytokine levels, and joint damage progression. Hence, allowing not only the 
identification of patients in poor prognostic groups but also the identification of 
patients requiring aggressive therapy. Further, as the DAMAGE study patient 
cohort had synovium obtained arthroscopically from three distinct sites within the 
knee I also aimed to test the hypothesis that synovial inflammation (as determined 
by AS and DS) did not vary significantly throughout the knee joint 
Aims and Objectives 
Using both clinical data and synovial tissue available from an historical cohort of 
patients (the DAMAGE study cohort) the aims of this study were to determine 
whether: 
i. There was significant variation in AS and DS throughout the joint 
H. Lymphocytic organisation correlates with local synovial cellular and 
cytokine parameters 
M. Lymphocytic organisation predicts clinical phenotype and joint damage 
progression 
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Materials and methods 
Patients 
Tissue and clinical data were available from 52 patients within the DAMAGE 
study cohort, described in detail in (176). All patients fulfilled the 1987 revised 
ACR criteria for RA(12). Patients were all naive to biological therapy and took a 
range of disease modifying drugs. Oral corticosteroids and non steroidal anti- 
inflammatory drugs were allowed. All patients gave their informed consent for 
biopsy and the study received approval from the Ethics of Human Research 
Committee of St George Hospital, Sydney, Australia. 
Clinical, radiological and laboratory evaluation 
Disease characteristics assessed included disease duration and the presence of IgM 
RF as determined by latex agglutination and anti-cyclic citrullinated peptide (anti- 
CCP) antibodies as measured by the anti-CCP2 ELISA. Disease activity was 
measured by baseline measurements of the 28 swollen and tender joint count, DAS 
score, erythrocyte sedimentation rate (ESR), platelets and C-reactive protein levels 
(CRP). Joint damage progression at baseline and 24 months was assessed by 
comparison of radiographs of hands and wrists using a modified Larsen score as 
previously described(176) and magnetic resonance imaging (MRI) assessment of 
the dominant-hand metacarpophalangeal (MCP) joints. 
Synovial biopsy samples 
At baseline patients had undergone arthroscopy of the knee joint under local 
anaesthetic. Multiple synovial biopsy samples were obtained from predetermined 
sites (suprapatellar pouch (SPP), medial perimeniscal (MPM), and cartilage- 
pannus junction (CPJ)), as previously described (21). 
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Synovial biopsy samples were either immediately snap-frozen in liquid nitrogen 
and stored at -80°C for subsequent RNA extraction or placed in 4% formalin for 
histology. After paraffin embedding 5µm thick sections were cut and mounted 
onto glass slides. 
For histological assessment, sections were initially given a simple classification as 
either aggregate or diffuse. Aggregate sections had at least one identifiable grade 2 
(or 3) aggregate using a previously described scoring system according to radial 
cell count (334) and diffuse sections only grade 1 aggregates or no lymphocytic 
organisation. Next, using DIA, sections were digitized and scored using the 
overview method (Chapter 3) to determine both the DS and AS. 
Variability of the score throughout the joint 
To determine whether there was significant variation in AS and DS between 
biopsies taken within the same site and between biopsies taken at different sites 
within the knee joint both AS and DS were determined at each available site and 
compared using intra class correlation coefficients (ICCs). 
Agreement between repeated measurements of the same synovial biopsy 
(ICCRepeated Measurements, ICCRm) was determined by calculating the ICC. 
Agreement between first versus second biopsies within the same site (ICCwjthin_ 
site, ICCw5) (SPP, CPJ and MPM) was calculated by ICC. Any reduction below 
ICCRm may be attributed to variation in pathology between biopsies (rather than to 
measurement error). 
ICCwS - 62measurements/ (a2measurements+(y2within-site +a2measurement error) 
Agreement between synovial biopsies taken at different Sites (ICCBenee,,. sites _ 
ICCBS) was calculated using ICC. Any reduction of the ICCBS below the ICCRM 
may be attributed to variation in pathology between sites. 
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ICCBS = 02measurements / (a2measurements+ß2between-site +a2measurement error) 
Correlation of lymphocytic organisation with synovial cellular and 
cytokine parameters 
5µm thick paraffin embedded synovial sections were stained using 
immunohistochemistry to detect B cells (anti-CD20) and macrophages (anti- 
CD68). After Ag unmasking using Target retrieval solution (pH 6; 
DakoCytomation) and incubation with protein block solution (DakoCytomation) 
primary Ab (anti-CD20 or antiCD68[Table 5]) was incubated at an appropriate 
dilution for 1h at room temperature and biotinylated rabbit anti-mouse Ig was 
used as a secondary Ab. Following a 1-h incubation and three washes, HRP or AP- 
streptavidin-biotin complex (DakoCytomation) was added to the section and 
incubated for 30 min. After further washes colour reaction was developed with 
diaminobenzidine (HRP, DAB; DakoCytomation) or Vector red (for AP; Vector 
Laboratories). Numbers of both macrophages and CD20+ B cells per hpf per each 
slide were determined using manual counting and a mean number of cells per hpf 
per section determined. Significant differences in numbers of macrophages and B 
cells in aggregate and diffuse tissues was then determined. 
Synovial biopsy levels of mRNA for IL 10, TNFa, IFN? and IL 1ß had been 
determined previously and the technique is described in (176). Briefly total RNA 
was extracted from snap-frozen synovial biopsy samples in parallel, using the 
Chomczynski technique then quantified and stored at -80°C before reverse 
transcription-polymerase chain reaction (PCR) analysis. Quantification was 
performed using an external standard curve, in a modification of a previously 
204 
reported technique (421). Cytokine mRNA levels in tissues graded as both 
aggregate and diffuse were then analysed for significant differences. 
Correlation of lymphocytic organisation with clinical parameters 
In order to minimise sampling error introduced by variability in cellular infiltration 
throughout the joint only those patients with synovial tissue available from at least 
3 separate sites (SPP, MPM or CPJ) were chosen for analysis. 2 sections at least 
50µm apart from each block containing tissue samples from each site were 
assessed using DIA to obtain a QAS. Mean scores for each site and for each 
patient were then calculated and correlated with clinical parameters (including 
DAS, CRP, ESR, platelets, disease duration, autoantibody status and degree of 
erosive damage over time). In addition significant differences in clinical 
parameters were examined in patients classified as either aggregate or diffuse. 
Statistical Analysis 
ICCs were used to analyse reproducibility of the QAS, to determine agreement 
between first versus second biopsies within the same site and to determine 
agreement between synovial biopsies taken at different sites. Multiple ANOVA 
was used to determine whether systematic differences existed between first and 
second biopsies within each site and between biopsies taken at different sites. 
Differences in quantitative variables were analysed by the Mann Whitney U test. 
Spearman's rank correlation was performed to correlate pathological scores with 
clinical parameters. All the statistical analyses were performed using GraphPad 
Prism version 3.03 for Windows, GraphPad Software, San Diego California USA. 
Ap value <0.01 was considered statistically significant. 
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Results 
Clinical assessments and drug history 
60 patients were recruited to the study and clinical data were available for all 
patients. 52 patients had synovial tissue suitable for histological analysis and were 
therefore used for validation of the score and to correlate lymphocytic organisation 
with synovial cellular and cytokine parameters. 29 patients had synovial tissue 
available from a minimum of 3 sites within the knee joint and so were used to 
assess correlation with clinical parameters. Data on radiographic progression (as 
determined by MRI and Larsen scores) was available from 44 patients. 
The main demographic and clinical characteristics of patients have been published 
previously(176) and therefore a limited summary is given in Table 13. Significant 
differences in age, sex, disease duration, autoantibody status and levels of CRP 
between each of the groups were examined and no significant differences found 
(P>0.05). 
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Table 12: Demographic details, autoantibody status and disease duration of 
the 60 patients recruited to the DAMAGE study. 
A total of 60 patients were recruited to the study. Clinical data was available for 
all patients, 52 had synovial tissue suitable for histological analysis and were used 
for determining variability of lymphocytic organisation throughout the joint and 
for correlating lymphocytic organization with synovial cellular and cytokine 
parameters. 29 patients had synovial tissue available from 3 sites throughout the 
knee joint and were used to correlate lymphocytic organisation with clinical 
parameters. 
AutoAb status Synovial sample 
Pt ID Sex 
(yrs) DD (yrs) RF CCP Suitable (n=52) >_3 sites (n=29) 
I M 66 2.66 + - n/a n/a 
2 F 68 0.112 + n/a n/a n/a 
3 F 73 0.54 + + n/a n/a 
4 F 49 11.7 + n/a a n/a 
5 F 49 29.7 + + a n/a 
6 F 42 19.7 + + n/a n/a 
7 F 42 2.75 + + a n/a 
8 F 41 2.75 + + a n/a 
9 F 40 13.7 + n/a a n/a 
10 F 61 15.7 + a a 
I1 F 55 3.78 + + a a 
12 F 52 12.8 + n/a a n/a 
13 F 36 7.84 + a n/a 
14 F 37 0.665 + + a n/a 
15 F 69 1.32 + + a n/a 
16 M 69 1.41 - - a a 
17 F 56 13 + a a 
18 F 65 12.9 + + a a 
19 F 57 1.41 + n/a a a 
20 M 78 3.11 + + a a 
21 F 40 10 + + a a 
22 F 37 0.095 + n/a a a 
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23 F 63 14.1 + a n/a 
24 F 49 0.714 a n/a 
25 M 83 4.19 - a n/a 
26 F 80 13.1 + n/a a n/a 
27 F 50 10.1 - n/a n/a 
28 F 73 5.19 + n/a n/a n/a 
29 F 61 12.2 + + a n/a 
30 F 62 0.845 + + a n/a 
31 M 64 0.249 - - a a 
32 M 78 10.2 n/a a a 
33 F 37 6.28 + a a 
34 F 54 2.28 + a a 
35 M 49 1.07 + + a a 
36 F 43 12.3 + + a a 
37 M 46 4.32 + + a a 
38 F 73 5.32 - + a a 
39 F 50 2.33 + n/a a a 
40 F 62 1.51 + + a n/a 
41 M 47 7.92 + + a a 
42 F 52 7.26 + + a a 
43 M 54 9.43 + + n/a n/a 
44 M 74 0.517 - - n/a n/a 
45 M 32 4.07 - + a a 
46 M 77 8.49 + + a a 
47 M 54 0.996 + n/a a a 
48 M 61 1.91 - + a a 
49 M 55 6.17 + n/a a n/a 
50 F 55 1.43 + n/a a n/a 
51 F 60 5.5 + n/a a n/a 
52 F 56 10.5 + + a a 
53 F 68 10.5 + + a a 
54 M 77 7.51 + n/a a n/a 
55 F 64 2.6 + + a a 
56 M 78 0.273 - a n/a 
57 F 76 0.29 - a n/a 
58 M 70 0.331 n/a n/a a n/a 
59 M 68 0.323 - - a a 
60 M 60 0.451 + + a a 
Pt patient, F Female, M male, RF rheumatoid factor, DD disease duration, a 
available, n/a not available 
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Table 13: Baseline patient demographics and clinical characteristics of 
DAMAGE study (176) patients. 
Column A shows all patients recruited to the study (n=60). Column B details the 
52 patients used to determine variability of histological score throughout the joint 
and correlation of lymphocytic organisation with synovial cellular and cytokine 
parameters. Column C details the 29 patients with synovial tissue available from 3 
sites within the knee joint and used for correlating lymphocytic organisation with 
clinical parameters. 
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A (n=60) B (n=52) C (n=29) 
Disease duration range 
(median/IQR) (years) 




Age, mean +/-SD (years) 58+/-13.3 57 +/-13.3 59 +/-12.5 
Female (%) 67 65 56 
Clinical Characteristics 
RF +ve (no (%) 70 76 75 
*anti-CCP+ve (U/L) % (no) 68 (35) 68 (26/38) 70 (17/24) 
CRP, mean +/- SD mg/dL 17.6 +/-21.8 17.1 (+/-44.8) 17.6 (+/-23.7) 
Drug therapy 
Receiving DMARD therapy 
no (%) 
40 (67) n/a n/a 
Receiving corticosteroids, no 
(%) 
30 (50) n/a n/a 
*data available from 51 patients. RF, rheumatoid factor, CRP C reactive protein, 
DMARD disease modifying therapy 
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Increased lymphocytic organization is associated with other measures 
of synovial inflammation 
Individual components of the QAS, the AS and diffuse scores DS were compared 
to assess the relationship between degree of overall cellularity of tissue (as 
determined by the DS) and the degree of aggregation seen within a tissue. I found 
a close correlation (Spearman r=0.69, p<0.05) between increasing overall 
cellularity of the tissue (as determined by the DS) and increasing aggregation (as 
determined by the AS). 
In order to investigate the relationship between lymphocytic organization and B 
cell and macrophage infiltration I compared cellular infiltration with B cells and 
macrophages in those tissues categorized as aggregate versus diffuse. I found a 
significantly higher infiltrate of both B cells (7.22 vs 2.46, p<0.001) and 
macrophages (7.22 vs 1.32, p<0.0001) in tissues classified as aggregate (Table 14), 
indicating that the presence of ELN is associated with a more inflammatory 
cellular infiltrate, a finding reported by other studies(388). 
In addition I investigated whether the presence of ELN was associated with the 
differential expression of a number of key cytokines involved in disease 
pathogenesis, as has been suggested by previous data (421). 1 found no significant 
differences in the levels of IL10, IL17 or RANKL, and although levels of TNFa 
were higher in those tissues graded aggregate, significant differences were only 
detected for IL13 and IFNy (Table 14). 
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Table 14: Relationship between cellular organization and measures of local 
synovial inflammation. 
Tissues were classified as either aggregate or diffuse. Significant differences in 
gene expression levels of a number of key cytokines (as determined by RT-PCR) 
and number of macrophages (CD68) and B cells (CD20) in each group were 
determined. 
Cytokines (fg/0.13µg total 
mRNA) 






Cellular markers (per mm2) 
CD68 
1359 +/-912 1022 +/-605 0.25 
1471 +/-1132 1460 +/-1027 0.9 
24 +/-24 16+/-23 <0.05 
74+/-142 34+/-60 0.305 
234+/- 21 8 234+/-205 
7221/-4.2 1.32 1 i-3.24 <0.0001 
7.22+/-6.4 2.46+/-3.3 <0.001 
Values r(prt'sc'nt mean +%- SI), results were analysed using the Mann Whitney U 
test, p values <0.05 were taken as significant and are shown in bold face. 
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The aggregational and diffuse scores vary significantly at different 
biopsy sites throughout the joint 
52% (15/29) of patients were identified as showing features of an aggregate 
pattern (defined as presence of at least one grade 2 or grade 3 aggregate). The 
mean AS was 0.216 (+/-SD 0.45) and the mean DS 3.52 (+/-SD 3). Grade 3 
aggregates were only found in patients with mean aggregational scores greater 
than 1 (27%, 8/29 patients). 
ICCs were used to analyse reproducibility of the QAS, to determine agreement 
between first versus second biopsies within the same site and to determine 
agreement between synovial biopsies taken at different sites. 
For AS intra-observer reliability was excellent (ICCRM 0.92) as reported in 
Chapter 3. Agreement between biopsies within each site (ICCws 0.46) and 
between different sites (ICCBS 0.59) was only moderate suggesting that there was 
considerable variation between biopsies within and between sites in the knee joint 
(Table 15). 
For DS intra-observer reliability ICCRM was again excellent at 0.97, as reported in 
Chapter 3. Agreement between biopsies within the same site (ICCws 0.83) and 
between different sites (ICCBS 0.79) were lower suggesting that there was some 
variation between biopsies within and between sites in the knee joint although this 
tendency was not as strong as for the AS (Table 15). 
MANOVA was used to determine whether systematic differences existed between 
first and second biopsies within each site and between biopsies taken at different 
sites. MANOVA found significant differences in AS between biopsies taken at 
different sites (F 4.05, p 0.018) but not between biopsies taken at the same site or 
between assessments of the same synovial biopsy (Table 15). Figure 23 clearly 
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shows that AS were significantly higher at the MPM. MANOVA found no 
significant differences in DS within sites. However, variation between biopsies 
taken at different sites approached significance (F 2.93, p 0.055). Figure 23 





ý: rý . 
Diffuse score 
Repeated measurements (same 
Model 
ICC Multiple ANOVA 
I' 
0.97 0.40 0.848 
biopsy) 
Within site 0.83 0.58 0.446 
Between site 0.79 2.93 0.055 
Aggregate score 
Repeated measurements (same 0.92 0.51 0.48 
biopsy) 
Within site 0.46 0.41 0.52 
Between site 0.59 4.05 0.018 
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Table 15: Variability of aggregate and diffuse scores throughout the knee 
joint. 
288 synovial tissue sections from the DAMAGE study patient cohort underwent 
digital image analysis and the degree of aggregation (AS) and diffuse infiltrate 
(DS) quantified. Synovial tissue sections came from multiple biopsy sites within 
the joint (suprapatellar pouch, medial perimeniscal and cartilage pannus junction) 
and from multiple biopsies within each of these sites. In order to determine 
whether there was significant variability in both AS and DS throughout the knee 
joint intraclass correlation coefficients (ICC) generated from repeated 
measurements of the same biopsy (determining reliability of measurement) were 
compared to ICCs between biopsies within each site and between sites. Repeated 
measurement of the same biopsy demonstrated excellent intra-observer reliability 
(high ICC), whereas ICC were lower for both within site and between site 
measurements for both AS and DS, suggesting considerable variation between 
biopsies both within and between sites. Multiple ANOVA was used to determine 
significant differences in AS and DS within and between sites and demonstrated 
significant differences in AS and DS between sites. 
Significant p values are shown in bold 
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LYMPHOID AGGREGATE SCORE DIFFUSE SCORE 
SPP CPJ MPM 
Biopsy Site 
Bam show means 
Error ban show Mean . /. 1.0 SE 
p values for differences between alte by MANOVA after adjustment for. 
1. Variability from Repeated Measurements on some biopsy 
2. Variability from Repeated Biopsy (w lt inaib) 
Figure 23: Aggregate and Diffuse Scores at Different Sites within the Knee 
joint 
In order to determine whether systematic differences existed in both aggregate and 
diffuse scores from repeated biopsies from different sites within the knee joint 
(SPP: supra patellar pouch, CPJ: cartilage pannus junction, MPM medial 
perimeniscal) multiple (M)ANOVA was performed. The results clearly 
demonstrate a significantly higher aggregate score at the MPM, with a tendency to 
higher diffuse score at this site. 
Bars show mean scores, error bars show standard error of the mean. P values are 
for MANOVA. 
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sPP CPJ MPM 
Blopsy Site 
An increased aggregational and diffuse score correlates with elevated 
serum CRP, but not with the presence of autoantibodies in the serum of 
patients 
I next investigated whether the degree of cellular organization within synovial 
tissue associated with a number of clinical parameters, for this component of the 
study 29 patients were included who had tissue data available from at least 3 sites 
throughout the knee joint. I found a significant correlation with serum levels of 
CRP and both increasing cellularity of tissue (diffuse score spearman r= 0.57 
(P<0.01)) and increasing organization (aggregational score spearman r-0.51 
(P<0.01) (Figure 24). There was no significant correlation found with either AS or 
DS and DAS, Larsen score, disease duration or swollen joint count. 
There were no significant difference in serum levels of autoantibodies (either RF 
or anti-CCP antibodies), in patients with either an aggregate of diffuse appearance 
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Figure 24. Correlation between aggregate and diffuse score and serum 
CRP 
Aggregate and diffuse scores for each patient were generated and 
compared to serum CRP (C reactive protein). A significant correlation 
between both CRP and diffuse (a) and aggregate score (b) were seen 
(p<0.01). (n=29) 
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I found a significantly (p=0.036) reduced disease duration in patients with an 
aggregate pattern of synovial tissue (Table 16). 
I found no significant difference in clinical measures of disease activity as 
determined by the number of swollen joints, tender joints, DAS, ESR, platelet 
count or CRP between those patients with an aggregate or diffuse appearance to 
the synovial membrane (Table 16). 
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Table 16: Association of lymphocytic organization and degree of cellular 
infiltration with baseline clinical parameters. 
Patients from the DAMAGE study cohort (n=55) were classified as either 
aggregate or diffuse dependent on the presence of > grade 2 aggregates within 
synovial biopsies and significant differences in a number of baseline clinical 
parameters were investigated between the two groups. 
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RF 215 (+/-336) 
Anti-CCP antibodies (U/L) 153 (+/-158) 
Larsen score (0-150) 25.9 (+/-31.4) 
Disease duration (years) 3.5 (+/-3.55) 
280 (+/-468) 0.67 
293 (1/-163) 0.46 
24.1(+/-25.5) 0.76 
7.7 (+/-5.274) <0.05 
Swollen joint count 7.9 (+/-5.71) 11.05 (+/-15.6) 0.98 
Tender joint count 8.4 (+/-7.3) 11.3 (+/-8.7) 0.28 
DAS 4.6 (+/-1.5) 5.4 (+/-0.8) 0.21 
CRP (mg/L) 23.7 (+/-29.1) 9.70 (+/-9.73) 0.14 
ESR 33.1 (+/-28.9) 36.6 (+/- 25.7) 0.76 
Platelets 352 (+/-94.1) 315 (+/-143) 0.22 
values represent mean +/- SD results were analysed using the Mann Whitney U 
test, p values <0.05 were taken as significant and are shown in bold face. 
RF=rheumatoid factor, ACPA=anti-cyclic citrullinated peptide antibodies, 
CRP=C reactive protein, ESR=erythrocyte sedimentation rate, DAS=disease 
activity score 
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A higher aggregational score for synovial tissue does not predict the 
presence of erosions nor their development over a2 year period 
I next analysed whether baseline radiographic damage, at study entry, associated 
with the presence of aggregates within synovial tissue. I could find no significant 
differences in Larsen scores between those tissues classified as aggregate or 
diffuse (Table 16). Finally, as baseline radiographic scores do not incorporate 
erosive progression over time and as MRI has been demonstrated to be a more 
sensitive modality than conventional radiography to detect bone erosions (681), 
baseline aggregational and diffuse scores for patients determined to have 
progressed or not over a two year period as determined by MRI were compared. 
Although mean AS were higher in progressors vs non progressors (mean scores 
0.3 vs 0.13), the result did not reach statistical significance. In addition the 
presence of ELN at baseline (as determined by the presence of at least one grade 2 
or 3 aggregate) did not predict patients more likely to progress. 
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Discussion 
The biological relevance of lymphocytic aggregates within the synovial membrane 
is currently attracting much debate in the literature(426), with recent evidence 
suggesting in established as opposed to end stage disease a lack of correlation with 
clinical phenotype(388). However there is increasing evidence to support a role for 
ELN in local autoantibody production(424) and for a pathogenic role for 
autoantibodies, in particular anti-CCP antibodies(481). This current interest in 
synovial ELN has been further stimulated by evidence demonstrating a role for 
such structures in predicting response to therapeutic intervention(387). Sensitive 
pathological scoring systems are therefore required in order to accurately 
determine both single and sequential assessments of lymphocytic aggregation 
within the synovial membrane. Semi-quantitative scores have been shown to be 
prone to bias and lack of sensitivity(674) and so their application to quantification 
of lymphocytic organisation within synovial tissue maybe limited. Overcoming 
such limitations may permit the use of lymphocytic aggregates as a useful 
prognostic biomarker for both disease progression and response to therapy. 
I have developed a score for rheumatoid synovial tissue that quantifies, using DIA, 
both the aggregational tendency of tissue (AS) and overall degree of cellular 
infiltration (DS). 
In this cohort of RA patients with established disease I identified 52% as positive 
for ELN, as defined by the presence of grade 2 aggregates or above, in the 
synovial membrane and identified 27% as positive for grade 3 aggregates. This 
result is significantly greater than recently reported(388) but is in line with other 
data in the literature(217). 
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My data demonstrates a direct correlation between an increased aggregational 
score and increased overall cellular infiltrate within synovial tissue. This concept 
of a central role for ELN in mediating synovial inflammation is further supported 
by a significantly increased number of both synovial macrophages and not 
surprisingly B cells in aggregate containing synovial tissue, a result in line with 
data from another group(388)and data demonstrating that following B cell 
depletion therapy a significant reduction is seen in not only synovial B cells but 
also T cells and macrophages(388). This suggests that the production of 
proinflammatory cytokines and chemokines by activated B cells, functioning in 
both attracting and retaining inflammatory cells, is critical in determining synovial 
inflammation. 
Interpretation of the differential expression levels of a number of key 
inflammatory cytokines between tissues graded as aggregate and diffuse produced 
some interesting results. Firstly, I did not find significantly higher levels of TNFa 
in tissues graded as aggregate compared to tissues graded as diffuse as has 
previously been reported(421), although this was in end stage rather than 
established disease. This is interesting and requires corroboration by further 
studies, particularly as the presence of ELN (though not specifically higher levels 
of TNFa) has been demonstrated to predict resistance to anti-TNF therapy(387). 
Significantly higher levels of both IL-10 and IFNy in aggregate tissues were found. 
IL-10 has already been demonstrated to predict joint damage progression and IFNy 
conversely to confer protection from joint damage progression in this patient 
cohort(176). Both cytokines however have previously been associated with an 
aggregate synovial cell infiltrate(42 1). IL Iß is a macrophage derived cytokine and 
its significant expression in aggregate tissues likely relates to the increased 
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association with increased macrophage numbers, demonstrated by the results of 
this and other studies(388). The differential expression of IFNy, aT cell derived 
cytokine, within aggregate tissues maybe a result of T cells accumulating within 
GCs producing IFNy, rather than traditionally IL4, as has been suggested 
previously(421). RANKLigand is known to be a critical cytokine mediating 
erosive damage in RA(682) and a potential pathway linking ELN to a more erosive 
disease pattern was the report demonstrating activated T cells expressing 
RANKLigand localized within sublining cell clusters(683). Although I found no 
differential expression between aggregate and diffuse tissues in the expression 
levels of RANKLigand, crucially, I were unable to report on expression levels of 
OPG, the decoy receptor for RANKLigand. As OPG is capable of blocking tissue 
destruction differential expression of this key cytokine between tissues would 
impact critically on the interpretation of these results with regard to a potential link 
between ELN and cartilage erosion. Unfortunately due to the historical nature of 
the DAMAGE study patient cohort no futher RT-PCR experiments were possible. 
I demonstrate a significant correlation between increased aggregation (AS) and 
overall cellular infiltrate (DS) within synovial tissue and systemic inflammation 
(CRP) (388). Although a higher level of CRP was detected in patients with an 
aggregate vs diffuse appearance to the synovial membrane, this was not a 
significant result as has previously been reported(388) and likely reflects the 
smaller patient numbers in this cohort. The lack of correlation with tender and 
swollen joints is not surprising as clinical detection of synovitis has been 
demonstrated to be both unreliable and insensitive(684). A more robust measure 
maybe assessment of synovitis by either ultrasound using ultrasonography or 
MRI(685). Indeed, a study investigating a correlation between synovial 
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histopathological subtypes and ultrasound appearance of synovitis is currently 
underway within our group. 
I found an association between a less organized inflammatory infiltrate and an 
increased disease duration. This supports the concept that ELN is not just limited 
to chronic end stage disease but, as has been, reported can be documented in early 
arthritis(449). I suggest that this relationship needs to be investigated in a cohort of 
patients specifically with early arthritis. 
I do not report an association between the presence of ELN and the detection of 
autoantibodies in the serum of patients, in agreement with recent reports in 
established(416) as oppose to end stage disease(421). However, I do not believe, 
as has been suggested by others(388; 416; 426), that this demonstrates a lack of 
role for ELN in autoantibody production. Although I minimized sampling error 
examining tissue from multiple sites within a joint, the process of ELN is likely a 
dynamic modality between and within joints and thus limited bioptic sampling is 
unlikely to ever detect the true functionality of tissue. Importantly previous reports 
have suggested that different sites throughout the knee reflect different levels of 
inflammation (365; 686), although these data has not been supported by a number 
of other studies(687; 688) it is a particularly important consideration with the 
advent of minimally invasive synovial biopsying techniques, (679; 689) which for 
the knee joint in general only sample the SPP. Indeed I demonstrate significant 
variability between biopsy sites (although not within sites) for both AS and DS, 
suggesting that limited sampling of one site from the knee joint may not be 
representative of the whole joint. In this study significantly higher levels of 
aggregation were demonstrated at the MPM rather than the SPP or CPJ. Further a 
direct comparison of sera (or indeed synovial fluid) with ELN within the synovial 
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membrane is compounded by the demonstrated production of antibodies at other 
ectopic sites such as the lung(386). Indeed when synovial tissue is examined 
directly, evidence points to a role for ELN in local autoantibody production(424). 
Thus there is a pressing requirement for further arthroscopic studies (able to access 
multiple sites within the knee) powered to determine the optimum site for 
acquisition and minimum amount of synovial tissue required to reliably classify a 
patient as of an aggregate or diffuse synovial pathotype. 
As far as I am aware this is the first study to investigate the prognostic value of 
ELN in predicting radiographic progression in established RA. The prospective 
study of radiographic progression is of more biological relevance than quantifying 
radiographic damage at one time point, which is particularly difficult to interpret in 
patients of differing disease duration with exposure to multiple therapeutic agents. 
Further the use of MRI is demonstrably more sensitive than conventional 
radiography in detecting erosive disease(690). Despite this I was still unable to 
demonstrate a relationship between the presence of ELN and radiographic 
progression. I was hampered by the lack of progression in the majority of patients 
assessed (47%, 21/44), despite exposure to biological therapy. This lack of 
progression is likely a result of the inclusion of a variety of patients with widely 
varying disease severity on a diverse range of therapies. Further, as radiographic 
progression is a periodic event it would likely be more revealing to follow the 
patients over a longer time course. Further finally, as has already been discussed, 
significant variation in lymphocytic aggregation throughout the knee joint may 
have affected the result. 
In conclusion, although the presence of ELN in this cohort of RA patients does 
not predict joint damage progression I suggest that the demonstrated association 
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with both synovial inflammation and increasing aggregation correlating with 
systemic inflammation (CRP) demonstrates a critical role for these structures in 
disease pathogenesis. I further suggest that this relationship needs to be 
investigated in patients with early arthritis, naive to all disease modifying drugs, a 
trial that is currently ongoing within our group, and that will use the QAS to assess 
the synovial membrane at baseline and sequentially. 
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Chapter 5: Ectopic Lymphoid Structures Support 
Ongoing Production of Class-Switched Autoantibodies 
in Rheumatoid Synovium. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory erosive polyarthritis with an 
associated significant morbidity and mortality (691). One of the hallmarks of the 
disease is the presence of circulating autoantibodies, such as rheumatoid factor 
(RF) (11) and anti-citrullinated protein/peptide antibodies (ACPA) (472-477), that 
have prompted the notion of an autoimmune pathogenesis. The presence of such 
antibodies, particularly anti-CCP antibodies, has been shown to be a poor 
prognostic factor linked with a higher erosive burden (529; 530), while anti-CCP 
antibody titres have been reported to fall in line with clinical response to 
biological therapies (491). Additional support for a pathogenic role for anti-CCP 
antibodies comes from recent work in a mouse model of RA that indicated a 
direct role for anti-CCP antibodies in tissue destruction (481). 
Physiologically, antigen-driven antibody responses take place within germinal 
centres (GCs) of secondary lymphoid organs where the processes of somatic 
hypermutation (SHM) and class switch recombination (CSR) of the Ig genes in GC- 
B cells occur, leading to affinity maturation and differentiation to memory B and 
plasma cells (692; 693). However, recent evidence suggests that CSR and low-level 
SHM can also be sustained at extrafollicular sites in the spleen (202) and the gut 
(203). Both CSR and SHM are initiated by and critically dependent upon the 
expression of the enzyme activation-induced cytidine deaminase (AID) (197). 
Although the exact mechanism of action of AID is currently unclear (694), CSR 
occurs via excision of switch circles following the introduction of double strand 
breaks in the Ig switch regions of DNA, with the subsequent substitution of IgM 
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and IgD with IgG, IgE, or IgA (413), and hence production of antibodies with 
specific effector functions. AID also initiates SHM by introducing point mutations 
in the variable genes encoding the antigen-binding region of Igs (199), and affinity 
maturation then occurs through cycles of antigen-dependent selection in GC. 
Accordingly, AID expression in secondary lymphoid organs has been 
demonstrated to be restricted to GC-B cells actively undergoing CSR/SHM and to 
the recently described population of IF large(IF) large B cells (5; 196; 695). 
Therefore, delineation of its expression within tissue allows identification of 
whether and where B cells activate the molecular machinery responsible for the 
production of affinity-matured antibodies. 
The presence of ectopic lymphoid structures resembling GCs and characterized by 
follicular dendritic cell (FDC) networks is a common finding in chronically inflamed 
tissues in several autoimmune diseases (383) including RA. GC-like structures 
have been reported to occur in the synovial membrane in approximately 25% of 
patients with RA (421). It has been shown that alongside the frequent recognition 
of disorganized cell clusters in the synovium, some of the sublining lymphoid 
aggregates can recapitulate qualitative features of secondary lymphoid organs, 
such as FDC networks, the in situ production of homeostatic chemokines, as well 
as the acquisition of variable degrees of T/B cell segregation or high endothelial 
venule development (217; 334; 404; 416). However, whether ectopic lymphoid 
structures in RA can be functional and directly implicated in promoting the 
production of disease-specific and potentially pathogenic autoantibodies such as 
ACPA, or whether the synovium acts as a "reservoir" for long-lived plasma cells 
producing ACPA is at present unclear (416). Circumstantial evidence, such as the 
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presence of clonally mutated B cells from GC-like structures microdissected from 
RA tissues (415; 423), suggests that an antigen-driven B cell response is taking 
place in the RA synovium. Likewise, the detection of ACPA in the synovial fluid of 
patients with RA (419; 696), the demonstration that ACPA are concentrated at this 
site (420), and the detection of ACPA in the sera of SCID mice xenotransplanted 
with human synovium (418), support the possibility that ACPA might be directly 
generated in the synovium. These data, however, cannot rule out the possibility 
that already mutated, autoreactive B cells are preferentially recruited to the 
inflamed synovial tissue. In addition, lymphoid aggregates can also occur in the 
synovium of patients with other rheumatological conditions currently not 
associated with autoantibodies of known specificity(416), and further no 
correlation has been found between their presence and serum/synovial fluid 
ACPA(388; 416). These concepts have been taken as an indication that these 
structures may not be functional and that B cell autoimmunity in RA synovitis 
may be independent of ectopic lymphoneogenesis (388; 416; 426). 
Aims and objectives: 
The purpose of this study was to investigate whether ectopic lymphoid structures 
in RA synovium are functional by determining whether they: 
(i) Express AID, the enzyme required for SHM and CSR of Ig genes; 
(ii) Support ongoing CSR and the production of high-affinity ACPA; and 
(iii) Remain functional and promote B cell survival, proliferation, and 
autoantibody production in a RA/SCID chimera model devoid of any new 
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immune cell influx into the synovium and where the ongoing 
immunological activity of secondary lymphoid organs is excluded. 
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Materials and methods 
Patients and samples 
Following written informed consent, synovial tissue was collected from 55 
patients with RA fulfilling the revised 1987 ACR criteria for RA (12). Tissues were 
collected consecutively within each group studied, which included arthroplastic 
joint surgery (40) and ultrasound-guided synovial biopsy (15). The majority of the 
patients were on methotrexate, and none were on anti-TNF therapy at the time 
of surgery. Demographic data are given for the study population in Table 17. 
From 24 of the 55 patients who underwent joint replacement surgery between 
1999 and 2005, only formaldehyde fixed, paraffin-embedded tissue was available 
and therefore was exclusively used for histological analysis. From an additional 25 
patients (of whom ten underwent arthroplastic surgery and 15 underwent 
ultrasound-guided biopsy), enrolled between 2005 and 2008, paired paraffin and 
RNA samples were available and were used for histological analysis and QT-PCR. 
Finally, from six patients with RA undergoing joint replacement surgery, synovial 
tissue was obtained and stored in liquid nitrogen until use for transplantation into 
SCID mice. 
Procedures were approved by the hospital Ethics Committee (REC/98/11/27 Guys 
and St. Thomas' NHS Trust and REC 05/Q0703/198 Barts and the London NHS 
Trust) and performed after written informed consent. 
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Table 17: Clinical and Histological Characteristics of RA Patients (n = 55) 
Group Characteristic 
Age (y) mean ± SD 53 ±12.2 y 
Clinical Characteristics Female (%) 76.3% 
Disease duration (y) mean ± SD 13.2 ± 17.1 
y 
Rheumatoid factor+ (%) 80% 
Pathological scores of 
synovial tissues 
Aggregate (CD21 network+) tissue (%) 29% 
Aggregate (CD21 network-) tissue (%) 31% 
Diffuse tissues (%) 40% 
Patients with paired 
synovial tissue and 
serum n= 21 
ACPA+ (%) 71% 
Serum; ACPA+, tissue; AID/CD21L+ (%) 75% 
Serum; ACPA+, tissue; AID/CD21L- (%) 67% 
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Immunohistochemistry 
A list of primary and secondary antibodies (Abs) used is reported in Table 5. 
Histological Grading of Tissues 
The histological grading of tissues and degree of lymphoid organization was 
assessed by immunohistochemical staining of sequentially cut sections of RA 
synovial tissue, as previously reported (334). Briefly, paraffin-embedded 5 µm 
sections underwent routine staining with haematoxylin and eosin in order to 
define the predominant histological pattern of RA synovitis as either diffuse or 
aggregate (421). The number of lymphocytic aggregates was counted in each 
section and graded according to a modified, previously published grading system 
(334; 391) with grade 1 (G1) aggregates displaying a radial cell number between 2 
and 5 cells, grade 2 (G2) between 6 and 10 cells and grade 3 (G3) greater than 10 
cells. 
Staining for CD3 and CD20 (using antibody dilutions of 1: 50 and 1: 20 
respectively), following antigen retrieval with Target retrieving solution (DAKO), 
was used to analyse T/B cell segregation as previously reported (697). In addition, 
following proteinase K digestion (DAKO), single staining with CD21 at a dilution of 
1: 20 was performed to identify FDC networks characterising GC-like structures 
(697). 
Based on the results of the CD21 staining and the presence of G2/G3 aggregates, 
samples were qualitatively classified as either diffuse, aggregate/CD21-, or 
aggregate/CD21+ as previously described (217). In order to minimize bias due to 
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cutting level, all blocks of tissue were cut and stained at three cutting levels 50 
µm apart. 
Relationship between Histological Grade of Tissue, Degree of Inflammatory 
Infiltrate Organization, and AID Expression within Tissues 
Staining for AID was performed, as previously reported (675), on sequential 
sections of RA synovial tissue in order to correlate AID expression with the 
histological grading and degree of lymphoid organization. Briefly, after Ag 
unmasking using Target retrieval solution (pH 6, DAKO) and incubation with 20% 
rabbit serum (DAKO), incubation with the EK2-5G9 primary Ab was carried out at 
a dilution of 1: 20 for Ih at room temperature. This step, in turn, was followed by 
a ih incubation with the biotinylated rabbit anti-rat Ig secondary Ab. The HRP- 
streptavidin-biotin complex (DAKO) was then added to the section and incubated 
for 30 min. The colour reaction was developed with diaminobenzidine (DAKO). 
Relationship between AID and CD21L Expression, as Determined by QT-PCR and 
Histological Characterization of Synovial Tissues 
Synovial samples were obtained from a further 25 patients with RA. Each 
specimen was divided into 2 parts; one was formalin fixed and paraffin 
embedded for immunohistology and the second was stored in a 10: 1 v: v of RNA- 
later (Ambion) at -80 °C for RNA extraction and QT-PCR analysis. Histological 
characterization of the RA tissue was carried out as described above. Total RNA 
was extracted from the remaining portion of synovial tissue, using the RNeasy 
Mini Kit (Qiagen), with on column DNase I digestion to avoid genomic DNA 
contamination. cDNA was generated from 1 µg of RNA using the Thermoscript 
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RT-PCR System for First-Strand cDNA Synthesis (Invitrogen). QT-PCR was 
performed to detect mRNA expression levels of AID and CD21L together with 
CXCL13, LTß, BAFF and APRIL using specific primers and probes (Table 6). The RT- 
PCR was run in triplicate with an equal loading of 20 ng of cDNA/well. Results 
were analysed after 40 cycles of amplification using the ABI PRISM 7900HT 
Sequence Detection System Version 2.1. Relative quantification was measured 
using the Comparative CT (Threshold Cycle) Method. cDNA from peripheral blood 
mononuclear cells sorted for CD3 by fluorescence activated cell sorting (FACS) 
were used as a negative control for AID and CD21L, whereas cDNA from lymph 
node was used as a positive control. 
Detection and Characterization of ACPA-Producing Cells within Rheumatoid 
Synovial Tissue 
Citrullinated Fb (CFb) was generated as previously described with minor 
modifications (386; 483). Briefly, plasminogen-depleted human Fb (Calbiochem: 
EMD BioSciences) was incubated at 0.86 mg/ml with 10 U/ml of rabbit skeletal 
muscle peptidyl arginine deiminase (Sigma-Aldrich) in 0.1 M Tris-HCI (pH 7.4), 10 
mM CaCI2, and 5 mM DTT for 2h at 50 T. The enzyme was inactivated by adding 
2% SDS and heating at 100 °C for 3 min and removed by serial spinning and 
washing with 0.01 M sterile bicarbonate buffer in a 100 kDa Amicon filter device 
(Millipore). CFb was then biotinylated using NHS-LC biotin (Pierce Biotechnology). 
In addition, an aliquot of unmodified Fb of the same concentration as the CFb , 
was biotinylated and used as a negative control for all staining experiments. 
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To confirm effective citrullination and the specificity of CFb for ACPA Abs, two 
aliquots of CFb and uncitrullinated Fb were first separated by SDS-PAGE on 7.5% 
polyacrylamide gels. Proteins were then electrotransferred onto Hybond-C extra 
reinforced nitrocellulose membranes (Amersham). Membrane strips were probed 
with human sera (1: 100) pooled from three ACPA+ patients with RA and three 
ACPA- patients with RA. A goat anti-human IgG peroxidase (Sigma) was used for 
detection of the primary Ab. Peroxidase activity was visualized using ECL Western 
blotting reagents (Amersham) following the manufacturer's instructions. 
To detect and characterise ACPA-producing cells in the RA synovium, sequentially 
cut 5µm paraffin and/or frozen sections of five RA synovial samples 
representative of different degrees of histological organization (three 
aggregate/CD21+, one aggregate/CD21-, one diffuse) were chosen for analysis. 
ACPA-producing cells and B cell follicles were identified using double 
immunofluorescence with biotinylated CFb followed by incubation with 
streptavidin ALEXA-555 and CD20 followed by rabbit anti-mouse ALEXA-488 with 
subsequent DAPI counterstaining (386). AID+ FDC networks were identified on 
sequential sections by staining for CD21 using conventional IHC as described 
above and immunofluorescent staining for AID using streptavidin-ALEXA-555 
following incubation with biotinylated rabbit anti-rat secondary Ab. Plasma cells 
producing ACPA were identified by performing double immunofluorescence for 
CD138 followed by goat anti-mouse ALEXA-488 and biotinylated CFb as described 




A total of 56 samples of human synovium from six patients with RA undergoing 
arthroplasty (classified prior to transplantation histologically as two diffuse, two 
aggregate/CD21-, and two aggregate/CD21+) were transplanted subcutaneously 
into Beige SCID-17 mice as previously described (637; 645). In this model, full 
engraftment of human tissue is reached at 7 d, and significant levels of ACPA 
antibodies in mouse sera have been described from a similar time point and up to 
84 d (418). Four weeks post-transplantation I determined: (i) the 
histomorphology of the transplanted synovium with regard to the presence of 
CD21+ aggregates; (ii) the mRNA expression levels of AID, CD21L, and genes 
involved in ectopic lymphoneogenesis; (iii) the presence of ongoing CSR by 
assaying for the presence of IV-Cµ circular transcripts (molecular by products of 
IgM to IgG class switching); and (iv) the serum levels of human ACPA in the mouse 
circulation. 
Animals were humanely killed at 4 wk and the grafts divided into two parts; one 
part was paraffin embedded for later histological examination and one part was 
stored in 10: 1 v: v of RNA-later (Ambion) at -80 °C for QT-PCR. Grafts were 
examined macroscopically and histologically to confirm viability. In addition, 
transplanted synovial tissues were characterised by staining for CD21 and AID to 
identify persisting AID+ FDC networks. Proliferating B cells were identified by 
performing double immunofluorescence for Ki67 followed by goat anti-mouse 
IgGI ALEXA-488 and CD20 followed by goat anti-mouse IgG2a ALEXA-594. 
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Finally, mice underwent a terminal bleed, and serum was collected and stored at 
-20 °C for subsequent ACPA analysis. 
Gene Expression Analysis by QT-PCR and Detection of Circular Transcripts in 
Transplanted RA Synovial Tissues 
RNA was extracted from each transplant, and cDNA was generated as described 
above. QT-PCR was performed to measure mRNA expression levels of AID, CD21L, 
APRIL, BAFF, TNFa, LTß, and CXCL13 (Table 6). 
Detection of IV-CV circular transcripts was performed on the same cDNA. Circular 
transcripts were detected following 30 cycles of RT-PCR amplification using the 
reverse primer Cµ (5'-GTTGCCGTTGGGGTGCTGGAC-3') together with the forward 
primer IV (5'-GGGCTTCCAAGCCAACAGGGCAGGACA-3') recognizing both lyl and 
ly2 (the RT-PCR product was 557 bp) as previously reported (698). Before each 
RT-PCR, cDNA were denatured for 5 min at 94 °C. The PCR conditions were as 
follows: denaturation for 1 min at 94 °C, annealing for 1 min at 60 °C, and 
extension for 1 min at 72 °C. 
Detection of Human IgG ACPA in Human and Mouse Sera 
ACPA were detected in both mouse and human sera using a commercially 
available anti-cyclic-citrullinated antibody (anti-CCP2) ELISA kit (Axis Shield), 
following the manufacturer's instructions. A positive result was taken as >5 U/L. 
Statistical Analysis 
Differences in quantitative variables were analysed by the Mann Whitney U test 
when comparing two groups, and by the Kruskal-Wallis with Dunn's post test 
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when comparing multiple groups. x2 test with Yates' correction when required or 
Fisher's exact test when appropriate were used to evaluate associations of 
qualitative variables in the different groups. Spearman's rank correlation was 
performed to correlate expression levels of AID and CD21L mRNA in RA synovial 
grafts. All the statistical analyses were performed using GraphPad Prism version 




In the Rheumatoid Synovial Membrane AID Is Expressed Only in 
Association with FDCs 
In order to investigate whether AID was expressed within the rheumatoid 
synovial membrane and its potential association with specific patterns of 
rheumatoid synovitis, I first performed an IHC analysis on sequential sections of 
synovial tissue in 24 patients with RA. I analysed AID expression in relation to the 
degree of lymphoid organization of the inflammatory infiltrate, including T/B cell 
segregation and FDC network formation. 
As shown in a representative example in Figure 25, AID expression in RA 
synovium was invariably associated with the presence of FDCs (Figure 25A-H). 
This was the case even in CD21+ G3 aggregates that lacked uniform T/B cell 
segregation and distinct dark -light zones within the B cell rich area (423) (Figure 
25A-1D). The pattern of AID staining within compartmentalized CD21+ G3 
aggregates (Figure 25E-1H) was highly reminiscent of the pattern seen in 
secondary lymphoid organs, such as lymph node, with strong AID expression 
within GC B cells (Figure 251-L). CD21+ FDC networks were observed in seven out 
of 24 patients (29%), with 100% of G3 aggregates displaying CD21+ FDC networks 
also expressing AID. Conversely, AID and FDC networks were not detectable 
either in smaller G1 or G2 aggregates or in diffuse tissues. 
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Figure 25: AID Expression within the Rheumatoid Synovial Membrane Is 
Restricted to Lymphoid Aggregates with FDC Networks 
A representative example of sequential paraffin-embedded sections of LN and RA 
synovial membrane stained for (brown, A, E, I), T cells (CD3, brown, B, F, J), B cells 
(CD20, red, C, G, K) and follicular DCs (CD21, red, D, H, Q. The presence of FDC 
networks was invariably associated with the expression of AID even in FDC+ grade 
3 aggregates (arrow, A), without morphologically detectable dark and light zones 
within the B cell rich area (A-D). In more organised grade 3 aggregates (E-H), 
expression was more prominent and closely resembled that seen in secondary 
lymphoid organs, such as the LN (I-L) (original magnification was 20x). Scale bars 
200 µm. 
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QT-PCR Evaluation Confirms the Exclusive Association between AID and FDCs 
In order to confirm whether AID expression was also exclusively associated with 
FDC networks at the mRNA level, I analysed synovial samples from an additional 
cohort of 25 patients with RA in which paired RA specimens for IHC and QT-PCR 
were available. In this cohort, I investigated the expression of CD21L, a marker 
exclusively expressed by FDCs (699), and AID transcripts. Indeed, AID mRNA 
expression was detected in all 12 of the CD21L+ RA samples but in none of the 13 
CD21L- RA samples analysed (Figure 26A, p<0.0002). Amplicons of the expected 
length (99 bp for AID and CD21L, and 171bp for ß-actin, Figure 26B) were seen in 
samples positive for AID and CD21L by QT-PCR (lane 2) and human lymph node 
(lane 5), but not in RA samples negative for AID and CD21L (lane 3) or in the 
negative control (lane 4, cDNA from CD3 sorted cells). 
In the same cohort of 25 patients I compared the expression of AID and CD21L 
mRNA by QT-PCR with histological characterization of the same piece of synovial 
tissue. I identified by IHC an aggregate pattern AID+/CD21+ in seven patients 
(28%), aggregate pattern AID-/CD21- in seven (28%) patients, and diffuse 
infiltrate negative for both AID and CD21 in 11 patients (44%). On the other hand, 
when the same samples were analysed by QT-PCR, I demonstrated a higher 
prevalence of RA synovial tissues expressing AID and CD21L mRNA (12/25,48%). 
Notably, the increased proportion of RA synovial tissues expressing AID and 
CD21L mRNA was exclusively characterised by an aggregate and not a diffuse 
pattern, confirming that lymphoid structures are required for the expression of 
both AID and CD21L mRNA in the RA synovial membrane. 
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Expression of AID Is Associated with the Up-regulation of CXCL13 and LTß within 
the Rheumatoid Synovial Membrane 
As synovial tissues containing sites of ectopic lymphoneogenesis have been 
demonstrated to be closely associated with increased expression levels of CXCL13 
and LTß mRNA (217), 1 then sought to determine whether the expression levels of 
these and other key factors involved in lymphoneogenesis were also significantly 
associated with the up-regulation of AID and CD21L mRNA. As shown in Figure 
26, AID mRNA+ tissues displayed significantly higher levels of CXCL13 and LTß 
mRNA (Figure 26C and D) but not of the B cell survival factor BAFF (Figure 26F). 
Conversely, although APRIL mRNA showed an increase in AID+ synovial tissue, 
these differences did not reach statistical significance (Figure 26E). 
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Figure 26: AID mRNA within Rheumatoid Synovial Tissue Is Expressed 
Exclusively in Association with CD21L-Isoform Transcripts 
QT-PCR was used to measure levels of transcripts of AID and CD21L in synovial 
samples from 25 patients with RA. Results were normalized for the endogenous 
control (human ß-actin) and expressed as relative quantification. 
(A) The presence of AID is restricted to those tissues expressing CD21L. 
(B) Representative examples of the PCR products were run in a 1.8% agarose gel 
to ensure the presence of a single specific amplification product and confirm 
specficity of QT-PCR. Amplicons of the expected length (99 bp for AID and CD21L 
and 171 bp for ß-actin) were observed in samples that gave positive signals at QT- 
PCR (lane 2), while no bands were detected in samples negative for AID/CD21L by 
QT-PCR (lane 3). No AID/CD21L amplification was detectable in negative controls 
(CD3-sorted cells, lane 4), while AID and CD21L were both detectable in control 
human lymph node (lane 5). 
(C-F) CXCL13, LT(3, BAFF, and APRIL transcript analysis by QT-PCR. AID expression 
within synovial tissue was associated with the up-regulation of both CXCL13 and 
LT(3 but no significant difference was seen in the levels of APRIL and BAFF. The 
lower and upper margins of the box represent the 25th and 75th percentiles, with 
the extended arms representing the 10th and 90th percentiles, respectively. The 
median is shown as a horizontal line within the box. p-Values were calculated 
using the Mann-Whitney U test. 
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A AID +ve AID -ve 
CD21L +ve 12 0 
CD21L -ve 0 13 
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AID-Positive Follicles Are Surrounded by Plasma Cells Producing ACPA 
a 
I next investigated whether AID+/FDC+ GC-like structures within the rheumatoid 
synovial membrane were associated with the in situ production of ACPA. 
Biotinylated citrullinated fibrinogen (CFb) was produced as previously reported 
(386) and tested for specificity using pooled sera from three ACPA+ and three 
ACPA- patients with RA. As expected, ACPA+ sera showed reactivity to CFb but 
not to unmodified Fb (A, lanes 1 and 2), whilst no reactivity was observed with 
ACPA- sera (Figure 27A, lanes 3 and 4). Biotinylated CFb and biotinylated Fb were 
then used to detect in situ production of ACPA in sections double stained for 
CD20 (Figure 27B and 4C). Numerous positive cells were detected with CFb 
(Figure 27B) but not when using Fb as a negative control (Figure 27C) in ACPA+ 
patients. Conversely no staining was seen around germinal centres from a sample 
from an ACPA- patient (data not shown). 
ACPA+ cells were localised around AID+/CD21+ aggregates (Figure 27D, E and F), 
were CD20- (Figure 27F and 4G) and CD138+ (Figure 27H and I), confirming their 
plasma cell origin. These results suggest that AID+ GC-like structures within 
rheumatoid synovial tissue can support the local differentiation of ACPA- 
producing plasma cells. 
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Figure 27: AID + Aggregates Are Surrounded by Plasma Cells Producing 
ACPA within Rheumatoid Synovium 
(A) Immunoblot analysis of reactivity of pooled ACPA +ve and -ve RA sera to 
citrullinated fibrinogen (CFb) (lanes 2 and 4) and control non-citrullinated 
fibrinogen (Fb) (lanes 1 and 3). Two protein bands between 60-8OkDa in size, 
corresponding to the a- and 0-chains of CFb, are recognized by the ACPA+ve RA 
sera (lane 2) but not control Fb (lanes 1). ACPA-ve sera (lanes 3 and 4) show no 
immunoreactivity towards either citrullinated or control Fb. (B-G) Double or 
single immunofluorescence analysis showing phenotypic characterization and 
immunoreactivity towards citrullinated proteins within RA synovial tissue. 
Sequential sections of RA synovial tissue were double stained with anti-CD20 to 
detect B-cells (green) together with either biotinylated CFb (B, red) or control 
biotinylated Fb (C). Sections were counterstained with DAPI. Positive staining is 
only seen in the sections incubated with biotinylated CFb confirming the presence 
of anti-citrullinated protein immunoreactivity. (D-G) Sequential sections of 
rheumatoid synovium stained with anti-CD21 to detect FDC (D), anti-AID (E), 
double stained with anti-CD20 (green) and biotinylated CFb (red) (F-G) and 
double stained with anti-CD138 (green) to detect plasma cells and biotinylated 
CFb (red) (H-I). CD21 was visualized with vector red. AID, CD20, CD138 and 
biotinylated CFb were incubated with secondary Abs/streptavidin conjugated to 
ALEXA fluorochromes. AID and CD20 were counterstained with DAPI. ACPA 
Ab producing cells were seen scattered around FDC and AID+ve aggregates (F). 
ACPA+ve cells were consistently CD20-ve (G) (x60 magnification of F) and 
CD138+ve (H) (x60 magnification of G). (Original magnification x20 B-F, H). 
Scale Bars: 200µm (D-F, H), 50µm (B, C) 20gm(G, I) 
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The histomorphological analysis described above suggested that ectopic 
AID+/CD21+ aggregates are capable of sustaining in situ ACPA production in the 
RA synovium. I next examined a) the direct functional relationship between the 
synovial expression of AID and CD21L and the production of ACPA and b) whether 
ectopic lymphoid aggregates within RA synovium maintain functionality 
independently from incoming immune cells from the periphery. To this end, I 
generated Hu-RA SCID mice chimeras by implanting fragments of RA synovial 
tissue into these animals (Figure 28A and B), and analysed the results at 4 wk. 
(i) AID/CD21L expression and B cell proliferation are maintained within RA 
synovial grafts. 
Histomorphology and immunohistological analysis of paraffin-embedded 
sections of transplanted RA synovium demonstrated viable grafts with residual 
inflammatory infiltrates (Figure 28C), often characterized by persistent FDC 
networks and associated AID expression (Figure 28D and E). Importantly, AID was 
detected only in the presence of CD21L in synovial grafts and AID mRNA 
expression levels closely correlated (r=0.88) with those of CD21L (Figure 28G). In 
addition to the expression of AID, further evidence of functional activation of B 
cells within synovial grafts was determined by performing double staining for the 
B cell marker CD20 and Ki67, a marker of cell proliferation. Double stained, 
proliferating B cells were identified within aggregates within grafts at 2 wk (Figure 
28F), confirming that B cells within synovial grafts are able to both survive and 
proliferate in this micro environment, and hence, retain the capacity to function 
as GC B cells. 
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Figure 28: Rheumatoid synovial grafts in SCID mice maintain AID 
expression and the upregulation of genes determining lymphoneogenesis. 
Rheumatoid synovial tissue (n=56) was transplanted into SCID mice (A) (arrows 
depict site of transplants). (B) Transplanted RA synovial tissue in SCID mouse. 
(C) Montage image of a paraffin embedded H and E stained section of 
transplanted tissue depicting the whole graft (original magnification x4, area 
outlined in black equates to aggregate seen at higher magnification in D and E). 
Sequential sections of transplants stained using conventional IHC for CD21 (D), 
AID (E) and double immunoflouresence for Ki67 (green) and CD20 (red) (F) 
(inset x40 magnification arrowheads indicating cells staining positively for Ki67 
and CD20) demonstrated persistent FDCs, associated expression of AID (original 
magnification x40) and continued proliferation of B cells. Four weeks post- 
transplantation, total RNA from the grafts was reverse transcribed and used for 
TaqMan quantitative real time-PCR (QT-PCR) to determine the mRNA expression 
levels of AID and CD21L and a number of genes known to correlate with 
lymphoid tissue organization. (G) A significant correlation between levels of 
transcripts for AID and CD21L was seen and AID was detected only in the 
presence of CD21L. Tissues were stratified according to the presence or absence 
of AID as determined by QT-PCR and analysed for the expression of the selected 
cytokines/chemokines genes between the groups. A significant difference is seen 
in levels of APRIL (H), CXCL13 (I), TNFa (J) and LTß (K). Significant p values 
are depicted, Mann-U Whitney test. No significant difference is seen between 
levels of BAFF (L). The lower and upper margins of the box represent the 25th 
and 75th percentiles, with the extended arms representing the 10th and 90th 
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percentiles, respectively. The median is shown as a horizontal line within the box. 
Scale Bars: 6mm (B) 2mm (C), 50µm (D, E, F) 
(if) AID and CD21L expression in RA synovial grafts is associated with the up- 
regulation of genes regulating ectopic lymphoneogenesis. 
To evaluate whether the sustained expression of AID and CD21L mRNA in RA 
synovial grafts was associated with dynamic gene expression regulating ectopic 
lymphoneogenesis, I analysed mRNA expression levels of CXCL13, LTß, TNFa, 
APRIL, and BAFF. As shown in Figure 28H-K, expression levels of the TNF family 
members LTß, TNFa, and APRIL, as well as the lymphoid chemokine CXCL13 were 
significantly higher in AID+ RA grafts as compared to AID- grafts. Conversely, 
although BAFF was abundantly expressed in all RA synovial grafts, no significant 
differences between AID+ and AID- grafts were found. These results are in 
keeping with previous reports (644), showing no difference in the expression 
patterns of BAFF between CD21+ and CD21- synovial tissues, but an up- 
regulation of APRIL mRNA in GC+ synovitis, and indicate that ectopic 
lymphoneogenesis in RA synovium develops and is maintained in the presence of 
high expression levels of these factors. 
(iii) AID and CD21L expression in RA synovial grafts is associated with ongoing 
CSR and in situ production of ACPA antibodies. 
In order to confirm that AID expression in RA synovial grafts was functional, 
evidence of ongoing CSR was sought by analysing for the expression of circular 
transcripts. Circular transcripts are known to be specifically associated with AID 
expression and exclusively detectable in B cells undergoing CSR, but not by 
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plasma cells, which have already undergone CSR (201). By performing RT-PCR for 
IV-CV circular transcripts, which are transiently produced for around 48 h 
following class switching from IgM to IgG (201), 1 demonstrated (Figure 29A) their 
invariable detection in those RA transplants also expressing AID and CD21L 
mRNA, confirming the functionality of AID expression in synovial grafts. 
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Figure 29: ACPA production in the HuRA-SCID mouse is associated with 
functional AID expression within synovial grafts 
Human RA synovium was transplanted into 34 SCID mice. Four weeks post- 
transplantation mice were sacrificed and all sera tested for the presence of ACPA, 
while mRNA from the grafts was reverse transcribed and used for TaqMan 
quantitative real time PCR (QT-PCR) to determine the number of transcripts for 
AID and CD21 L and for RT-PCR to determine the presence of circular transcripts. 
(A) 1.8% agarose gel showing representative PCR products from RT-PCR 
performed for ly-Cµ circular transcripts (double bands representing alternatively 
spliced transcripts and confirming specificity (698)) indicating ongoing class 
switch recombination (CSR) in synovial grafts positive for AID, CD21L and 
producing ACPA (lane 3 and 4) but not in transplants negative for AID, CD21L 
(lane 2). (B) Synovial transplants from 6 RA patients were grouped according to 
histological classification, as aggregate vs diffuse and AID, CD21L mRNA 
expression as high (++), low (+) and negative (-). Significantly higher levels of 
ACPA were seen in those mice transplanted with synovium expressing high 
mRNA levels of AID, CD21 L. Notably, ACPA were not seen in the absence of 
AID. (C) To establish the relationship within the same patient between levels of 
AID expression and ACPA production, synovial grafts from an illustrative patient 
(PI) were stratified according to the presence or absence of AID as determined by 
QT-PCR (D) (horizontal line indicates cut off for positivity). Circulating ACPA 
from synovial grafts were produced at a significantly higher level in AID+ve 
compared to AID-ve grafts. Error bars indicate mean levels of ACPA + SD. P 
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(iv) Human ACPA in the mouse circulation are associated with intra-graft 
expression of AID and CD21L mRNA. 
Finally, I investigated whether there was a direct relationship between AID and 
CD21L mRNA expression within transplanted RA synovial grafts and the 
production of class-switched human IgG ACPA detectable in the mouse 
circulation. Strikingly, ACPA were only detected in the sera of mice transplanted 
with RA synovial tissues expressing AID and CD21L mRNA (Figure 29B). In 
addition, the highest levels of ACPA in the serum were detected in the RA 
transplants that were histologically characterized by an aggregate pattern and 
high levels of AID mRNA expression (Figure 29B). The levels of ACPA decreased in 
line with the decrease of AID mRNA expression, whilst no ACPA were detected in 
AID- grafts with a diffuse pattern (Figure 29B). To establish the relationship 
within the same patient between the variable levels of AID expression and ACPA 
production, multiple synovial grafts (n = 20) obtained from the same joint of the 
same patient with RA were stratified according to the presence or absence of AID 
as determined by QT-PCR (Figure 29D, P1). I demonstrated that circulating ACPA 
from synovial grafts were produced at a significantly higher level in AID+ grafts, 
while ACPA were negligible in the serum of animals transplanted with AID- grafts 
(Figure 29C). These data indicate that, despite the known variability between 
different synovial biopsies within the same patient, a functional relationship 
between AID expression and ACPA production is maintained. 
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Discussion 
In this report I provide strong evidence that lymphoid structures in the target 
organs of a human autoimmune disease are functional by demonstrating that 
within the synovial membrane of patients with RA, ectopic lymphoid aggregates 
characterized by FDC networks invariably express AID and are surrounded by 
ACPA producing plasma cells. In addition, using the human RA-SCID mouse 
chimera model, I demonstrate that transplanted RA synovial grafts containing 
ectopic lymphoid structures support B cell survival and proliferation, maintain AID 
expression, continuously promote ongoing CSR and produce human IgG ACPA. 
This phenomenon, characterized by the sustained high expression levels of genes 
regulating ectopic lymphoneogenesis and in the absence of new influx of immune 
cells, indicates that the establishment of follicular structures in the synovium can 
lead to self-perpetuating autoimmunity. The self-sustained survival of B cell 
niches, within rheumatoid synovium, may also have a critical impact on the 
capacity of B cell depleting biologics to modulate chronic inflammation and 
autoimmunity. 
The elucidation of the mechanisms coupling chronic inflammation and the 
production of disease specific autoantibodies within RA synovium is of pivotal 
importance because ACPA are highly disease specific markers of RA, are strongly 
associated with a more destructive arthritis and are independent predictors of a 
poorer prognosis (529; 530). However, despite recent evidence that ACPA can 
mediate tissue damage in animal models (481), confirmation of a direct 
pathogenic role for ACPA in patients with RA is currently lacking. The presence of 
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ectopic GC-like structures, characterized by T/B cell aggregates and CD21+ FDC 
networks, in the synovium of a subset of patients with RA has long been known. 
These structures have been associated with the expression of cellular and 
molecular markers associated with GC responses in secondary lymphoid organs 
(217; 334; 673) and analysis of Ig sequences from microdissected GCs from 
synovial tissue has demonstrated hypermutated and clonally related sequences 
(415), suggesting that an antigen driven B cell response is ongoing within RA 
synovium. Nonetheless, direct evidence that ectopic lymphoid tissue in RA 
synovium contains the required molecular machinery to sustain ongoing CSR and 
affinity maturation of autoantibodies has so far been lacking. Recent evidence 
has demonstrated that the processes of SHM and CSR are critically dependent on 
the expression of the enzyme AID (197) and that AID expression is exclusively 
associated with B cells undergoing SHM and CSR (700). Therefore delineating its 
expression pattern has allowed us to establish that B cells activate the molecular 
machinery responsible for production of affinity matured antibodies in follicular 
structures within the RA synovial membrane. 
In this study I provide, to my knowledge, the first demonstration that AID is 
invariably expressed within rheumatoid synovial T/B cell aggregates containing 
CD21+ FDC networks, with a distribution closely recapitulating that seen in 
secondary lymphoid organs, providing direct evidence that ectopic GC-like 
structures represent a functional tertiary lymphoid organ capable of activating 
the molecular machinery necessary to sustain SHM and CSR within the synovial 
membrane. Accordingly, ongoing CSR, as demonstrated by the expression of 
circular transcripts, was invariably detectable within AID+/FDC+ RA synovial 
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tissues. These results confirm and expand our recent observations in Sjögren's 
syndrome (675) in which FDCs appeared necessary for sustaining AID expression 
in the ectopic lymphoid tissue found in salivary glands, where an antigen-driven B 
cell response can occur (701). This evidence, further supported by my data 
demonstrating the presence of AID transcripts only in the presence of CD21L 
mRNA, strongly supports the conclusion that within the rheumatoid synovial 
membrane, AID requires the presence of FDCs for expression. I also provide 
further histological evidence supporting both the functionality of these AID+ 
structures and their involvement in the production of ACPA by showing that these 
structures are surrounded by ACPA producing plasma cells. 
By evaluating the expression of CD21L and AID mRNA using QT-PCR, a sensitive 
and highly specific method, I were able to identify functional sites of ectopic 
lymphoneogenesis in about 50% of the RA synovial samples. This prevalence was 
significantly higher than that observed using histological analysis and semi 
quantitative PCR reported in approximately 25% (217), and is in line with a recent 
observation by other groups (317). These additional (low) CD21L+ tissues were 
always of aggregate appearance, and were invariably accompanied by AID 
expression and ongoing CSR, strongly supporting the concept that such aggregate 
structures are also functional. These results demonstrate that the presence of 
lymphoid aggregates and ongoing GC reactions in RA synovium is a phenomenon 
considerably more common than has recently been proposed (388; 416; 426). 
In this report, by using the HuRA-SCID mouse model I was able to provide direct 
evidence of functionality and to present a number of novel findings regarding the 
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production of ACPA within the rheumatoid synovial membrane. First, as in the 
original RA synovial tissue, the expression of AID within the transplanted tissue 
was consistently associated with the presence and levels of CD21L. This, in turn, 
was invariably associated with ongoing CSR and the production of human IgG 
ACPA detectable in the mouse sera. In addition, levels of AID within the RA 
transplants directly correlated with the levels of ACPA in the mouse sera. Finally, 
even low-level expression of AID and CD21L within the transplants was still 
associated with significant ACPA detection in the sera, while ACPA were barely 
detectable in the absence of AID mRNA expression in the RA grafts. Overall, these 
results strongly support the notion that lymphoid structures expressing AID and 
CD21L can directly contribute to ACPA production within the rheumatoid synovial 
membrane. Indeed, as further evidence of AID functionality within synovial 
tissue, I demonstrated that AID expression supports the expression of IV-Cµ 
circular transcripts in the RA synovial grafts, and hence the presence of ongoing 
class-switching from IgM to IgG. Because circular transcripts are only transiently 
produced in association with CSR (201), this demonstrates that class-switching is 
still ongoing within the RA synovial grafts, a result in line with the detection of 
human IgG ACPA in the mouse circulation. It is important to emphasise that these 
experiments cannot formally exclude the possibility that pre-existing long-lived 
plasma cells, either generated in situ or migrated from secondary lymphoid 
organs, might also contribute to the production of ACPA in RA synovium and in 
transplanted animals. Despite this limitation, the topographical proximity of 
ACPA-producing plasma cells to AID+ follicular structures and the close 
association between the level of ACPA production in the mouse serum and higher 
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levels of AID within the same tissue strongly suggest that autoreactive plasma 
cells can be generated within ectopic lymphoid tissue. This concept is in 
agreement with the significantly higher levels of synovial ACPA recently 
demonstrated in synovial tissues containing lymphoid aggregates (424). The lack 
of detection of GC CD20+ B cells reacting with citrullinated fibrinogen is in line 
with previous reports showing that reactivity toward labelled autoantigens is 
typically restricted to plasma cells surrounding ectopic GCs (386; 702), and is in all 
probability due to the low density of antigen-specific antibodies on the cell 
surface of CD20+ B cells compared to the much higher quantity of high-affinity 
antibodies produced by plasma cells as they migrate out of GC. Finally, although 
the evidence that I provide is highly suggestive of a direct role for AID+ lymphoid 
structures in generating in situ autoantibody-producing cells, a formal 
demonstration would require evidence, i. e., in the SCID-HuRA model, that 
disruption of FDC networks abrogates plasma cell differentiation and ACPA 
production. 
A final and highly relevant observation obtained in the HuRA-SCID chimera is that 
the RA synovium, in the presence of follicular structures expressing AID and 
CD21L, behaves as a self-sustained microanatomical unit of ectopic lymphoid 
tissue. Furthermore, within the time frame analysed, the RA synovium supports 
the proliferation of B cells and maintains an intrinsic ability to function as an 
autoantibody-producing site independent of circulating immune cells. The 
continued expression of AID and CD21L and the association with ongoing CSR and 
ACPA production in this environment support a key role for ectopic lymphoid 
tissue within the synovial membrane in driving the ongoing disease process, and 
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may also explain the lack of direct correlation between peripheral B cell depletion 
and clinical response to the anti-CD20 monoclonal antibody rituximab (703; 704). 
The persistence of ectopic lymphoid structures in RA synovial tissues following 
transplantation into SCID mice is likely to be related to the sustained 
overexpression of genes regulating ectopic lymphoneogenesis and autoreactive B 
cell survival, such as the TNF family members LTß, TNFa, and APRIL, as well as the 
lymphoid chemokine CXCL13 (217; 334). LTD, TNFa, and CXCL13 were all 
significantly more highly expressed in AID+/CD21L+ as compared to AID-/CD21L- 
RA tissues, and high expression was maintained in RA synovial grafts displaying 
AID, ongoing CSR, and ACPA production. I suggest that the up-regulation of these 
key cytokines within RA synovial tissue allows differentiation and maintenance of 
FDC networks within T/B cell aggregates to form functional microanatomical 
immunological units, and hence, allow the up-regulation of AID and subsequent 
production of ACPA. In addition, my results might also explain the fall in ACPA 
levels resulting from the dual blockade of TNFa and LTa with etanercept (705), 
and the blockade of TNFa by infliximab (491) in patients with RA. 
In conclusion, my work demonstrates that ectopic GC-like structures are not only 
functional in rheumatoid synovitis, but that their presence may contribute to 
disease pathogenesis via the production of ACPA. These data elucidate the 
mechanism of production of ACPA in the synovial membrane and thereby provide 
evidence of a pivotal role for AID in the pathogenesis of RA. I therefore propose 
that AID may be targeted for the development of novel therapeutic agents. 
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Chapter 6: The Identification and Characterisation of 




B cell maturation begins in the bone marrow where B cell precursors undergo 
rearrangement of their variable (V), diversity (D) and joining (J) segments under 
the control of recombination activating genes (RAG) genes. The joining of these 
V, D and J segments is accompanied by the generation of random-linking N 
segments, under the control of terminal transferase. Naive B cells (carrying IgM 
and IgD as their surface antigen receptor) emerge from the bone marrow carrying 
inherent diversity within their antigen binding regions of antibody. Further 
diversity within the antigen binding sites of surface immunoglobulin (Ig) is then 
introduced following entry into germinal centres (GC) within lymphoid tissue. 
This diversity is a result of a process of somatic hypermutation (SHM), a process 
critically dependent on the enzyme activation induced cytidine deaminase 
(AID)(197). Mutations introduced that confer increased binding affinity of antigen 
for antibody result in escaped apoptosis and, either re entry to the GC reaction to 
undergo further cycles of SHM, or final differentiation into plasma or memory 
cells. B cells have thus been traditionally classified into naive and GC/post GC B 
cells, dependent on the pattern of somatic mutations within the V region segments 
of the Ig heavy chain (H). Additional diversity in effector functions of antibodies 
are introduced as result of a process of class switch recombination (CSR), again 
critically dependent on AID(197). 
A report in 2003 by Marafioti et al (5) identified a novel B cell subtype in 
association with GCs within lymphoid tissue, that of Interfollicular (IF) large B 
cells. These cells were characterised by a large dendritic like morphology, a 
mutated IgH and a location within T cell rich interfollicular areas. This cell type 
had been previously reported in mice as extrafollicular plasmablasts. The authors 
269 
of this paper suggested these cells were post GC B cells, due to their mutated IgH, 
though noted them to be distinct from the classical post GC plasma and memory B 
cells, lacking in particular the markers CD27 and CD138. Although the dendritic 
phenotype of these cells suggested a role in antigen presentation, this was not 
supported by the lack of expression of the co stimulatory molecules such as CD80 
and CD86 and thus their immunological role was uncertain. In addition no single 
marker was found to be capable of reliably identifying these cells from other cells 
such as monocytoid or MZ B cells, complicating their identification within other 
tissues. This work was immediately followed by data from another group 
demonstrating that IF large B cells were the only cell outside of GCs to express 
AID(196). As AID is critically required for both CSR and SHM its association 
with a cell previously noted to have a somatically mutated IgH locus raised the 
possibility that IF large B cells may represent an extrafollicular antibody response, 
rather than originating and mutating their IgH within the environment of the GC. 
This report confirmed ongoing AID activity via the detection of circular transcripts 
and thus ongoing CSR in IF large B cells, but did not re examine the IgH for SHM. 
The presence of ectopic GC within the RA synovial membrane has been 
acknowledged for some time and evidence suggests a number of similarities with 
GCs within secondary lymphoid tissue including the detection of follicular 
dendritic cell networks (FDC) networks, high endothelial venule expression, TB 
cell segregation(334; 673) and ongoing clonal B cell proliferation(415; 423). I had 
previously noted the presence of CD20+, IgD- B cells surrounding ectopic GC 
within RA synovial tissue, and the large dendritic phenotype of a cohort of these 
cells suggested that ectopic GCs within RA synovial tissue may be capable of 
supporting IF large B cells. Although the detection of IF large B cells within 
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ectopic lymphoid tissue had not previously been reported, their identification 
particularly within RA synovial tissue was thought to be of potential clinical 
relevance with the suggestion that they represented likely precursors for diffuse 
large B cell lymphomas(196), the most common malignancy associated with 
RA(706). 
Aims and objectives: 
The aims of this chapter were to: 
1. Determine whether a cohort of CD20+, IgD- large B cells surrounding 
ectopic GC represented the recently described novel IF large B cells 
2. Determine whether extrafollicular AID expression within IF large B cells 
within lymph nodes and within the RA synovial membrane is associated 
with a somatically mutated IgH. 
271 
Materials and Methods 
Patients and samples 
Synovial tissue was collected from 21 RA patients following arthroplastic joint 
surgery. All patients fulfilled the 1987 revised ACR guidelines for RA. Paraffin 
embedded tissue was available from all patients and from 10 patients additional 
samples were available that had been snap frozen in O. C. T. Normal human lymph 
nodes, obtained from 2 patients undergoing vascular surgery were also available. 
In addition from 3 patients with Sjogren's syndrome, formaldehyde fixed paraffin 
embedded tissues were obtained from the minor salivary glands of 2 patients and 
from the parotid gland of 1 patient, all known to contain FDC+ lymphocytic 
aggregates. All patients fulfilled the revised criteria of the American-European 
consensus group(707) for either primary (pSS) or secondary (sSS) Sjogren's 
syndrome. All procedures were performed following written informed consent 
approved by the hospital's ethics committee (REC 05/Q0702/1). Demographic and 
main laboratory characteristics of RA patients are described in Table 18. 
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Table 18: Demographic and laboratory characteristics of the RA patients 
enrolled in this study 
RA patients 
Number of patients 21 
Age (y) mean ±SD 51 ±10 
Female (%) 74 
Disease duration (y) mean f SD 16 ± 13.5 
Rheumatoid factor+ (%) 76 
Aggregate (CD21 network+) tissue (%) 24 
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Grading analysis, histological characterization of lymphoid proliferation 
and AID expression in RA synovial tissue 
As IF large B cells had been identified in lymphoid tissue in association with GCs 
all 21 synovial tissue samples were assessed for degree of lymphoid organisation. 
5µm sections were cut sequentially from 3 levels of each paraffin block 50µm 
apart. Following routine H&E staining synovial tissue was classified as aggregate 
or diffuse according to the predominant lymphocytic infiltrate, as previously 
reported(421). Sequential sections of synovial tissue characterised as aggregate 
then underwent double staining for the markers CD21 and Bcl2, identifying FDCs 
and GC mantle zone B cells respectively. Following antigen retrieval with Target 
retrieving solution (DAKO) and proteinase K digestion(6 minutes incubation), 
slides were sequentially incubated overnight with Bc12 (1: 50 dilution) and CD21 
(1: 20 dilution), followed by appropriate secondary antibodies and developed with 
DAB and vector red respectively. Sequential sections of synovial tissue also 
underwent double staining for CD20 (1: 20 dilution) and IgD (1 in 80 dilution) with 
one hour primary antibody incubations and followed by the Dako EnVision 
Doublestain system (DakoCytomation) used according to manufacturer's 
instructions. Frozen sections of aggregate synovial tissue also underwent double 
immunofluorescent staining for CD20 and IgD in order to confirm the results of 
conventional IHC. Finally sequential sections were also incubated with CD3 (1 in 
50 dilution) for one hour and following incubation with biotinylated goat anti- 
rabbit Ig developed with DAB, in order to identify T cells. The presence of 
ectopic GCs was determined by the presence of lymphocytic aggregates with FDC 
networks and T/B cell segregation. 
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Staining for AID was performed on sequential sections of all 21 RA synovial 
tissue samples in order to determine whether IF large B cells could be identified 
within RA synovial tissue and to determine whether they were found solely in 
association within ectopic GC. After Ag unmasking using Target retrieval solution 
(pH 6; Dako) and incubation with protein block solution (Dako) primary Ab EK2- 
5G9 was incubated (1: 20 dilution) for one hour at room temperature and 
biotinylated rabbit anti-rat Ig used as a secondary Ab. Following alh incubation 
and three washes, HRP or AP-streptavidin-biotin complex (Dako) was added to 
the section and incubated for 30 min. After further washes colour reaction was 
developed with diaminobenzidine (HRP, DAB; Dako) or Vector red (for AP; 
Vector Laboratories). Double staining for AID and the cellular markers CD3 and 
CD20 was also performed in order to determine the cellular source of AID+ cells. 
AID expression within minor salivary glands and parotid tissue of 
Sjogren's syndrome patients 
In order to determine whether IF large B cells were specific for RA synovial 
tissue, samples of another chronically inflamed tissue known to acquire features of 
ELN, the salivary glands of Sjogren's patients(383), was used as a control tissue. 
3 tissue samples known to contain FDC+ lymphocytic aggregates were identified 
from the tissue bank. The cellular infiltrate and degree of lymphoid organization 
were assessed by immunohistochemical staining of sequential sections of minor 
salivary glands with Abs to CD3, CD20 and CD21, as previously reported (11, 
12). Briefly after de-waxing and re-hydration formalin fixed, paraffin-embedded 
3µm thick sections underwent appropriate Ag retrieval with Target retrieval 
solution or proteinase K (DakoCytomation). Double staining for CD3 and CD20 
was used to analyze T/B cell segregation using the Dako EnVision Doublestain 
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system (DakoCytomation) as previously reported (11,12). Sections sequential to 
those identified as expressing CD21 and T/B cell segregation underwent staining 
for AID as per synovial protocol although including a step to block endogenous 
biotin with the avidin biotin blocking system (DakoCytomation). 
Single cell microdissection of IgD+, IgM+ and AID +B cells from lymph 
node 
In order to determine whether AID+ IF large B cells expressed a somatically 
mutated IgH 10µm thick sections of frozen lymph node were cut for subsequent 
laser capture microdissection (LCM). Sections were mounted onto PALM 
membrane slides (ZEISS) in order to maintain morphological integrity of the tissue 
specimen. Slides were then covered with silver foil and stored at -80°C until use. 
Prior to staining slides were defrosted in silver foil for 10 minutes before 
undergoing immunohistochemical staining for IgD and AID. Once defrosted tissue 
sections underwent fixation in 95% acetone at 4°C for 10 minutes. Tissue was then 
incubated with protein block solution (DAKO) and tissue undergoing staining for 
AID was additionally incubated with 20% rabbit serum (DAKO) for 30 mins. This 
step was followed by incubation with primary antibody (Table 5). IgD was 
incubated at a dilution of 1: 80 for 30 minutes and AID 1: 20 for lhour. Following 
two washes with TBS buffer, tissue for AID staining was incubated with rabbit 
anti-rat biotin secondary antibody (Table 5) for 30 mins and following two TBS 
washes with ABC HRP (DAKO) and developed with DAB solution (DAKO). IgD 
tissue was subsequently incubated with ABC-HRP (DAKO) and developed with 
DAB (DAKO). Following counterstaining with haematoxylin slides were washed 
for 5 minutes in tap water and then left to air dry overnight. Slides were then 
stored in an air tight container until needed. 
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Naive IgD+ cells carrying an unmutated IgH have been reported to result in a 
higher amplification efficiency than cells carrying a mutated IgH(5), so in order to 
establish experimental technique and determine efficiency of amplification of the 
IgH chain locus, single IgD+ cells were used for initial experiments. Single IgD+ 
cells were identified surrounding GCs within sections of lymph node and 
underwent LCM followed by pressure catapulting using a PALM microbeam 
system (ZEISS). Specimens were collected onto the caps of PCR tubes specifically 
developed for increasing retention of tissue due to a specialised adhesive coating 
on the cap (PALMAdhesive cap200 opaque). Each cap was prefilled with 20µ1 of 
proteinase K buffer (made up of lOµl of 2.5mg/ml proteinase K stock solution, 
10µl of Taq DNA polymerase lOx buffer (promega) and 80µ1 of dH2O(BDH)). 
Tubes were attached to the caps and kept inverted, to ensure catapulted cells 
remained within the proteinase K solution for digestion. Inverted tubes were then 
transferred to a hybridising oven preheated to 56°C (pre saturated with distilled 
water), for a ih digestion. Proteinase K was subsequently inactivated by heating 
to 95°C for 10 mins in a PCR machine. Tubes were then placed on ice and spun in 
a microfuge at 13000 rcf for 5 minn and kept at 4°C until use. 
Although previous reports had noted a success rate of 60% when amplifying IgH 
from single cells, in order to determine optimum sampling efficiency within our 
laboratory between 1 and 20 singly microdissected cells were catapulted into each 
cap. In addition, as a positive control, IgM+ peripheral blood mononuclear cells 
(PBMCs) were sorted using a fluorescence activated cell sorter (FACSCaliber) 
into single and groups of 10 cells. Once sampling efficiency was determined, AID 
+ve IF large cells were microdissected from lymph node. 
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Amplification of IgH chain from microdissected cells 
IgH chain genes were amplified using a semi nested PCR approach with internal 
and external JH family primers as previously described(708; 709). For the first 
amplification step FR1 primers for the VH family members and JH primers were 
both used at a concentration of 50ng/50gl of PCR reaction, with 20mM dNTPs to 
a final concentration of 0.2mM, lx Taq buffer (Promega), and 25mM MgC12 to a 
final concentration of 2mM made up to a final volume of 28µl per reaction with 
dHZO. 28µl of mastermix was then added to each tube containing the digested 
microdissected cell and centrifuged for lmin at 1000rpm. DNA was then 
denatured for 10mins at 95 °C and the PCR conditions were as follows cycle 1; 7 
cycles of denaturation for 1 min at 94 °C, annealing for 2 mins at 64 °C, and 
extension for 45s at 72 °C, cycle 2; 39 cycles of denaturation for 30s at 94 °C, 
annealing for 30s at 52°C and extension for 90s at 72°C. The mastermix for the 
second step of the PCR was made up with same final concentrations of dNTPs, 
Taq buffer and MgC12, but with both VH and JH primers at a concentration of 
100ng/50µ1 PCR reaction. On completion of the first PCR 3µl of PCR reaction 
was then added to 45gl of mastermix and the second PCR programme run as the 
first round however with an annealing temperature of 66°C in the first cycle and a 
reduction to 35 cycles and for cycle 2 an annealing temperature of 54°C. PCR 
products were then run on a 1.8% agarose/TBE gel to check size of PCR product 
(424bp). 
DNA was then purified and ligated into pGEM T-Vector plasmids (Promega). 
JM109 High Efficiency Competent cells (Promega) were then transformed and 
plated onto LB/ampicillin/IPTG/X-gal plates. White colonies were then picked off 
and PCR performed for specific markers of the ß-galactosidase gene (M13 
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primers), allowing PCR using M13 primers to detect clones with correct size insert 
(expected band size 550bp). Stab colonies were then sent off for sequencing. 




AID Identifies Interfollicular Large B Cells within the Rheumatoid 
Synovial Membrane in Association with FDC+ Aggregates 
Ectopic GC with FDC networks (Figure 30A) and TB cell segregation (Figure 
30B-C) were identified in 24% (5/21) of RA patients analysed. GCs were 
consistently surrounded by large CD20+ IgD-ve cells identified using IHC (Figure 
30C-D) often with a dendritic morphology (Figure 30E). In order to confirm single 
positivity for CD20, frozen sections of RA synovium underwent 
Immunofluorescent staining for CD20 and IgD (Figure 30F). Numerous single 
CD20+ cells were confirmed to surround ectopic GC. Such CD20+, IgD-ve cells 
had a dendritic like appearance and morphologically resembled IF large B cells 
(Figure 30D-E). 
In order to specifically characterise these cells as IF large B cells I performed IHC 
staining for AID. In addition to AID+ B cells within FDC+ networks (described in 
Chapter 5), a second set of cells within the synovial membrane expressed AID 
outside this compartment. These cells were characterised by a large cytoplasm, 
often with a dendritic morphology, and were localized in close association with 
neighbouring T cells exclusively in CD21+ aggregates (Figure 31A and B). Using 
double immunofluorescence for AID and CD20 (Figure 31C and D), I confirmed 
that these AID+ cells were of B cell origin. The morphological appearance, tissue 
distribution, and predominant cytoplasmic AID expression in these cells (Figure 
31E and F) closely resembles the population of IF large B cells recently described 
in lymph nodes (5) where AID+ IF large B cells are mainly localised within the T 
cell area surrounding the follicles (196; 695). 
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Figure 30: Ectopic germinal centre like structures within RA synovium are 
surrounded by large CD20+, IgD- B cells 
Sequential sections of paraffin embedded RA synovium were double stained 
with (A) CD21 (red) and Bc12 (brown), (B) singly stained with CD3 and (C) 
double stained with CD20 (red) and IgD (brown) in order to identify tissues 
containing ectopic GC (original magnifications x20). (D) CD20+, IgD- cells 
were found surrounding ectopic GC within the T cell rich area (x40 
magnification of C)(E) a subset of these cells morphologically resembled 
interfollicular large B cells with a large cytoplasm and dendritic like structure( 
x60 magnification of Q. (F) In order to confirm single positivity for CD20, 
frozen sections of RA synovium underwent double staining using 
immunoflouresence for CD20 (green) and IgD (red). Scale Bars: 200µm (A, B, 
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Figure 31: AID Identifies Interfollicular Large B cells within the Rheumatoid 
Synovial Membrane in Association with FDC-positive aggregates 
(A) Paraffin-embedded sections from RA patients were stained for AID (x 20 
magnification). AID +ve cells with a large cytoplasm and sometimes dendritic like 
morphology (arrows) were frequently and exclusively seen in RA synovial tissue 
characterized by the presence of large aggregates predominantly in close 
proximity to CD21 +FDC networks. (B) Paraffin sections were double stained for 
AID (brown) and CD3 (red) (x60 magnification), demonstrating the close 
relationship between AID positive cells (arrows) and T cells in the peripheral T 
cell areas of the lymphoid aggregates. (C) Merged double staining for CD20 
(green)/AID (red) on frozen RA sections confirmed that AID +ve cells were of B 
cell origin (double stained cells are identified in yellow) (D) Higher magnification 
of an example of an AID positive, CD20 positive cell (X60 magnification of (C)). 
Scattered AID positive cells (E) with the appearance of IF B cells (F) were 
occasionally found away from the central focus of the aggregate. Scale Bars: 
200µm (A, C, E), 50µm (B, F) 15µm (D) 
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AID Expression Identifies IF Large B cells Surrounding Germinal Centres in Minor 
Salivary Glands and Parotids of Sjogren's Syndrome Patients 
In order to test for disease specificity another chronically inflamed tissue, the 
salivary glands of patients with Sjogren's syndrome, was examined. In addition to 
GC B cells within FDC networks, a second pattern of AID expression was 
observed in minor salivary glands and parotids of SS patients. As shown in Figure 
32, numerous large B cells often with dendritic morphology strongly expressed 
AID, mainly in the cytoplasm and to a lesser extent in the nucleus, and were 
localized in close association with CD21+AID+GCs in Sjogren's syndrome minor 
salivary glands (Figure 32, A and D) and Sjogren's syndrome parotids (Figure 32, 
B and E). Importantly, this population was exclusively observed in salivary glands 
where lymphocytic aggregates with CD21+ FDC networks were present. 
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Figure 32: AID expression in Sjogren's syndrome minor salivary glands and 
Sjogren's syndrome parotids also identifies cells resembling the recently 
described population of IF large B cells. 
Sequential paraffin-embedded sections from Sjogren's syndrome patients were 
double stained for bcl-2 (brown) and CD21 (purple) (A-C) and single stained for 
AID (brown) (D-F). Representative examples of Sjogren's syndrome minor salivary 
glands (A-D) and parotids (B-E) are shown with a tertiary lymphoid follicle in a 
lymph node (C-F) for comparison. AID+ cells with a large cytoplasm and sometimes 
dendritic morphology (arrowheads, D-F) were frequently and exclusively observed 
in Sjogren's syndrome salivary glands characterised by the presence of large 
lymphocytic aggregates, often in close proximity with CD2I+FDC networks (D, E). 
The morphology and pattern of distribution are highly reminiscent of the population 
of IF large B cells recently described in secondary lymphoid organs as shown in 














SS MSG Lymph node 
'"y 4ý \ýý, -. -j" JPY`« 
C 
\. 





Single cell laser capture micro dissection reliably amplifies the 1gH locus from 
groups of 5 IgD+ cells 
In order to determine the efficiency of IgH amplification from singly dissected 
cells, IgD+ cells were microdissected from lymph node using LCM (Figure 33 A 
and B). IgD+ cells were chosen as theoretically a lack of somatic mutations within 
the IgH results in a higher rate of primer binding and thus a higher frequency of 
PCR product than compared to cells such as IF large B cells carrying a mutated 
IgH(5). Caps were filled with single, 5,10 or 20 cells. As a positive control IgM+ 
PBMCs were sorted using FACS singly and into groups of 5 and 10 cells and IgH 
amplified. Although previous reports had documented a 60% efficiency when 
amplifying the IgH gene from single IgD+ cells (5) 1 was unable to replicate such 
results. When amplifying DNA from microdissected IgD+ single cells only 14% of 
PCR reactions resulted in a PCR product (Figure 33D lanes 2-8) vs 50% with 
single IgM+ sorted cells PBMCs and 70% with groups of 10 IgM+ cells (data not 
shown) . If 5 singly microdissected cells were grouped together however a PCR 
product was detected in approximately 83% (5/6) cases (Figure 33C lanes 3-8), 
and if 10 or 20 cells grouped together in a single cap 90% of PCR runs resulted in 
a positive PCR product (data not shown). Thus in order to both maximise the 
number of IgH genes amplified but to ensure only IF large AID+ cells were 
microdissected from tissue the experimental protocol was to micro dissect single 
cells but to group together 5 cells in each cap. 
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Figure 33: Single cell laser capture microdissection and semi nested PCR 
reliably amplifies the IgH locus from groups of 5 lgD+ cells 
A laser microdissection microscope (PALM) (A) was used to microdissect single 
IgD positive cells from frozen sections of lymph node stained with IgD using 
immunohistochemistry (B) (original magnification x20 and inset x40). When 5 
single microdissected cells were grouped together a PCR product was noted on 83% 
(5/6) of occasions (C), however when single cells were amplified a PCR product was 
noted only 14% (1/7) of times (D). 
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AID+ Interfollicular Large B cells from lymph node express a somatically 
mutated IgH chain locus 
Two sequentially cut sections of reactive lymph node from 2 patients were chosen 
for analysis. Groups of 5 IF large B cells were microdissected from frozen tissue 
surrounding GC and a semi nested PCR performed for amplification of the IgH 
gene. Following cloning 65 colonies were sent for sequencing (LARK). 
I was unable to microdissect AID+ IF large B cells from frozen RA synovial 
tissue. IF large B cells are seen less frequently within synovial tissue and the 
morphological integrity of frozen tissue samples is poorer than that of paraffin 
embedded tissue. These factors, together with poor quality immunohistochemical 
staining made attempts to singly microdissect IF large B cells using this approach 
unfeasible. 
Results from lymph node are summarised in Table 19 and include a number of 
IgD+ cells sent for sequencing. A total of 28/65 AID+ colonies produced 
sequences, a number of these were repeated sequences, a result of sending an 
identical colony for sequencing. In addition of the 28 sequences obtained from IF 
large cells, 9 were unique sequences and of these 7 were mutated and two were 
unmutated. Results also demonstrated low level mutation within 1 IgD+ cell. The 
mean mutation rate for IF large B cells from the 2 lymph node samples examined 
was 3.3%(range 0-14.5% ) which was lower than reported by Marafioti et al 
(mean 9% range 2-13%)(5). 
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Figure 34; Single cell microdissection and amplification of IgH chain from 
interfollicular large B cells from lymph node 
Sections of frozen lymph node underwent routine immunohistochemical staining 
for AID, arrow heads (A). Single cells were microdissected and the IgH gene from 
groups of 5 cells amplified using a semi-nested PCR. Positive PCR products 
(expected band size 424bp) were seen in this example from groups of 5 cells. 
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Lane 1: PCR marker 
Lanes 2-8: groups of 5 AID+ 
interfollicular cells 
Table 19: Results of sequencing the IgH chain locus from interfollicular B 
cells microdissected from lymph node 
The IgH chain locus from AID+ and IgD+ cells microdissected from lymph node 
was sent for sequencing. 68 stab colonies were sent from AID+ cells and 5 stab 
colonies from IgD+ cells. A number of sequences came back as nonsense and a 
number were repeated, thus overall only 9 sequences from AID+ cells and 2 from 
IgD cells were suitable for further analysis. The bold red line separates results 
from 2 lymph nodes from 2 patients. Cap code refers to sequences obtained from 
amplified cells within the same cap. 
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Cell Cap VH Clone Sequence No D segment J family V Gene and 
type code family number summary mutations family 
AID B VH3 Fi 37 Mutated 3 Short and complete JH4 DP32 (VH3) 
+ve Fi 82 mutated 6 (mostly is X9051 JH3B DP58 (VH3) 
cells to Cs) 
Fi 88 Not 0 Short and complete JH3B DP32 (VH3) 
mutated 
D VH3 Fi 69 mutated 2 JH 6 DP 353-11 
E VH6 Fi 18 mutated 18 No matches JH2 DP- 
15Z12317V1- 
8 
F VH3 Fi 41 Mutated 24 plus JH6B DP 473 
(heavily) deletion 
VH6 Fj 7 Low level 3 No matches JH313 VH6f 
mutation 
Li 2 VH3 FH18 Highly 44 No matches JH5A DP58 (VH3) 
mutated 
FH19 Lnmutated 0 JH3B DP47-3 (VI-13) 
IgD VH5 Fi127 Low level 4 X97051 JH6A/13 DI'-I(1Zl2312 
cells mutation 
FH45 Low level 3 X97051 Jh5bf DP- 
mutation 10/ 12312tdp 
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Discussion 
Ectopic GCs within RA synovial tissue, capable of recapitulating many of the 
features of GCs found within secondary lymphoid organs have long been 
recognised(673). The micro architecture of these structures includes T/B cell 
separation and FDC networks(673). The identification of large CD20+, IgD- cells 
often with a dendritic like structure surrounding FDC+ aggregates within RA 
synovial tissue raised the possibility that these structures may also be capable of 
supporting IF large B cells, a novel subset identified within human peripheral 
lymphoid tissue(5) and recognised to uniquely express AID within the 
interfollicular area outside of the GC(196). Thus the identification of a cohort of 
CD20+, IgD- cells expressing AID outside of ectopic GC both in RA synovium 
and within the salivary glands of patient's with Sjogren's syndrome is the first 
report of IF large B cells at an ectopic site. Their characterisation within synovial 
tissue demonstrates a number of similarities with IF large B cells in secondary 
lymphoid organs, namely their localisation within the peripheral T cell area, a 
predominantly cytoplasmic staining pattern and a dendritic morphology. The role 
of IF large B cells is currently unknown, but their dendritic-like morphology and 
close association with T cells has led to speculation that they may play an 
important role as antigen presenting cells (5), although this is not supported by 
their lack of expression of costimulatory molecules such as CD80 and CD86 and 
only weak positivity for CD40(5). Interestingly, I also confirmed that the 
expression of IF large B cells is not limited to ectopic GCs within synovial tissue, 
and their identification in the salivary glands of patients with Sjögren's 
syndrome(675) suggests that these cells are associated with sites of ELN in the 
target organs of several autoimmune disorders. 
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Importantly, IF large B cells have also been proposed as non neoplastic precursors 
of B cell malignancies, including that of diffuse large B cell lymphomas, some of 
which harbour translocations generated by erroneous CSR(196). An association of 
RA with an increased risk of lymphoma has been recognised for some years, but 
only recently has a striking predominance of diffuse large B cell lymphoma been 
identified, particularly associated with increased RA disease activity(706). Thus 
the identification of IF large B cells within the synovial membrane in exclusive 
association with ectopic GCs, structures associated with both increased local and 
systemic inflammation(388) and further likely lacking normal immune regulatory 
mechanisms may provide an explanation for the excess of diffuse large B cell 
lymphoma seen within RA patients. 
Although IF large B cells are recognised to express a somatically mutated IgH(5), 
initial suggestions that this may indicate a post GC B cell were questioned when 
around 10-20% of such cells were identified as expressing AID(196). This 
extrafollicular AID expression suggests that IF large B cells may represent an 
extrafollicular antibody response, with ongoing SHM occurring outside of the 
GC(196). Although AID activity within AID+ IF large B cells has been confirmed 
previously by the detection of circle transcripts, evidence for a somatically 
mutated IgH was not specifically examined. By micro dissecting only AID + IF 
large B cells from lymph node I can however confirm the earlier report that these 
cells have a somatically mutated IgH, although at a much lower level than 
previously reported (3.3 vs 9%). There are a number of reasons for this 
discrepancy in levels of SHM. Firstly, although the initial report of somatically 
mutated IF large B cells used single cell dissection, a technique of 
micromanipulation (710) was utilised rather than LCM. In addition double 
296 
immunohistochemistry was used to identify IF large B cells prior to isolation 
rather than the use of a single marker, inherently more distinctive used within this 
study. Both these approaches likely make the isolation of pure IF large B cells 
technically more difficult. Further, as only a cohort of IF large B cells express AID 
(10-20%)(196), the identification of IF large B cells using other markers is likely 
to include both AID+ and AID- cells. It could therefore be hypothesised that those 
IF large B cells that do not express AID have already undergone a process of 
SHM, whereas those cells expressing AID are actively mutating their IgH, thus 
micro dissecting AID + cells would result in the isolation of cells with a 
inherently less mutated IgH. In addition when establishing the technique of LCM 
and amplification of the IgH within our laboratory I was unable to reproduce the 
previously reported sensitivity of 60% when amplifying the IgH locus from IgD+ 
cells, with a sensitivity of only 10% when using a semi-nested PCR. Thus in order 
to increase the chance of micro dissecting a whole nucleus (in general around 5pm 
in diameter) I used 10µm thick tissue sections. However, the use of sections with 
an increased diameter does increase the risk of including DNA not from the cell of 
interest, such as naive B cells, that may carry a non mutated IgH. This additionally 
may explain my result of low level SHM in a single IgD+ cell. Furthermore, 
although IgD+ cells surrounding GCs are theoretically naive B cells and thus carry 
an unmutated IgH, there are reports of infrequent IgD+ B cells carrying a 
somatically mutated IgH(711). 
Finally, attempts to microdissect single IF large B cells from RA synovial tissue 
were not successful due to a number of problems. Firstly as IF large B cells are 
found in much reduced number within RA synovial tissue, morphological integrity 
of synovial tissue and high quality of IHC staining for AID was essential in order 
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to resolve and thus microdissect single IF large B cells within synovial tissue. Due 
to both the quality of frozen synovial tissue available and the poor results of IHC 
staining on frozen RA samples single cell micro dissection was not feasible. 
Although it is possible to amplify the IgH from paraffin embedded tissues (using 
primers for the FR3 region of IgH), the specialised membrane covered slides 
required for LCM do not tolerate heat based antigen retrieval techniques required 
for AID staining on paraffin tissue and the AID staining protocol could not be 
optimised with other enzyme based antigen retrieval techniques (including trypsin 
and proteinase K). Membrane covered slides suitable for heat based antigen 
retrieval are currently under development with PALM and when commercially 
available the single cell micro dissection of IF large B cells from RA synovial 
tissue could be undertaken. 
In summary I present the novel fording that IF large B cells can be identified 
within RA synovial tissue in exclusive association with FDC+ lymphocytic 
aggregates, their identification in the salivary glands of Sjogren's syndrome 
patients further suggests they may be found in ectopic sites in a number of 
autoimmune disorders. I also demonstrate that AID+ IF B cells in lymph node 
express a somatically mutated IgH. Further work needs to investigate whether IF 
large B cells within RA synovial tissue express a somatically mutated IgH and a 
study of expression patterns of dendritic cell markers and co stimulatory molecules 
will aid in elucidating the function of these cells. 
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Chapter 7: General discussion 
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The presence of ectopic GCs within RA synovial tissue has been recognised for 
some time, although controversy has surrounded whether their detection defines a 
poorer prognostic category and further whether they are themselves directly 
pathogenic(426). 
As current prognostic markers are unable to reliably predict those RA patients 
most at risk of rapid disease progression and thus direct the most intensive 
therapeutic interventions to those patients in greatest need, additional prognostic 
markers are urgently needed. Previous work has suggested that histological 
classification of synovial tissue into a diffuse, aggregate or GC + infiltrate 
associates with clinical phenotype (217; 421). Such a mutually division is not 
reflected however on examination of synovial tissue from other patient cohorts, 
with a frequent overlap of all 3 subdivisions(388). Furthermore, no account is 
made of the degree of diffuse or aggregate tendency of tissue. The first major 
component of this thesis therefore, sought to develop and validate a quantitative 
aggregational scoring system for RA synovium using DIA that quantified both the 
degree of aggregation and diffuse infiltration within synovial tissue. It further 
aimed to examine both whether the presence of ELN or the degree of 
aggregation/diffuse infiltration correlated with clinical phenotype and with joint 
damage progression. 
I am able to report a number of observations: 
" Firstly that the novel quantitative aggregational score developed is a highly 
reliable scoring system 
" Secondly that ELN associates with synovial inflammation, and the degree 
of aggregation (AS) and overall cellular infiltrate (DS) within the synovial 
membrane correlates with systemic inflammation 
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" Thirdly, that there is no association between the presence of ELN within 
synovial tissue and the presence of serum autoantibodies, and 
" Finally, that neither the degree of aggregation nor diffuse infiltrate 
predicted joint damage progression over a2 year period 
The demonstration that the quantitative aggregational scoring system developed is 
highly reliable suggests a high degree of sensitivity to detect change within the 
synovial membrane and thus suggests potential long term application to both 
clinical studies and drug trials. However this study also demonstrated significant 
variability in both diffuse and aggregatibnal tendency within the joint. How much 
synovial tissue to sample to detect reliably a specific parameter has been 
investigated by a number of studies, and indeed consensus opinion is that the 
examination of six synovial biopsies is sufficient to eliminate significant 
variability(674). Whether this applies to the detection of aggregates has so far not 
been specifically addressed and in particular whether sampling of the joint from 
one site (for example from the SPP) is adequate is not known, and indeed is not 
supported by My results. This consideration is particularly important when 
considering the results of this study demonstrating a lack of association found with 
serum autoantibodies, a result reported by a number of other groups and taken to 
imply lack of functionality of such structures(416). It is likely however that ectopic 
GC form asynchronously and/or heterogeneously in different joints or areas within 
the same joint and thus such structures could easily be missed by limited sampling 
of a single site or by limited biopsies from different sites. Thus a specific study 
powered to determine the variation in aggregation within the joint is required in 
order to determine the number of biopsies and sites required to reliably categorise 
a patient as diffuse or aggregate. 
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A further limitation of this study is addressing correlations with clinical and 
biochemical markers on a historical cohort of patients with varying disease 
duration and on a number of DMARDs. Although this was the first study to 
investigate whether the aggregational tendency of synovial tissue predicted joint 
damage progression (rather than associate with erosive damage in a cross sectional 
study), it is known in particular that DMARDs are capable of modifying the 
histological appearance of the synovial membrane(712). In addition the long term 
aim of novel biomarkers is their use in early arthritis to predict early on which 
patients require the most intensive therapeutic interventions (including biologics). 
Therefore the optimum study to investigate the prognostic value of the 
aggregational tendency of synovial tissue to predict joint damage progression 
would recruit patients with early RA, naive to all therapy, a study that is currently 
underway within our group. Indeed there is already evidence suggesting that 
lymphoid neogenesis may relate to specific clinical-biological behaviours when 
patients are prospectively analyzed. Kraan et al. (713) in a 2-year follow-up study 
observed that high scores for B cell, plasma cell, and macrophage infiltration 
evaluated in early stages (n = 95) were the best discriminating markers in 
predicting the diagnosis of RA versus other forms of arthritis. Further, Canete et 
al. (387) demonstrated that the presence of lymphoid aggregates plus T-B cell 
segregation and PNAd+ HEV, assessed at baseline in a cohort of 86 patients, is a 
highly significant negative predictor of moderate-good EULAR response to anti- 
TNF therapy. 
Importantly as stated although I demonstrated a lack of an association between 
aggregational tendency of the synovial membrane and autoantibodies within the 
serum of patients I did not take this to imply lack of functionality of such 
302 
structures. The lack of an association may not only be a result of limited sampling 
being unable to reflect the histological picture of the whole joint, but the 
production of autoantibodies including RF and ACPA has been demonstrated to 
occur at other distant ectopic sites such as the lung, complicating the relationship 
between detection in the sera and local production within synovial tissue. Whether 
ectopic GCs are indeed functional or merely by products of inflammation has 
created much debate in the literature(416; 424; 426), and is a crucial question to 
address in order to understand the pathogenic mechanisms driving local 
inflammation and autoimmunity within the synovial membrane. Thus the second 
main component of this thesis investigated whether ectopic lymphoid structures 
within RA synovial tissue expressed the molecular machinery required for the 
production of high affinity class switched antibodies and further by transplanting 
synovial tissue into SCID mice, whether such structures were actively involved in 
the pathogenic process via the production of potentially pathogenic autoantibodies. 
This work resulted in a number of important observations in particular: 
" At both mRNA and protein level AID is expressed within RA synovium in 
exclusive association with lymphocytic aggregates expressing FDCs 
" That AID expression is maintained within synovial grafts transplanted into 
SCID mice up to 4 weeks post transplantation and associated with the 
detection of human IgG anti-CCP antibodies in mouse sera; 
" That AID expression is functional, as determined by the detection of Iy-Cµ 
circular transcripts (a marker of ongoing CSR) in AID+ RA_synovium and 
grafts; 
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" That AID is associated with high levels of molecules regulating the 
development and maintenance of ectopic lymphoneogenesis (CXCL13, 
TNFa, LTD) and the B-cell proliferating factor APRIL. 
This work demonstrates the potential of the autonomous capacity of the RA- 
synovium to sustain B-cell growth, maturation and differentiation suggesting a 
pathogenic role for ectopic lymphoid structures in disease relapse/resistance after 
rituximab therapy. 
This unique model enabled the detection of autoantibodies in tissues transplanted 
into SCID animals in the absence of confounding factors, such as their possible 
production in secondary lymphoid organs or the migration of new B and plasma 
cells to the grafted tissues. By transplanting RA synovial tissue with and without 
lymphoid aggregates into SCID mice, I demonstrated that AID+CD21 L+ RA 
synovial grafts produce high levels of human IgG ACPAs, which can be measured 
in the mouse circulation, and whose titres are associated with the expression levels 
of AID mRNA in the synovial grafts. Of relevance, production of ACPA by 
synovial grafts persisted several weeks after transplantation, and was associated 
with persistent proliferation of B cells, and concomitant detection of ly-Cµ circular 
transcripts, suggesting that TLS can in part behave as self-sustained 
microanatomical immunological units capable of supporting functional AID 
expression and IgM to IgG class switching independently from the systemic 
circulation. In keeping with these observations, I also demonstrated that ectopic 
lymphoid follicles in RA patients can be surrounded by CD 138+ plasma cells 
producing antibodies directed against citrullinated fibrinogen. 
Collectively, these data indicate that in addition to accumulation from the 
periphery, autoreactive plasma cells can be supported in situ by AID+ lymphoid 
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aggregates, suggesting that they may function as `protective niches' for local B- 
cell differentiation (Figure 35) and auto-antibody production with the potential of 
directly contributing to the autoimmune and response. Expanding on this evidence 
I have recently proposed a working model for lymphoid tissue response and 
autoantibody production in RA (Figure 36)(6) in which a sensitization phase 
would take place outside the joint following an environmental insult [i. e. 
citrullination of lung proteins in smokers (110) in association with other 
predisposing risk factors (i. e. HLA shared epitope), resulting in presentation of 
auto-immune epitopes and leading to T- and B-cell priming in secondary lymphoid 
tissues. B-cell sensitization leads to the production of auto-antibodies followed by 
a period of latency that could last years. A second systemic `hit' related to 
unknown triggers (possibly infection) could then lead to specific or polyclonal B- 
cell activation with a rise in circulating antibodies and immune complex (IC) 
fonnation(714). IC activation of FcRs in the portal circulation results in the 
secretion of systemic vasoactive amines in a mechanism that would have a 
selective effect on endothelial permeability. The distinct vascular properties of 
synovial endothelium would result in a preferential extravasation of 
macromolecules and auto-antibodies to the joint, potentially explaining why 
arthritis accompanies many human infectious and autoimmune disorders(715). 
Again subsequent unmasking of neo-epitopes (such as citrullinated proteins) 
within synovial tissue would lead to local pathology. Thus it is possible that such 
tissue damage would promote further exposure of synovial antigens, also 
supported by spreading to unrelated epitopes and in situ presentation of cryptic 
determinants (716; 717). This would lead a persistent immunostimulation, 
triggering, in some individuals or disease stages, the described mechanisms of 
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lymphoneogenesis, and the consequent modulation of the humoral response, 
supported by transient developmental cycles or persistent localization of newly 
formed tertiary lymphoid structures (Figure 36). 
Further, a crucial question leading on from this work is whether response- 
resistance to rituximab treatment in RA patients is defined by i) distinct cellular 
and molecular phenotypes within RA-synovium and ii) whether response- 
resistance-relapse to rituximab is determined by B-cell depletion and/or survival 
(in "protected" self-driven synovial niches). This study is currently ongoing in the 
department, recruiting RA patients resistant to anti-TNF therapy for pre and post 
rituximab minimally invasive ultrasound guided synovial biopsies. Following 
histopathological characterisation and gene expression analysis of synovial tissue 
critical pathways involved in B-cell survival, activation and repopulation will 
therefore be determined. 
In addition this work crucially validates the SCID-HuRA chimera as a 
translational tool to investigate/modulate B-cell function and following the 
identification of novel pathways involved in B cell activation and survival 
identified within the synovial membrane pre and post rituximab I will also have 
the opportunity to target these pathways in the Hu-RA SCID mouse model. This 
will permit proof of concept studies to be performed using a variety of systems 
including intra-graft injection of monoclonal Ab (e. g. anti-BAFF), fusion proteins 
(e. g. TACI-Ig, CTLA4-Ig), siRNA and dominant negative mutants in adenoviral 
vectors as appropriate. Biological readouts will include graft modulation of. a) 
BAFF, APRIL, PBEF and TSLP as detected by IHC and QT-PCR; b) survival and 
proliferation of synovial B-cells and IHC analysis of ectopic lymphoid aggregates; 
c) AID expression and ongoing CSR; and d) human class-switched anti-CCP 
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antibodies. This work is critical as one limitation of My study is a lack of a direct 
link between AID+ lymphoid structures and anti-CCP antibody production, 
evidence that could be provided in the SCID-HuRA if anti-CCP antibody 
production is abrogated, for example, following the disruption of FDC networks 
with compounds such as LT3R-Ig or TACI-Ig. Thus the potential for this ongoing 
work is to advance knowledge of the mechanisms regulating B-cell activation, 
AID expression and ectopic antibody formation and subsequently translate these 
new observations back to RA patients. Indeed a number of recent studies focusing 
on the synovial membrane's response to specific biologic agents 
(387; 389; 680; 718) have resulted in a number of important observations regarding 
the role of specific immunological pathways related to B cell activation within 
target tissues in disease pathogenesis. A number of other biologic agents with the 
potential to interfere with lymphoid tissue response are in clinical development 
(Table 20) and future data examining their effect on the synovial membrane and 
lymph node will undoubtedly lead to further advancements regarding the 
pathogenic role of these compartments during early, established and advanced 
stages of the disease. 
Finally, a further important question remains unanswered despite important work 
in this area, that of the specific antigen driving the production of ectopic GCs 
within RA synovial tissue. This is a crucial question to address to not only further 
the understanding of RA pathogenesis but in addition to develop novel treatment 
approaches for RA such as the induction of tolerance. Thus further experiments are 
planned to identify not only the antigen specificity of B cells within ectopic GCs 
within synovial tissues but also antigen specificities within GCs within locally 
draining lymph nodes. This line of investigation will allow us to identify whether 
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the immune response within the synovial membrane becomes uncoupled from that 
in local draining lymph node. Understanding the relationship between B-cell 
activation in the synovium and local lymph node is crucial to enable therapeutic 
targeting of the primary site of initiation and maintenance of the disease process. 
The third main component of this thesis aimed to investigate whether a cohort of 
large CD20+, IgD-ve cells surrounding ectopic GCs were IF large B cells and 
whether AID+ interfollicular B cells, both within lymph node and the synovial 
membrane, expressed somatically hypermutated IgH genes. I report the following 
novel findings; 
" Firstly I demonstrate that IF large B cells are found within synovial tissue, 
in exclusive associated with FDC+ lymphoid aggregates, and 
" That IF large B cells within lymph node express a somatically mutated IgH 
gene. 
My finding of IF large B cells within both rheumatoid synovial tissue and within 
the salivary glands of patients with Sjogren's syndrome suggests that such cells 
may be found in ectopic lymphoid tissue of a number of auto inflammatory 
conditions. Although I demonstrate that IF large B cells at ectopic sites share a 
number of similarities with those reported in lymph node and tonsil, such as 
location within the T cell rich interfollicular area, a close association with T cells, 
and a dendritic morphology, the next steps are to identify their functional role. A 
number of molecular markers may aid in addressing this question such as the 
expression of MHC class II markers and costimulatory molecules, if indeed they 
do play a role in antigen presentation, autoantibody expression (including RF and 
anti-CCP) and importantly the relationship of their IgH gene to GC B cells within 
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the local GC. A weakness of our study was the inability to microdissect IF large B 
cells from synovial tissue, however these technical issues are likely to be 
addressed imminently and thus the relationship of IF large B cells to the nearby 
GC could be addressed both in secondary and ectopic lymphoid tissue. Crucially 
understanding this relationship will allow us to address whether IF large B cells 
originate from the GC (and thus express a IgH in common) or whether they are an 
independent site of extrafollicular antibody production. 
Understanding the functional role of IF large B cells has a number of important 
implications for understanding RA pathogenesis. Firstly, are these cells GC 
founder cells? If so could such cells be directly targeted to abrogate the local 
immune response within synovial tissue? Secondly, do these cells play a role in the 
extrafollicular production of autoantibodies? Thirdly, a link has been suggested 
between IF large B cells and diffuse large B cell lymphoma(196), recently 
identified as the predominant lymphomatous subtype in RA patients(706). It may 
be suggested therefore that such an excess of diffuse large B cell lymphoma in RA 
patients arises because of the aberrant development of IF large B cells within 
ectopic lymphoid tissue, at a site lacking normal regulatory immune mechanisms. 
In summary, the present thesis provides evidence to support a direct role for ELN 
in the pathogenesis of RA, linking its presence to increased synovial inflammation 
and suggesting a direct pathogenic role via the production of autoantibodies. 
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Figure 35: Functional T/ B cells aggregates with FDC networks support 
(auto)antibody repertoire diversification and isotype class switching in B cells 
infiltrating rheumatoid synovial membrane. 
Proposed schematic model of (auto) reactive B-cell activation within RA 
synovium. During chronic RA synovitis, different B-cell and T-cell subsets have 
been shown to be recruited to the inflammatory site. Perivascular lymphocytic 
aggregates developing in the synovial sublining can acquire features of secondary 
lymphoid organs such as FDC networks which support expression of activation- 
induced cytidine deaminase (AID) in B lymphocytes within these structures. In 
this environment B cells undergo Ig repertoire diversification and affinity 
maturation via rounds of somatic hypermutation (SHM) and isotype class 
switching via CSR in a germinal centre-like humoral response (1-in situ 
production of (auto)antibodies). In parallel (or in some RA patients, alternatively), 
plasma cells generated in other locations may also be recruited from the systemic 
circulation (2-accumulation of (auto)antibody-producing cells from the periphery) 
and be released into synovial environment where they can survive as terminally 
differentiated long-lived plasma cells. It still uncertain whether ectopic lymphoid 
structures can support the `de novo' recruitment of naive T and B cells or whether 
memory cells undergo cycles of amplification within these micro-immunological 
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Figure 36: From extra-synovial sensitization triggered by non-specific antigen(s) 
to joint-specific inflammation in rheumatoid synovium: from increased vascular 
permeability to ectopic lymphoid tissue formation. 
(A) An environmental insult (i. e. citrullination of lung proteins in smokers) in 
association with other risk factors (i. e. HLA shared epitope) results in modification of 
amino acid residues leading to antigen presentation and priming. (B) Antigen 
presenting cell (APC) and T-cell dependent B-cell sensitization and production of 
autoantibodies is followed by a period of latency. (C) A `second hit' resulting in 
polyclonal B-cell activation (i. e. viral infection), induces rise in circulating antibodies 
and immune complex formation. (D) Activation of FcRs in the portal circulation and 
possibly mast cells results in the secretion of systemic vasoactive amines in a 
mechanism also dependent on neutrophils. These have a selective effect on endothelial 
permeability to macromolecules in the joints with extravasation of autoantibodies. (E) 
Resulting non-specific inflammatory process leads to unmasking of novel joint 
specific antigenic epitopes (i. e. citrullination of synovial proteins) and local 
pathology. (F) Chronic antigenic exposure within synovial tissue results in persistent 
immune stimulation triggering the described mechanisms of TLS formation and the 
consequent local modulation of the immune-inflammatory process. PC, plasma cells; 
N, neutrophils, MC, mast cells; C, complement. Reproduced from(6). 
Developmental Agent (s) Mechanism of action 
Licensed for Rituximab (Chimeric t3 cell depiction 
use in RA anti-CD20 Mab) 
Abataccht ((`I I.. A4-1g) Disruption of "1' cell co stimulatory 
pathway" 
Infliximab, adalimumab Blockade of'FNFa 
(anti-TNF-u Mabs) 
Ftancrceht (l Nl: R-Ig) l3k ckadc ol" 1. II NI'u 




TRU-O 15 (SM 11) anti- 13 cell depiction 
('1)2U) 
Belimumab Inhibit B cell development, 
(Humanised anti-BAFF activation and survival via blockade 
Mab) of BAFF 
ßA\lG 623 (1383 BAFF blockade 
Ig 13R3-Fc) 
Anti-BR3 Mab BAFF blockade 
Ataciccpt ('I'A('I- Ig) Inhibit 13 cell activation, 
development and survival via 
hlockadc of BAFF A1'RII. 
Baminercept (1-TIM-1g) Disruption of GC Fon-nation and 
survival via LTß blockade 
SMIP, small modular immunopharmaceutical protein; GC, germinal centre; Mab, monoclonal 
antibody. Modified from ((719)) 
Table 20: Summary of therapeutic agents both licensed and undergoing 




TBS buffer 10x PH 7.6 
60.6g Trizma HCL 
13.9g Trizma base 
90g NaCl 
Make up to 1L with distilled water 
Tris/HCL pH 8.2 
24.22g Tris Base to IL of distilled water 
Vector Red 
To 4.75m1 of TrisHCl (pH 8.2) add 0.25m1s of levamisole, followed by 2 drops of 
reagent 1,2 drops of reagent 2 and 2 drops of reagent 3. Mix well following each 
addition. Working solution should be used immediately. 
1% Acid alcohol 
Levamisole 
1 mM levamisole solution was prepared from stock solution 20x (Invitrogen) 
Avidin-Biotin Comulex (ABC) (DAKO K0355) 
To make up solution add 10µl of solution A to 1 ml of TBS (x 1), mix well then add 
l0µl of solution B and incubate for at least 30 mins prior to use 
REAGENTS FOR MOLECULAR BIOLOGY 
lx TBE(Tris borate EDTA) buffer (0.089M TRIS. 0.089M Borate. 0.002M 
EDTA 
IL of concentrate (VWR EM8800) was made up to 5L with dH20 
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Aear 
Yeast extract 2g 
Agar 6g 
NaC12g 
Bact tryptone 4g 
And make up to 400mls with distilled water 
LB/ampicillinAPTG/X-Gal for plates 
To 400m1 of agar add: 800µl of ampicillin (50mg/ml) (Sigma A9518) 
2mis IPTG (0.1M) (Promega V3955) 
640µ1 Xgal (50mg/ml) (Promega V3941) 
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